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Abstract 
 
 Arrhythmia mechanisms rely on multiple factors including structural (myogenic), 
nervous (neurogenic), and interrelated (the neuro-myogenic interface) factors. I hypothesized 
that due to this neuro-myogenic interface, the intrinsic cardiac autonomic nervous system 
(ICANS) is involved in most atrial arrhythmias. This thesis also provides a "Threshold 
Model" as a tool to assess the role of different physiological factors influencing arrhythmia. 
This model allows relative comparison and interpretation of the role of various factors 
influencing arrhythmogenesis. The mouse allows relatively simple manipulation of genes to 
determine their role in arrhythmia.  This thesis determined what atrial arrhythmias are 
inducible in the mouse (in vivo) and how to systematically study those arrhythmias. I found 
that atrial tachycardia/fibrillation (AT/F) and junctional tachycardia (JT) are inducible in the 
mouse. AF and JT pose significant clinical challenges as many patients do not respond well 
to current interventions. Neurogenic AF relies on acetylcholine, while myogenic AF relies, in 
part on gap junctions formed by connexins (Cxs). The atria has muscarinic M2 and M3 
receptors. The duration of M2R/M3R G protein signalling is regulated by GTP hydrolysis, a 
process accelerated by the regulators of G protein signalling (RGS). RGS2 deficient (RGS2-/-
) mice had reduced refractory periods that were normalized with a selective M3R blocker 
(Darifenacin) and increased susceptibility to AT/F induction compared to littermates. For the 
first time, this showed a role of M3 and RGS in atrial arrhythmia. Cx40 deficient (Cx40-/-) 
mice were protected from carbachol induced AT/F, while Cx43 G60S mutant (Cx43G60S/+) 
mice, with an 80% reduction in phospho-Cx43 in the atria were highly susceptible to AT/F 
that was terminated by darifenacin. This shows a novel neurogenic component to what was 
previously described as myogenic arrhythmia. Another novel finding was that JT has a 
neurogenic component, resulting from inappropriate AV nodal pacemaker activation initiated 
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by autonomics. Ivabradine hydrochloride, a selective pacemaker channel blocker, prevented 
JT and may be useful in patients with JT. 
In conclusion, this thesis has provided novel findings of the vital role of the neuro-
myogenic interface in atrial arrhythmias and has provided the basis for future investigations 
of potential therapeutic options for patients. 
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CHAPTER 1: LITERATURE REVIEW 
1.0 OVERVIEW 
 The focus of this thesis is the study of atrial arrhythmia (in vivo) in the mouse. An 
adequate understanding of the various mechanisms of arrhythmia necessitates a brief 
discussion of the electrical origins of the cardiac action potential, with the interspecies 
variation in the expression levels and subtypes of ion channels and transporters being of 
particular interest. These differences are responsible for the different morphology of action 
potentials within different areas of the heart and between species. The interspecies 
differences in cardiac action potential morphology (due to differences in underlying currents) 
may obscure the extrapolation to humans of data such as that obtained from phenotyping 
genetically altered mice. Not only does the mouse heart beat ~10 times faster than the human 
heart, the action potential morphology is more triangular in shape and is almost 10 times 
shorter in duration. However, the ease of performing genetic alterations in the mouse 
provides a unique and powerful tool for extrapolating the function of specific genes in 
regulating cardiac excitability and arrhythmogenesis to the human, that is not yet readily 
available in other model organisms (sheep, dog, pig, rabbit, rat). However, the question has 
been raised as to whether or not the mouse is an appropriate model for investigating cardiac 
arrhythmia93. At the cellular level attempts have been made to anthropomorphize the mouse 
cardiomyocyte action potential, using a novel dynamic patch clamp method1, to behave like 
human cardiomyocytes. While this has potential for bridging the gap between studies in 
mouse and human at the cellar level, results gained from whole animal studies, while 
potentially informative, must be interpreted with caution. This however, has not stopped 
research into arrhythmia mechanisms using mouse models, as evidenced by an ever 
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expanding scientific literature on the subject. This thesis attempted to hone the use of whole 
animal (mouse) electrophysiological investigations, while exploring specific genetic factors 
influencing the neurogenic and myogenic components and their interrelationship, (the neuro-
myogenic interface) in atrial arrhythmia. In the following section, the electricity in the heart 
will be discussed with a focus on the major ionic constituents of the cardiac action potential, 
cardiac excitability and impulse conduction. Detailed comparisons of mouse and human 
cardiac action potentials are available elsewhere93. 
1.1 ELECTRICITY IN THE HEART 
 1.1.1 The Fast Response Cardiac Action Potential 
 Cardiac action potentials (AP) can be divided into two types, the fast response and the 
slow response types. Fast response action potentials occur in atrial, ventricular and Purkinje 
cells. Slow response action potentials are observed in the sinoatrial (SA) and atrioventricular 
(AV) nodes and will be discussed in the next section. The cardiac action potential has 5 
phases which are characterized by the dominant ion channel conductance during that phase. 
The action potential is initiated during phase 0, where the upstroke velocity (Vmax) of the 
AP characterizes the specific cardiac cell type as having either a fast or slow response. Fast 
response human and mouse myocardial cells have a rapid upstroke (human=216 V/s27, 
mouse=278 V/s94) produced by high conductance sodium channels (INa). The membrane 
potential becomes maximally depolarized (~20mV) during phase 1 which is followed by a 
brief rapid repolarization due to activation of the transient outward potassium current (Ito). 
The plateau phase (phase 2) is determined by a balance of inward calcium depolarizing 
current (ICa,L) and outward potassium hyperpolarizing currents (IKs, IKr, IK1). The interspecies 
variation in AP morphology is primarily due to this differences in the duration of the calcium 
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mediated plateau phase93 which is an important component of the long action potential 
duration (APD) observed in human (APD90= 297 ms27), relative to the mouse (APD90= 37.4 
ms94). Rapid repolarization occurs during phase 3 as calcium channels close, allowing the 
outward conducting potassium channels to act unopposed. The delayed rectifier potassium 
channels (IKs, IKr) in humans close during phase 3 and IK1 becomes the dominant current at 
the end of phase 3 returning the cell to its resting membrane potential (RMP, phase 4). At the 
RMP, myocardial cells are almost exclusively permeable to potassium ions K+, which drive 
the RMP close to the equilibrium potential for K+ (Ek= -94mV). The RMP of the human 
atrial myocardial cell was found to be -81.2 mV27, while the mouse is -76.8 mV94. During 
phase 4, the sodium channels inactivation gates move to the permissive position due to the 
hyperpolarized RMP and thus are prepared to fire another action potential. Following 
activation, all excitable cells enter a period in which another activation is impossible, known 
as the refractory period. The refractory period is divided into an absolute and a relative 
refractory period. No action potential can be generated during the absolute refractory period 
no matter the stimulus intensity due to the closure of the Na channels inactivation gate. The 
relative refractory period is determined by the time frame in which an action potential can be 
generated by a supernormal stimulus, and results from an incomplete recovery of Na+ 
channel from their inactivated state and a greater than normal (at rest) outward potassium 
conductance. All phases of the atrial cardiac action potential are sensitive to autonomic 
regulation by acetylcholine.  Importantly phase 4 is modified by activation of M2 muscarinic 
receptors and downstream G protein gated inward rectifier potassium channels (GIRK1/4 or 
IK, ACh). IK, ACh activation hyperpolarizes the resting membrane potential, having significant 
effects on the refractory period and thereby the duration of the AP. The autonomic 
"neurogenic" regulation of the cardiac action potential is an important factor regulating 
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electrophysiological properties and susceptibility to atrial arrhythmia and will be discussed in 
great detail in coming sections a swell as in Chapter 2 of this thesis.  
 1.1.2 The Slow Response Cardiac Action Potential 
 Slow response cardiac action potentials of SA and AV nodal cells are so named due 
to the slow rate of rise (Vmax) of the action potential in phase 0, relative to that of fast 
response cells. Slow response cells have limited Na+ channel expression and so phase 0 
responses are "slow" as they are carried by low conductance L-Type and T-Type Calcium 
(Ca2+) Channels (ICa,L) (ICa,T). Patch-clamp studies in isolated AVN cells show that ICa, L is a 
major constituent of the action potential (AP) upstroke63, 86, while IKr contributes to both AP 
repolarization and diastolic depolarization. The maximal diastolic potential of slow response 
SA and AV nodal cells are variable ranging from about -50 to -65 mV.  In the rabbit, two 
morphologically distinct populations of AVN cells were identified: ovoid cells which had 
Nodal or Nodal-His-like AP configurations, and rod-shaped cells that are Atrial-Nodal-like86. 
The rapid inward sodium current (INa) was found in all rod-shaped cells but in only 30% of 
ovoid cells. The diastolic membrane potential of SA and AV nodal cells is unstable and 
spontaneously depolarizes at rest, forming the basis of the intrinsic cardiac pacemaking 
activity. Genetic markers of pacemaking tissue (high: Cx30.2/Cx45/ HCN4/Tbx3, low: 
Cx40/Cx43/SCN5a) are expressed in both the mouse SA and AV node21. The If channel 
density is much greater in the SAN12, than the dominant AVN pacemaker region72, located in 
the posterior nodal extension35. This suggests that If channel expression density correlates 
with intrinsic pacemaker rate. The human AVN also contains HCN4, with little HCN4 
detected in the surrounding atrium132. Diastolic depolarization occurs in 2 phases, the early 
and late phase. A net inward current at rest is generated during these phases by two 
biological clocks named the membrane clock and the intracellular calcium clock. Interaction 
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between these two clocks (mutual entrainment) is the foundation of the proposed coupled 
clock pacemaker system70, allowing membrane events to regulate cytosolic function and vice 
versa. The membrane clock (M clock) initiates the early phase 4 diastolic depolarization due 
to the interplay of many time and voltage dependent ion channels. The M clock is formed by 
L-type Ca2+ channels (ICaL), T-type Ca2+ channels (ICaT), delayed rectifier K+ channels (IK), 
Na/Ca2+ exchanger (NCX) (INCX), and Na/K ATPase (INaK) and importantly the 
hyperpolarization-activated cyclic nucleotide-gated pacemaker funny channel (If). The Ca2+ 
clock operates based on the rhythmic oscillation of local Ca2+ release from the sarcoplasmic 
reticulum (SR) due to the interplay and status/function of SR calcium pumps (SERCA), 
calcium release channels, and ryanodine receptors (RyR)70. Spontaneous release of calcium 
raises cytosolic calcium levels to regulate activation of an inward Na+/Ca2+ exchange current 
(INCX) which greatly contributes to the exponential rise in membrane potential during the late 
diastolic depolarization70. Autonomic nervous regulation of these 2 mechanisms is important 
for normal heart rate control and response during rest and exercise70. The role of the 
autonomic/neurogenic influences in pacemaking will be discussed in following sections as 
well as in Chapter 4 of this thesis. 
 1.1.3 Determinants Of Cardiac Excitability  
 Cardiac excitability can be defined as the ability of a cell to fire an action potential. 
Excitibility is characterized by "the threshold response elicited by a square-wave stimulus of 
appropriate amplitude (strength) and time (=duration or pulse width)"44. Excitability of 
cardiac cells was examined by Cabo and Rosenbaum16 using the DiFrancesco-Nobel cardiac 
membrane model29. Excitability was determined by plotting combinations of values of 
electrical stimulus strength versus duration to form a "strength-duration curve", where values 
above the curve indicate the cell is excited. This concept becomes important when 
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considering source-sink relationships (due to excitatory inward currents and passive electrical 
properties respectively) and local current responses involved in influencing excitability and 
impulse propagation.  
 The level of cell excitability changes during the action potential, decreasing upon 
depolarization and gradually increasing upon repolarization. Excitability is therefore ". . . a 
measure of the current condition of the cell and how easy it is to generate an action 
potential"16. This effect of: ". . . the current condition of a cell . . ." can be observed by 
changing the timing of delivery of successive cardiac impulses, which illustrates the 
existence of a "rate-dependence" of cardiac electrical function (e. g. decremental conduction) 
and arrhythmia susceptibility, which is discussed throughout this thesis. Similar to the 
strength-duration curve, excitability can be measured by plotting the minimum current 
stimulus required to elicit an action potential against the timing or coupling interval of the 
previous action potential, forming the "strength-interval curve". Following complete 
repolarization to a steady-state level the strength-interval curve is near flat; however ". . . as 
the time interval decreases, stimulation threshold first decreases during the supranormal 
period and then sharply increases during the absolute refractory period"16. Biophysically this 
response can be understood in terms of the steady state voltage and time dependence of 
inactivation of the sodium channel53(which forms the upstroke of the action potential), and 
the changes in membrane conductance during the relative refractory period (increased K+ 
permeability) which increases the threshold for eliciting an action potential. The supranormal 
period occurs because during the late phase of repolarization the difference between 
membrane voltage and threshold are smaller, reducing the current necessary to generate an 
action potential. The frequency of action potential firing causes changes in action potential 
duration and amplitude. A decrease in both the amplitude and duration of the action potential 
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are observed with an increase in firing frequency, imposing a rate dependence on 
refractoriness16. This rate dependence of APD is commonly described by the "cardiac 
restitution curve", where APD is plotted against the basic cycle length of the stimulation.  
 The level of cardiac excitability is of critical importance as it determines how a 
propagating electrical wave front in the electrical medium of the heart will respond after 
breaking into two wavelets following the interaction with an electrical or anatomical 
obstacle. Due to the importance of excitability in the mechanisms of arrhythmia the 
interrelation of these concepts will be discussed briefly here and then again in Section 1.5. 
When an electrical wave breaks it has the potential to curl and rotate around the broken ends 
forming a circularly conducting spiral wave. These high frequency circularly conducting 
waves forms the basis of many rapid heart rates or tachycardias. Whether or not a broken 
wave will begin to rotate depends on the level of cardiac excitability. If excitability is too 
high, the broken waves will refuse. If excitability is too low, the broken wave will shrink as 
they propagate away and disappear (a phenomenon known as decremental conduction). 
However, if excitability is relatively low a broken wave can form counter rotating spirals 
thus generating a rapid arrhythmia58. 
 How individual cardiac cells are activated within the cardiac milieu depends on 
current transfer from one cell to another via gap junction channels and this is another 
component of cardiac excitability106. The degree and orientation (anisotropy) of cell-to-cell 
coupling regulates the source to sink relationships (cable properties) within the heart and is 
critically important to propagation of the action potential. The interrelation of cardiac 
excitability, gap junction channel conductance and impulse conduction are considered in the 
following section. 
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 1.1.4 Determinants Of Cardiac Conduction   
 The propagation of the cardiac action potential is determined by current source (Phase 
0) and sink factors (passive electrical properties/IK1), where a modification of either 
component alters the cardiac conduction velocity. These factors are considered in a model 
where two cells are connected end to end by intracellular gap junction channels. The current 
source is determined by the level of excitability while the passive electrical properties 
(important for current transfer between cells) include the cytoplasmic resistance and the gap 
junction channel resistance. As such gap junction discussed below are a critical determinant 
of cardiac conduction.  
 Gap junction channels are composed of 4 transmembrane domain proteins, connexins 
(Cxs), which oligomerize in the Golgi apparatus to form hexamers called connexons69. 
Connexons from adjacent cells dock, primarily at the intercalated disc forming low resistance 
channels that allow rapid propagation of electrical signals17. While 4 primary isoforms of 
Cxs are found in cardiomyocytes (mouse Cx30.2/ human Cx31.9, Cx40, Cx43, Cx45), only 
Cx40 and Cx43 are abundant in the working myocardium. The atrium expresses similar 
amounts of Cx40 and Cx43 71. Thus atrial gap junctions may have varying stoichiometry of 
connexin oligomerization. In a homomeric gap junction both connexons are formed by the 
same type of connexins. Heteromeric gap junctions have connexons with different types of 
connexins. Homotypic gap junctions have connexons are the same while heterotypic 
indicates they are different. In Chapter 3, the functional consequences of coexpression of 
Cx40 and Cx43, as well as their individual influences in determining the susceptibility to 
atrial tachycardia/fibrillation, will be discussed. Here I will summarize the role of gap 
junction channels in determining cardiac conduction velocity (θ) which include the degree of 
gap junction conductance and functional status of the channel (whether it is open or not).  
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These properties have been detailed by Robert Weingart in a recent text49 which was used as 
the primary source for the following summary.  
 As gap junctions form an intracellular connection between adjacent cells they allow 
the conductance of electrical current from cell to cell.  The degree of junctional conductance 
is determined by composition of the channel, and the regulation of that channel by intrinsic 
gating mechanisms.  These gates close in a voltage and time dependent manner upon 
exposure to a voltage gradient across the junction (transjunctional voltage) 49. These 
properties have been investigated utilizing dual patch clamp of cell pairs connected by gap 
junctions. With this dual patch clamp technique, the membrane potential of each cell (V1 and 
V2) can be controlled thereby setting up a voltage gradient across the gap junction (Vj) 49. 
The current passing through the gap junction (Ij) can be determined at different 
transjunctional voltages (Vj), and both the junctional conductance (gj=Ij/Vj) and voltage 
gating mechanism of various gap junctions (composed of different connexins) can be 
determined49. The results of these studies indicate that cardiac gap junctions tend to be open 
at rest (Vj=0 mV), and close in a voltage and time-dependent manner during the course of the 
action potential49. Depending on the stoichiometry of oligomerization, gap junctions can 
have unique gating and conductance properties 25 which are discussed below. There are two 
phases of the junctional conductance that occurs upon exposure to a transjunctional voltage 
gradient. Initially a large instantaneous current (Ij,inst) passes through the gap junction which 
rapidly decays to a second "steady state" current (Ij,ss) value49. The steady state junctional 
conductance (gj,ss) decays in a voltage dependent manner depending on the composition of 
the gap junction. This voltage dependent decay has a negative effect on cardiac conduction 
following a hierarchy where Cx45>Cx40>Cx43>Cx30.249. The time-dependent gating of gap 
junctions during the action potential also results in a reduction in conduction velocity49. This 
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inactivation follows a rank order where the effect of inactivation is greater for channels 
composed of Cx40<Cx43<Cx45<<Cx30.249.  As such it is likely that the voltage and time 
dependent gating will impose greater limitations on conductance for Cx40 containing 
channels then Cx43 containing channels in the atrium49.  This has important implications 
which must be considered when interpreting the results of the studies in Chapter 3. 
The above discussion described results for cell pairs connected by many gap junction 
channels, however studies have also been performed describing the properties of single 
channels.   These single channel properties are investigated using induced cell pairs where 
the experimenter will patch individual cells and position them next to one another. The first 
occurrence of cell-to-cell conductance represents a single newly formed gap junction 
channel. It was found that the single channel conductance (γj) fluctuates between a main state 
(γj,main) and a residual state (γj,residual) where γj,main is greater then γj,residual
49. The comparison of  
results from many studies of homomeric-homotypic gap junction channels has revealed that 
γj,main and γj,residual follow a rank order where Cx40>Cx43>Cx45>Cx30.249.   
The contribution of different gap junctions in determining cardiac conduction velocity 
will rely on their static and their dynamic properties. In general, reduced channel number 
(structural change), or either reduced channel conductance or increased voltage sensitivity 
(functional changes) will reduce conduction velocity. The dynamic factors have been 
describes as being more complex depending on a number of parameters including the 
interplay of voltage and time dependent gating properties of individual channels49.   
 Within the heart, the effect gap junctions have on the propagation velocity of a 
cardiac action potential will depend on a number of factors including cell geometry, tissue 
architecture and the action potential characteristics. Conduction velocity depends critically 
on the length of the AP upstroke, the voltage gradient along the tissue axis, the number of 
 11 
gap junctions sensing the voltage gradient, and the actual voltage across single gap 
junctions49. There is a complex interrelation between the cardiac action potential (sections 
1.1.1-1.1.3) and the composition and functional status of gap junction channels in 
determining conduction velocity. These concepts are worth noting because, in general, 
reduced cardiac conduction velocity and excitability promotes arrhythmia. In the following 
section I discuss the role of the autonomic innervation of the heart, neural transmitters and 
the associated G-protein coupled receptors, G proteins, and regulator of G protein signalling 
(RGS) proteins that regulate the downstream effectors (ion channels, adenylyl cyclase) that 
influence cardiac electrical properties and arrhythmia. 
1.2 AUTONOMIC REGULATION OF CARDIAC ACTIVITY 
 1.2.1 Anatomy Of Cardiac Autonomic Innervation 
 This thesis is mostly concerned with the role of the parasympathetic autonomic 
nervous system’s influences on cardiac arrhythmia susceptibility. However, the heart 
receives both sympathetic and parasympathetic efferent innervations as well as having the 
ability to process information internally via an intrinsic intracardiac autonomic nervous 
system (ICANS). The ICANS may interact with the efferent nerve supply in a complex 
fashion to regulate cardiac function and is thought to act as a "mini-brain" on the heart. 
Subpopulations of intrinsic cardiac neurons express multiple neurotransmitters50; however, in 
Guinea pig posterior ganglia, choline acetyltransferase immunostaining of all neurons 
indicates major parasympathetic cholinergic input to the myocardium79. These neurons of the 
ICANS are primarily located in 5 groups of atrial ganglionated plexi (GPs) which have been 
described by Arora et al.6 and may represent areas of local control of cardiac muscle. The 
hetergeneous distribution of GPs could be considered the first level of the heterogeneous 
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autonomic regulation of cardiac function.  These factors are important in promoting 
arrhythmia and will be discussed in Section 1.5 on atrial tachycardia/fibrillation. Although 
close contact of the neuron with muscle does not mean exclusive control of the adjacent area, 
it is an important consideration. The necessity of close proximity for neural control is 
consistent with the “local brain” in the intestinal tract40. This postulate has been examined 
using subthreshold stimulation of cardiac GPs and has revealed local control over the 
duration of refractory periods. Below I discuss the function and role of acetylcholine-
activated muscarinic G protein-coupled receptors and their effectors in the heart.  
 1.2.2 G Protein-Coupled Receptor Signalling  
 G protein-coupled receptors (GPCRs) are 7 transmembrane domain cell surface 
receptors that bind extracellular ligands (hormones, neurotransmitters, and drugs) and 
transduce signals into the intracellular environment. There are approximately 864 genes in 
the human which encode for GPCRs81. These GPCRs control most physiological process in 
the body126 and are targets of >60% of the available pharmaceutical agents44, 71. Most 
sympathetic and parasympathetic receptors are members of the GPCR superfamily which 
couple to various downstream signalling cascades including those controlling adenylyl 
cyclase, Ca2+ homeostasis, and ion channels126. In the heart, GPCRs control chronotropic 
(rate of contraction), inotropic (strength of contraction), lusitropic (speed of relaxation), and 
dromotropic (velocity of conduction) responses to acetylcholine and adrenaline126. Ligand 
binding will either stabilize or induce a conformational change in its GPCR that will activate 
a coupled intracellular heterotrimeric G protein (Gαβγ). There are 4 families of mammalian 
heterotrimeric G proteins including Gsα, Gi/oα, Gq/11α, and G12/13α with various subtypes, 
effectors and expression profiles81. When in an inactive state, the G protein is bound to GDP, 
forming a Gα-GDP-Gβγ complex. The Gα-GDP conformation is stabilized by the Gβγ 
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subunit, which acts as a GDP dissociation inhibitor (GDI), explaining the slow release of 
bound GDP from the complex. The release of GDP and activation of the Gα subunit is 
accelerated by guanine nucleotide exchange factors (GEFs) which catalyse GDP/GTP 
exchange at heterotrimeric G proteins (Gαβγ). The GEFs for most G proteins are GPCRs; 
however, intracellular GEFs have been identified130. Activation promotes a conformational 
rearrangement, or potentially dissociation of the heterotrimer into a free, GTP-liganded Gα 
and the Gβγ dimer124, both of which can regulate downstream effectors. Whereas GTP 
binding promotes activation, the on-switch of G protein signalling, GTP hydrolysis (GTP to 
GDP + P) controls the rate at which G protein signalling is switched off. The hydrolysis of 
bound GTP by the intrinsic catalytic activity of the Gα subunit is slow (t1/2= ~9 seconds to a 
few minutes). In order to maintain fast and efficient signal transduction, this deactivating step 
can be accelerated by GTPase activating proteins (GAPs) more than 1000 fold. The GAPs for 
G proteins are effector proteins such as phospholipase Cβ (PLCβ) and the regulators of G 
protein signalling (RGS) proteins. The efficiency of GAP activity on G proteins can be so 
high that G protein signalling and downstream effector activation can be completely 
supressed104. Studies of the kinetics of these reactions indicate that in order for downstream 
effectors of G-proteins to be activated in the presence of a GAP, the GAP must potentiate 
both the rate of GTP hydrolysis and the rate of receptor stimulated GTP binding, supporting 
the general concept of GAPs as accelerators104. As such, understanding how the timing of the 
activation and hydrolysis reactions are regulated is fundamental to understanding the role of 
G protein signalling in disease. For instance, an increased activity of an effector (such as 
GIRK1/4) downstream from a GPCR (M2 Muscarinic receptor) that promotes a disease state 
(Atrial Fibrillation) could be caused by multiple events such as: 1) increased ligand 
(acetylcholine) availability (by stimulating the vagal nerve or inhibiting acetylcholine 
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esterase); 2) mutation in the GPCR that increases its intrinsic activity of the receptor (such as 
in precocious puberty); 3) increased levels of GPCRs, G proteins or effectors, or 4) reduced 
content or activity of GAPs (RGS proteins). In the following sections, the atrial muscarinic 
receptors, associated effectors, and their regulation by RGS proteins are discussed. 
1.2.3 Atrial Muscarinic Acetylcholine Receptors And Effectors 
 Five different types of muscarinic acetylcholine receptors (mAChRs) have been 
cloned. M1, M3, and M5 receptors are Gαq coupled receptors, while M2 and M4 receptors 
are Gαi/o coupled. The classical notion is that the cardiac mAChR are exclusively of the M2 
subtype; however, there is increasing evidence supporting an important functional role of M3 
receptors111, 123. M3 muscarinic receptors were first identified in human atria in 2000 by 
Hellgren and coworkers51. In 2002 a Czech group attempted quantification of M1-M5 
muscarinic subtype mRNAs in rat atria utilizing the older competitive RT-PCR. Their results 
indicated that M2 mRNA represented more than 90% of the total muscarinic mRNA in the 
atria, while M3 was less than 3%68. More recent studies using quantitative PCR have also 
reported low level expression of M1, M4 and M5 muscarinic receptors in the atria, but this 
may be due to low level DNA contamination as RNA is most studies was not treated with 
DNAse 65. The functional consequence of co-expression of multiple muscarinic receptor 
types has been the focus of many studies discussed below, the most compelling of which use 
genetic M2 and M3 receptor knockout mice. 
 In the heart, the muscarinic type 2 (M2) receptors inhibit adenylyl cyclase (AC) 
activation and induce activation of the G protein-coupled inward rectifier K+ channel 
(GIRK3.1/3.4 or IK, ACh)67 by Gβγ released from Gαi. Inhibition of adenylyl cyclase production 
of cAMP reduces the activity of If (a cAMP dependent current) and the L-type Ca2+ current 
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(ICa, L) through Gαo. . ICa, L is also regulated by Gαi and nitric oxide13, 14.  It was also found 
that Adenylyl cyclase 5 deficient mice have a reduced ICa, L activity97. Further more, studies 
in Gαi2 knockout mice found that these mice lack muscarinic regulation of ICa, L
19. In the 
atria, activation of IK, ACh increases membrane K+ permeability, facilitating an outward 
current that hyperpolarizes the cell and reduces the action potential duration. There is a 
gradient of IK, ACh current in the mouse atria that, when combined with the heterogeneous 
distribution of parasympathetic ganglia (section 1.2.1), may augment the dispersion of atrial 
refractoriness 74. The dispersion of atrial refractoriness was mapped optically in mouse96. 
These studies revealed that APD was shorter in the left than the right96 atrium and that CCh 
could reduce APD in all areas except the left atrial appendage. The role of IK, ACh in the 
atrium was also determined using GIRK4 knock out (GIRK4-/-) mice which lack functional 
IK, ACh channels. GIRK4-/- mice have abnormal heart rate regulation 125and are resistant to 
CCh-induced atrial fibrillation67. In the SAN, IK, ACh hyperpolarizes the membrane potential, 
and decreases the pacemaker pre-potential slope, which contributes approximately 50% to 
the in vivo bradycardic response. M2 receptor activation of Gαi inhibits adenylyl cyclase, 
decreasing cyclic adenosine monophosphate (cAMP) production, which reduces protein 
kinase A (PKA) activation67. PKA, through phosphorylation, increases the activity of ICa, L 
and the rapid delayed rectifier potassium channel (IKr), which promotes repolarization during 
the plateau phase of cardiac action potential (AP)116. The inhibition of IKr prolongs AP 
duration23. In summary, the functions of the M2 receptor include activation of IK, ACh 
(hyperpolarization), inhibition of IKr (prolonging repolarization), and inhibition of If 
(negative chronotropy)49. 
 On the other hand, M3 muscarinic receptors couple to Gαq to activate PLC, PKC and 
IK, M3111. To date, IK, M3 is the only identified K+ channel activated by Gαq. IK, M3 current is 
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highly selective for K+. IK, M3 has delayed rectifier properties with a relatively slow activation 
time constant (approximately 150 ms at +50 mV), which is followed by a partial and slower 
decay123. The tail current is characterized by an initial rapid rising phase followed by a slow 
decay with a mean time constant of ~170 ms112. The waveform is similar to that of IKr; 
however, it is insensitive to the IKr blockers dofetilide and E-4031, and to the slow delayed 
rectifier K+ current (IKs) inhibitor, chromanol 293B. IK, M3 is blocked by the non-selective 
muscarinic antagonist, atropine123 and the M3 selective antagonist, Darifenicin (used in 
Chapter 2 and Chapter 3 experiments)122, 123.  
Of special note, M3 receptor distribution was more confined to the intercalated disk 
region123, and thus was suggested to regulate ventricular gap junction-mediated cell-to-cell 
conduction122.Yue et al. (2006)129 found physical and functional interactions between M3 and 
connexin 43 (Cx43) in rat ventricular myocytes, which were impaired during myocardial 
ischemia. Gap junction remodelling is an essential component promoting atrial as well as 
lethal ventricular tachyarrhythmias28, 32, 33, 46, 113. The functions of the cardiac M3 receptors 
suggested so far include: [1] depressed inotropy; [2] protection against myocardial ischemia; 
[3] regulation of cell-to-cell communication, and [4] participation in the generation and 
maintenance of AF123. Using the M3 receptor antagonist 4-DAMP, Wang et al., (2004)123, 
concluded that the M3 receptor does mediate, in part, the bradycardic response to vagal 
stimulation. However, the pKb of 4-DAMP for M3 is 8.9-9.3, only one order of magnitude 
greater the pKb for M2 receptors (7.8-8.4). Perhaps the weak inhibition of vagal bradycardia 
with high dose 4-DAMP used in Wang’s study was due to blockade of M2 rather than M3 
receptors. Vagal induced bradycardia was completely abolished in M2 muscarinic receptor 
(M2-/-) deficient mice but was not affected in M3 muscarinic receptor (M3-/-) deficient 
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mice37. However, this does not exclude a role for M3-mediated modulation of atrial or AVN 
function, as analysis of atrial or AVN function was not done. 
 The functional consequence of co-expression of M2 and M3 receptors in the atria was 
studied in M2-/-, M3-/- and M2/M3 double deficient (M2-/-/M3-/-) mice. In wild type mouse 
atria, CCh induces a negative inotropic response followed by a sustained positive inotropic 
response. M3-/- mice were devoid of the positive inotropic phase while M2-/- mice had only a 
positive inotropic response to CCh. M2-/-/M3-/- double knockout mice were devoid of any 
inotropic response65. The susceptibility to arrhythmia was not studied in these mice. These 
results strongly indicate that functional M3 muscarinic receptors are present in the atria. 
 The well known vagal modulation of AV nodal function24, 80 has long been attributed to 
M2 coupled IK, ACh24, 35. In the AVN, it is suggested that activation of IK,ACh causes 
hyperpolarization mediated inhibition of voltage-gated ICa, L63. However, there is conflicting 
evidence in the literature on muscarinic regulation of AVN function. Tertiapin-Q, a bee 
venom derived peptide43, potently inhibits the IK, ACh current60. In isolated guinea pig hearts, 
tertiapin abolished CCh-induced prolongation of PR interval31. However, His bundle 
electrograms were not measured, which is important for determining the site of block within 
the node, and neither were AVN effective refractory periods (AVNERP), nor Wenkebach 
cycle lengths (WCL). Kir3.4 deficient mice which lack functional IK, ACh channels, were 
primarily developed to determine the role of IK, ACh in AF67. When challenged with CCh, no 
significant difference in the changes in the AV interval, WCL, or AVNERP were found in 
the knock out compared to wild type (WT) mice.  This suggests that IK, ACh is not involved in 
autonomic control of AV nodal conduction. These conflicting observations have neither been 
explained nor previously discussed. It must be asked, "how is autonomic mediated 
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modulation of AV nodal conduction accomplished if IK, ACh is not involved?". Studies in mice 
deficient in Cav1.3, the atrial selective ICa, L isoform, have been found to have prolonged 
AVN conduction and loss of isoproterenol-induced enhancement of AVN conduction78. 
These observations, taken together, suggest that autonomic regulation of AVN conduction 
may principally involve modification of ICa, L. Regulation of ICa, L occurs: [1] through 
phosphorylation by PKA and PKC128; [2] by the voltage dependence of ICa, L, and [3] through 
modulation by Ca2+-calmodulin. If M3 muscarinic receptors are involved in regulating AV 
nodal function it could be through a PKC mediate modulation of ICa, L128. 
 In the following section I consider the role regulators of G protein signalling play in 
autonomic regulation of atrial function and arrhythmia. 
1.2.4 Atrial Regulators of G Protein Signalling (RGS) Proteins 
Regulators of G Protein Signalling (RGS) proteins were first identified as GTPase 
activating proteins (GAPs), accelerating the intrinsic GTPase activity of Gα subunits, as the 
duration of G protein activation is primarily controlled by GTP hydrolysis. Also, RGS 
proteins can interfere with G-protein binding to effector proteins, separate from their 
regulation of hydrolysis55. Thus RGS proteins are important regulators of GPCR signalling. 
Currently, 20 different genes encoding RGS proteins have been identified. The RGS proteins 
have been divided into 4 subfamilies, based on sequence and structural similarities: RZ/A 
(RGS17, 19 and 20); R4/B (RGS1–5, 8, 13, 16 and 21); R7/C (RGS6, 7, 9 and 11), and 
R12/D (RGS10, 12 and 14)8. The majority of RGS proteins are GAPs for Gαi/o and many 
also act on Gαq/1189; however, none are GAPs for Gαs but some RGS-like proteins such as 
p115RhoGEF do have GAP activity on the Gα11/12 subfamily. RGS2, 3, 4, 6, 10, RGSZ2 
and GAIP are all found in atrial cardiomyocytes30. To investigate the role of RGS proteins in 
regulating the chronotropic effects of adrenergic, muscarinic and purinergic receptor 
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stimulation, mutant Gαi and Gαo proteins were generated that are insensitive to binding of all 
RGS proteins39. Knockin cells expressing the Gαi2GS/GS insensitive mutant had an 
enhanced responses to M2 muscarinic but not A1 adenosine receptor stimulation, while the 
GαoG184S insensitive mutant had enhanced A1 adenosine and M2 receptor mediated 
responses39. Interestingly, Gαs stimulation of beating rate was almost completely abolished 
in the Gαi2GS/GS insensitive mutant cells. Gαi2GS/GS insensitive mutant mice also 
displayed pronounced (5 fold greater) muscarinic mediated bradycardia and 3rd degree AV 
nodal block38. These data from Gαi2-RGS-insensitve mutant mice indicate that in the SAN 
and AVN, M2 receptors primarily couple through Gαi2 to inhibit cAMP production and 
activation of PKA38, 39. Adenosine 1 and 3 receptor overexpressing mice have also have 
prolonged AVN conduction36, 64, which may involve receptor-mediated inhibition of adenylyl 
cyclase 5/6 (AC5/6), primarily coupling through Gαo38, 39. Susceptibility to atrial arrhythmia 
has not been examined in these mice. It is currently believed that specific RGS proteins may 
couple to specific signalling pathways within the cell. To explore the specific role of RGS 
proteins in regulating various signal transduction pathways in vivo, knockout mice for 3 
(RGS2, RGS4 and RGS6) of the 7 atrial RGS proteins (RGS2, 3, 4, 6, 10, RGSZ2 and GAIP) 
have been developed. These mice have revealed the critically important role of RGS proteins 
in regulating the specific autonomic responses in the atria. These functions are discussed 
below with attention paid to RGS2 as study of atrial arrhythmia in the RGS2 deficient 
(RGS2-/-) mouse is the topic of Chapter 2 of this thesis. 
RGS2, a member of the R4/B subfamily, is the second most highly expressed RGS 
protein in the heart30. RGS2 is a unique RGS protein as it is a selective GAP for Gαq134, and 
has little to no GAP activity on Gαi/o. RGS2 has also been identified as a regulator of AC 
signalling114. In HEK 293 cell culture, RGS2 inhibited Gαs stimulation of AC5 and AC6105, 
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108. The mechanism was not through its GAP activity, but rather through a physical 
interaction of the N-terminus of RGS2 with the C1 catalytic loop of AC59, 108.  Increases in 
cAMP levels produced by forskolin treatment increased RGS2 expression99. The potential for 
a role of RGS2 inhibition of AC signalling in the AV node is considered in Chapter 4. 
Removal of RGS2’s inhibitory effect on Gαq signalling increases the activity of Gαq-
dependent signalling. Interestingly, RGS2 has also been revealed as an important target in 
cardiovascular disease118 (cardiac hypertrophy and hypertension). RGS2-/- mice have a 
hypertensive phenotype52, 98 that is suggested to be mediated by vascular changes, possibly 
through angiotensin II, endothelin and/or α-adrenergic receptors, rather than cardiac 
alterations. However, direct analysis of cardiac “contractility”, by measuring left ventricular 
dP/dt, was not done in these mice52, 98. Chronic telemetry found an increase in mean arterial 
pressure of ~10 mm Hg, while heart rate was unchanged, indicating a resetting of the 
baroreceptor reflex45. This was confirmed by directly measuring baroreflex sensitivity 
calculated by cross-spectral analysis of heart rate variability. Heart rate variability was not 
different in RGS2-/- compared to RGS2+/+ mice45. This indicates that any observed cardiac 
phenotype cannot be explained by a baroreflex mediated enhancement of vagal nerve 
activity. As RGS2 is a specific regulator of Gαq signalling, it is possible that it is an 
important regulator of M3 muscarinic signalling in the atria. This indeed seems to be the case 
and is discussed in detail in Chapter 2. 
 Recently, RGS4 was demonstrated to be an important regulator of SAN function22. RGS4 
in the SAN inhibited parasympathetic signalling and IK, ACh activity. In mice expressing LacZ 
under control of the RGS4 promoter, high expression of LacZ-RGS4 was found in the SAN 
will little expression in the surrounding right atrium. RGS4-null (RGS4-/-) mice had lower 
baseline heart rates and a greater increase in heart rate following administration of atropine, a 
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non-selective parasympathetic antagonist. High expression of RGS4 was also present in the 
in the AVN (demonstrated using LacZ staining) suggesting that altered dromotropic 
responses (increased PR interval) might be observed in RGS4-/- mice.  This was found to be 
the case as RGS4-/- mice were highly susceptible to AVN conduction block when treated 
with isoproterenol; however, there is limited electrophysiological data describing this 
phenotype (location of conduction block) and results were obtained principally in 
Langendorff hearts (removed from in vivo autonomic influences). 
 As RGS4 was found only in the SA and AV nodal region, the RGS protein regulating 
parasympathetic signalling and IK, ACh activity in the atrium remained, until recently, 
unknown. RGS6-deficient (RGS6-/-) atrial myocytes exhibited a significant reduction in the 
time course of IK, ACh activation and deactivation. RGS6-/- mice also displayed bradycardia 
and AV nodal conduction block indicating that there is at least partial redundancy in RGS 
protein function in vivo. It would be interesting to compare the susceptibility to atrial 
arrhythmia between the RGS-insensitive-Gαi2 knockin, RGS4-/- and RGS6-/- mice, however 
studies of this nature have not yet been published.  
1.3 CLASSIFICATION OF SUPRAVENTRICULAR TACY-ARRHYTMIAS  
Cardiac arrhythmias (abnormal heart rhythms) can be organized and slow (bradycardia), 
organized and fast (tachycardia) or disorganized and fast (fibrillation). These arrhythmias are 
further classified by where they occur in the heart, i.e., either in the ventricles, or above the 
ventricles (supraventricular arrhythmia).  
Supraventricular tachycardias (SVT) are commonly seen in clinical settings. The 
different types of SVTs have been classified based on their anatomic location (sinus node, 
atrio-ventricular node, and atrial myocardium) and the apparent mechanism of the arrhythmia 
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(abnormal impulse initiation (focal) or abnormal impulse conduction (reentry)). The 
following is a non-exhaustive list of supraventricular tachy-arrhythmias, many of which will 
be discussed in this thesis: atrial tachycardia (AT, atrial myocardium/focal or multifocal 
arrhythmia), inappropriate sinus tachycardia (IST, sinus node/focal arrhythmia), junctional 
tachycardia (JT, AV node/focal arrhythmia, also called junctional ectopic tachycardia, JET), 
atrial flutter (AFl, atrial myocardium/anatomic re-entry), atrio-ventricular nodal re-entrant 
tachycardia (AVNRT, AV node/functional anatomic re-entry), and atrial fibrillation (AF, 
atrial myocardium/both focal and functional re-entrant mechanisms proposed). All atrial 
arrhythmias are produced by abnormalities of either cardiac impulse initiation, impulse 
conduction or both. In the following sections, the mechanisms of abnormal impulse initiation 
and impulse conduction will be discussed. 
1.4 ABNORMAL IMPULSE INITIATION 
Abnormal impulse initiation falls into three categories; enhanced normal 
automaticity, abnormal automaticity and triggered activity. Within the atrium, SA and AV 
nodal cells have an intrinsic ability to self activate (pacemaker activity/automaticity). A 
hierarchy of pacemaking activity exists within the human atrium, where firing rate is fastest 
in the SA node, 60-100 beats per minute (bpm), and slower in the subsidiary AV node 
pacemaker (40-60 bpm). This normal automaticity is tightly regulated by autonomic 
influences. Parasympathetic vagal stimulation (primarily acetylcholine) leads to a decrease in 
the slope of phase 4, the action potential upstroke velocity and thus heart rate (<60 bpm). 
Enhancement of normal automaticity occurs during parasympathetic withdrawal and 
sympathetic activation, which results in an increase in the slope of phase 4 with increases in 
rate to over 200 bpm. Metabolic abnormalities such as hypoxia (inhibits Na+-K+ pump) and 
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low extracellular K+ concentration can increase the slope of phase 4 depolarization causing 
enhancement of normal automaticity. As discussed above, SA and AV nodal cells have 
automaticity, whereas normally, contractile atrial myocardium does not, and thus 
automaticity there is considered abnormal. Abnormal automaticity arises from atrial cells 
when they are depolarized to levels between -60 to -10 mV. Depolarization induced 
abnormal automaticity may result from a decrease in K+ conductance allowing a net inward 
depolarizing current58.  
 Triggered activity is a mechanism of abnormal impulse generation that is caused by 
afterdepolarizations of the cardiac action potential. Afterdepolarizations can be defined as 
depolarizing oscillations in membrane potential that are dependent on the preceding action 
potential and can give rise to a new action potential120. Two types of afterdepolarization have 
been described, delayed afterdepolarizations (DADs) and early after depolarizations (EADs), 
named in relation to the phase of the action potential in which they occur. DADs are 
oscillations in membrane potential that occur following repolarization of the action potential 
while EADs occur during the action potential plateau (phase 2) or during the late phase 3 
repolarization120. Whether or not an afterdepolarization will "trigger" an action potential 
depends on the level of the membrane potential in which they are generated as well as the 
electrotonic interactions between inexcitable tissue with areas that have already recovered 
from refractoriness 58. In general, DADs are caused by conditions that lead to intracellular 
Ca2+ overload, and have found to be inducible by β-adrenergic stimulation (sympathetic 
response). β-adrenergic stimulation, among other things, increases the L-Type Ca2+ current 
which can lead to Ca2+ overload and activation of the transient inward current (ITI) through a 
Ca2+-dependent non-specific ion channel. ITI activation forms the major component of the 
DAD. EADs can result from factors that prolong action potential duration or result in a net 
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increase in inward current58. The latter can occur though β-adrenergic augmentation of the L-
type Ca2+ current while cholinergic (parasympathetic/vagal) stimulation can suppress EADs 
and triggered activity 58. 
 The abnormal initiation of a cardiac impulse is the "trigger" of many arrhythmias that 
involve the abnormal propagation of the cardiac impulse (reentry).  The factors leading to 
abnormal impulse propagation are discussed in the following section. 
1.5 ABNORMAL IMPULSE PROPAGATION (REENTRY) 
Abnormal impulse propagation occurs due to the slow conduction of cardiac impulses 
or when the same electrical activation front repetitively reactivates an area of tissue. The 
reactivation of tissue by the same wavefront or the reentry of an impulse into an area can be 
due to circular conduction around a circuit or the reflection of cardiac impulses along a linear 
pathway. Reentry along a linear pathway, called reflection reentry, requires the presence of 
severely impaired conduction or a narrow gap of refractory tissue5. Reflection is the back and 
forth activation of tissue across this gap due to passive electrotonic depolarizations. 
Reflection, within the accessory (atrio-ventricular) pathway of patients with manifest pre-
excitation in Wolff-Parkinson-White (WPW) syndrome, is a suggested mechanism of AF 
initiation and may explain the propensity of AF in this patient population109. Circular 
conduction, a more common form of reentry, can occur when electrical impulses propagate 
around a circuit and is also called circus movement reentry. Due to the rapidity of the circular 
conduction, which is dependent on the conduction velocity of the impulse and the size of the 
circuit, reentry results in high frequency repetitive activation of the myocardial substrate. 
Circular reentry often involves the conduction of a cardiac impulse around a predetermined 
circuit formed by an anatomic obstacle. Reentry that occurs in the absence of a 
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predetermined circuit is called functional reentry. Two examples of reentrant arrhythmia 
requiring an anatomic obstacle is that of AV reciprocating tachycardia (AVRT) in WPW 
syndrome, and atrial flutter (AFl). The anatomical circuit in AVRT involves conduction 
between the normal conduction system (atrium, AV node and ventricle) and an abnormal 
accessory pathway that directly links the atrium to the ventricle (AV pathway). Interrupting 
the circuit in WPW by destroying the accessory AV pathway surgically or by application of 
radiofrequency energy with a transvenous "ablation" catheter cures AVRT. In the anatomic 
circuit of typical AFl, a "critical isthmus" exists between the tricuspid valve annulus, the 
inferior vena caval orifice, the eustachian ridge, and the coronary sinus ostium. This isthmus 
is critical because ablation of this region terminates AFl. The rest of the circuit is bound by 
the triscupid valve ring, and the venae cavae. Reentry in AFl is not purely anatomic in origin 
as functional lines of block between the vena cavae or in the sinus venous region is important 
in the arrhythmia mechanism. 
A number of conditions must be met in order to achieve circus movement reentry 
around an anatomic circuit including: unidirectional block; slow conduction in one part of the 
circuit; and a wavelength that is shorter than the length of the circuit. These conditions are 
true of AVNRT which is discussed in Chapter 4 of this thesis. These conditions can usually 
be promoted by the abnormal "early" initiation of a cardiac impulse (Section 1.4). Blocked 
conduction in one direction (unidirectional) of an anatomic circuit allows circular conduction 
to be initiated, and in most cases occurs in the region with the longest refractory period 
(uncovered by the premature impulse). Slow conduction in one part of the circuit also 
facilitates the initiation of reentry as it allows other parts of the pathway to recover from 
refractoriness so that they can be re-activated by the reentrant impulse. 
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If the conduction time around the circuit is not long enough, the wavefront will 
collide with the refractory tail of the previous activation cycle and reentry will be terminated. 
This fact indicates an important concept in reentry known as the wavelength. The wavelength 
(λ) describes the minimum length of an electrical activation wave (from wave front to wave 
tail) within a predetermined circuit, necessary for reentrant activation to occur and is a 
product of the conduction velocity (CV) of the electrical impulse and the effective refractory 
period (ERP) of the tissue where, "λ =CV x ERP”2. If the wavelength is shorter than the 
length of the circuit, reentry will be stable and a gap of excitable tissue will be present 
between the wave front (depolarizing tissue) and the wave tail (repolarizing tissue). An 
externally delivered stimulus (from a electrode catheter) has the ability to invade this 
excitable gap and advance the time of the next cycle (entrainment) or terminate reentry by 
advancing the wavefront to a point at which it collides with refractory tissue. Clinical 
diagnostic catheter based electrophysiological studies rely on the concept of an excitable gap, 
where premature pacing that terminates an arrhythmia or demonstrates entrainment confirms 
a reentrant arrhythmia mechanism.  This concept is used in studies throughout this thesis 
(Chapter 2, Chapter 3 and Chapter 4) 
Reentrant activation occurring in the absence of a predetermined anatomic circuit is 
known as functionally determined reentry. Investigation of the leading circle model2 of 
functional reentry was the first to present experimental evidence for the presence of reentry 
in the absence of an anatomical obstacle. In this experiment, a reentrant tachycardia was 
initiated in an isolated rabbit left atrium using programmed electrical stimulation with 20 
impulses delivered at a coupling interval of 500 ms (the S1 stimuli) followed by an 
extrastimulus (the S2) delivered with an S1S2 coupling interval near the refractory period of 
the atrium. This technique is also used throughout this thesis (Chapter 2 and Chapter 3) to 
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induced and study atrial tachycardia/fibrillation (AT/F) in the mouse. By compiling 
electrogram recordings from over 300 sites, functional circus movement reentrant activation 
was observed for the first time2. The leading circle model attempted to explain this finding 
by hypothesizing that a functional zone of refractory tissue was present at the centre of 
rotation due to a continual electronic depolarization2. In this leading circle model, the 
wavefront must propagate through relatively refractory tissue where there is no fully 
excitable gap and the wavelength will be close to the length of the circuit. As a result of a 
lack of an excitable gap, this type of reentry would be very difficult to terminate with an 
externally delivered electrical stimuli. This model was found to not adequately describe 
many of the properties of functional reentry 58, including reentry in mouse atria (where the 
calculated wavelength is larger then the size of the atria), and the susceptibility to termination 
with electrical pacing (requiring an excitable gap). The leading circle hypothesis was 
however of great influence, driving research that lead to the concept of rotors and the spiral 
wave hypothesis of functional re-entry. A rotor in the context of functional re-entry is the 
organizing source (driver) of functional re-entrant activity. It is described as "the structure 
immediately surrounding the pivot of a rotating wave in two or three dimensions"58. A rotor 
is the source of spiral waves of excitation that propagate around the rotation centre. Rotors 
form when a propagating electrical wave “breaks” on an anatomical or electrophysiological 
heterogeneity, and under appropriate conditions of excitability (not too high or not too low, 
Section 1.1.3), begins to rotate 59, 119. The spiral wave hypothesis explains many properties of 
functional reentry which are not easily resolved by the leading circle hypothesis including, 
among other things, the presence of an excitable gap and functional reentry in the atria of 
mice (Chapter 2 and Chapter 3). 
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Importantly, many modifiable factors have been identified which may explain the 
initiation of reentrant tachy-arrhythmias in the atrium including the dispersion of 
refractoriness, altered conduction velocity/current source-sink relationships, and the degree 
of myocardial excitability. In the following section I will discuss in depth two specific 
supraventricular tachyarrhythmias, atrial tachycardia and atrial fibrillation, which rely on 
abnormal impulse initiation and conduction for their initiation and maintenance. 
1.6 ATRIAL TACHYCARDIA/FIBRILLATION 
 AT/F have distinct clinical diagnoses but as I will discuss these two arrhythmias may 
lie amongst a progressive mechanistic spectrum. Clinically, the major difference between the 
two arrhythmias is that the electrical activity of AT on the ECG is rapid and organized while 
AF is rapid and disorganized. This simple observation suggests that the underlying 
mechanisms of AT are deterministic while the presumed complexity and dynamic nature of 
AF alludes to a stochastic mechanistic nature. The stochastic mechanistic view was 
predominant for over 50 years and proposed that AF relied on multiple reentrant wavelets90. 
However, optical mapping studies of AF in isolated sheep atria have found that AF may 
involve both deterministic (a high frequency "mother rotor") and stochastic components 
(fibrillatory conduction of multiple wavelets spawned from the deterministic driver)56, 66. 
Remodelling of the atria may promote stochastic fibrillatory conduction (the propagation of 
multiple wavelets) as "AF begets AF" indicating that atria remodelling promotes sustained 
disorganized activity. In fact atrial tachycardia remodelling with rapid electronic pacemakers 
is commonly used experimentally to induce a fibrillatory substrate, indicating that AT and 
AF may belong to a progressive spectrum85, 110 of arrhythmogenesis. Atrial fibrillation relies 
on the interaction of triggers, perpetuators and substrate for initiation and maintenance of the 
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arrhythmia3. Triggers combined with dynamic substrates of structural heterogeneities, 
reduced refractoriness, enhanced spatial dispersion of refractoriness and abnormal impulse 
conduction, to initiate and perpetuate the arrhythmia92. As AT and AF may be related it is not 
surprising that focal atrial tachycardia originating from the pulmonary veins accounts for 
16% of focal AT, 78% of left atrial ATs and more than 90% of AF triggers48. 
 Abnormal impulse initiation and conduction contribute to the mechanism of AT, but 
are also involved in the initiation and maintenance of AF. Atrial tachycardia is an uncommon 
cause of supraventricular tachycardia, occurring in only 5% of adult and 10-15% of 
paediatric patients 49. Atrial tachycardia in patients depends on increased automaticity, 
triggered activity and micro-reentry20. Various observation suggest that the autonomic 
nervous system may play a role in AT. For instance, automatic AT in patients (7/36) can be 
initiated by isoproterenol infusion but not by programmed electrical stimulation20. Also, 
DADs observed from monophasisc action potential recordings in patients with triggered 
activity (9/36) were terminated with propranonol and vagal manoeuvres (Valsalva 
manoeuvre and carotid sinus massage)20. However, the majority of patients (20/36) have AT 
caused by micro-circuit reentry that is readily initiated and terminated by atrial pacing and do 
not display DADs20. Clearly there is a role for autonomic influences in focal arrhythmias. In 
Chapter 4, I study the role of abnormal autonomic (baroreflex) influences in a focal 
arrhythmia initiated in the AV node, Junctional Tachycardia.  
 While AT is relatively uncommon, AF is the most common cardiac arrhythmia seen 
in general clinical practice10, 62. AF increases with age with a prevalence of 0.02% of people 
18-39 years of age to 11.6% of people over 75 years of age95. These observations suggest 
that fibrillatory conduction at rapid atrial activation rates is a more likely state of the atria 
than uniform conduction at rapid rates. There is a rate-dependence of these arrhythmias, 
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where AT is presumed to occur at rates below the "breakdown frequency" necessary for 
fibrillatory conduction, which is a hallmark of AF. AT rates are generally reported between 
100-250 bpm while local activation rates during AF can exceed 400-600 bpm90. The 
breakdown frequency is an important electrical substrate of AF as a lower breakdown 
frequency promotes fibrillatory conduction at slower rates. As discussed above the rapid 
rates during AF promotes remodelling of the atria that potentiates AF duration (AF begets 
AF). There are however a number of factors that cause the pre-arrhythmia remodelling of the 
atrial substrate that is required for AF to occur in the first place.  These factors "prime" the 
initial substrate state, promoting the rapid triggers (e.g., pulmonary vein ectopy) and 
susceptibility to fibrillatory conduction necessary for AF. These "clinical risk factors"103 for 
the onset and development of AF are listed in Figure 1.1, which is a simple representation of 
the cycle of arrhythmogenesis. In this model, AF risk factors induce the pre-arrhythmia 
remodelling of the atria that may promote arrhythmogenic triggers and a substrate which is 
susceptible to fibrillatory conduction and AF maintenance. The breakdown frequency of 
conduction is, however, not an independent predictor of an atrial substrate that will maintain 
AF. For instance, Cx40-/- mice have a lower pacing induced breakdown frequency of 1-1 
right atrial impulse conduction then wild type mice but did not present with AF 7. This 
indicates that the factors that promote fibrillatory conduction may not necessarily contribute 
to the mechanism driving AF and even oppose it. However, in Chapter 3, I present data 
showing that reduced Cx43 content in the atria not only promotes AF initiation and 
maintenance but the conduction disturbances which are the hallmark of an AF substrate.  
 The rapid rates during AF cause remodelling of the atria that promotes long lasting 
permanent AF117. This process generally referred to as "AF begets AF" describes how new 
onset paroxysmal AF, will eventually become persistent AF, with the final state being 
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permanent AF. This classification system divides AF into groups based on the duration of AF 
episodes and the therapeutic history95, 127. Paroxysmal AF has episodes that last less than 1 
week and terminates spontaneously without electrical or pharmacological cardioversion. 
Persistent AF episodes last longer than 1 week or are susceptible to electrical or 
pharmacologic cardioversion. A patient is said to be in permanent AF when AF is continually 
present and a strategy of rhythm control has been abandoned or never tried95, 127. It must be 
recognized that as these divisions are based on the effectiveness of current medical 
interventions and as there can be significant overlap of clinical diagnoses amongst patient 
populations they may not be indicative of underlying mechanisms.  
 Lone and paroxysmal AF has been shown to be primarily initiated from the pulmonary 
veins and posterior left atrial regions47, 85. These venous segments are where most of the 
ganglionated plexi are in contact with the left atrium (Section 1.2.1). Both alterations in 
vagal responses and a significant increase in AF control87-89, 100-102 were found in patients 
where the ganglionated plexi (GPs) were targeted107 or inadvertently modified during 
catheter ablation of AF sources in the pulmonary veins. This observation demonstrates the 
importance of the intrinsic cardiac autonomic nervous system in AF, which is commonly 
referred to as neurogenic AF18, 26, 54, 73, 91, 133. Neurogenic AF relies  extensively on the action 
of acetylcholine (Section 1.2.2) and is also referred to as vagal AF42.  
 The role of acetylcholine in setting the stage for rotor development and stabilization of 
the leading sources of AF have been reviewed34. Acetylcholine has been found to promote 
left to right frequency gradients and enhance the dominant frequency of the AF driver77. 
These responses were also dependent on acetylcholine concentration, with higher 
concentrations resulting in faster dominant frequencies. AF studies commonly focus on  
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Figure 1.1: The Cycle of Arrhythmogenesis. 
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acetylcholine concentration dependence and the expression profiles of receptors and 
downstream effectors while ignoring the regulators of the G protein signalling cascades  
 (Section 1.2.2). Chapter 2 of this thesis attempts to address this issue by studying 
neurogenic atrial tachycardia/fibrillation in the RGS2 deficient mouse. 
 Persistent AF is associated with diffuse macroscopic and histological atrial myocardial 
changes, referred to as remodelling. Atrial arrhythmia can also cause ventricular remodelling 
and, if protracted, cardiac failure. This in turn, feeds back on the atria and produces 
irreversible interstitial atrial fibrosis61. Such remodelling is associated with multiple changes 
in the atrial myocardium, such as altered signalling, fibrosis, and ion channels consistent with 
a "myogenic" hypothesis of AF. Myogenic AF is generally considered to be distinct from 
Neurogenic AF and is suggested to involve all mechanistic components unrelated to 
neurogenic components. However, the neurogenic and myogenic components of AF 
mechanisms are not easily separable, and there may be an important neuro-myogenic 
interface in AF mechanisms. The study of the involvement of the neuro-myogenic interface 
in mechanism of atrial arrhythmia is a central goal of this thesis and is discussed below. 
  The comparison of multiple interrelated factors that promote AF can be discussed 
utilizing a simplistic "Threshold Model" of arrhythmogenesis, which I propose in this thesis. 
The complexity of AF lies in the nature of the interaction that occurs between the electrical 
and physiological medias of the heart. A two media conceptual perspective is useful when 
thinking of arrhythmia as it allows the simple recognition that there are multiple 
physiological factors which can allow the same electrical phenomena to occur. In other 
words, many potentially unrelated changes in the physiology of the atria can allow the same 
electrical phenomena to occur in the atria's electrical media. An example of this would be 
that both decreased upstroke velocity (reduced Na+ channel conductance) of the action 
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potential and decreased junctional conductance slow the propagation velocity of electrical 
waves in the heart (Section 1.1.4). The proposed "threshold model" of arrhythmogenesis is 
useful as it allows for the simple relative comparison of multiple physiological factors which 
can have complimentary or opposing roles in promoting an electrical AF substrate. A 
substrate that is susceptible to AF initiation by an appropriate trigger would be said to be 
above the threshold for promoting AF.  If the atrial substrate is well below the AF threshold a 
single arrhythmogenic perturbation (low concentration acetylcholine) might not bring the 
atria close enough to threshold to allow a trigger to initiate AF. If however the atria is well 
above the threshold for AF, and is in permanent AF, than an antiarrhythmic treatment (such 
as electrical cardioversion) might not terminate AF if it cannot force the atria below 
threshold. These concepts form the basis of the studies performed in this thesis and will be 
discussed in the following section outlining the rationale, objectives and hypotheses. 
1.7 RATIONALE 
 When experimental work began, utilization of the mouse for AF studies was in its 
infancy with only a few published papers demonstrating long lasting sustained AF in the 
mouse. AF studies have commonly utilized the sheep, the pig and the dog as models due to 
anatomic similarity with the human (critical mass hypothesis)41. To date, the mouse is the 
most commonly utilized organism where single genes can be manipulated to determine their 
role in arrhythmia. As such, an objective of this thesis was to determine what atrial 
arrhythmias are inducible in the mouse and how to systematically and reproducibly elicit and 
study those arrhythmias. Following this, I wanted to use the mouse to study the molecular 
factors involved in arrhythmia susceptibility and substrate formation. Genetic alterations in 
mice allow the investigation of single factors which can promote arrhythmia in vivo. One of 
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the greatest challenges in studying AF has been the difficulty of dissociating fibrillatory 
activation from its mechanism11 where it has been said that “atrial fibrillation has prevented 
the study of atrial fibrillation” 11.  Due to this limitation, most molecular data published to 
date is correlative and does not describe the initial substrate state that lead to AF 
development (the pre-arrhythmia remodelling).  Studies in genetically manipulated mice may 
address both issues as "induced pre-arrhythmia substrate remodelling", thereby allow for 
investigations of the initial state dissociated from fibrillatory activation and thus yield 
causative mechanistic insights.  This information will provide mechanistic insights into what 
physiological alterations will allow the excitable media to sustain arrhythmia. Based on such 
findings, novel interventions can be developed. The study of arrhythmia mechanism in the 
mouse with an eye toward the development of novel antiarrhythmic interventions is an 
objective of this thesis.   
 Both neurogenic18, 26, 54, 73, 91, 133 and myogenic75, 121 41 4, 57, 76, 82-84, 115, 131 hypotheses 
have been proposed to account for arrhythmia mechanisms. The separation of AF 
mechanisms into strictly neurogenic and myogenic types is difficult as there can be 
interactions between the two. Also, in considering a two media (physiological and electrical) 
perspective of the heart and arrhythmogenesis, where multiple unrelated factors can promote 
the same electrical phenomena, it can be seen that a neuro-myogenic interface is important. 
The central hypothesis of this thesis is that there is an interface of neuro-myogenic influences 
in arrhythmia mechanism. As such it is proposed that the intrinsic cardiac autonomic nervous 
system has a role in most atrial arrhythmias. In Chapter 2 I investigated the role of the 
regulator of G-protein signalling 2 (RGS2) protein in modifying G-protein signalling 
cascades (neurogenic AF) utilizing an RGS2 knockout mouse. It was hypothesized that, as a 
selective regulator of Gαq-mediated signalling, RGS2-/- mice would have enhanced M3 
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muscarinic receptor signalling and an increased susceptibility to electrically induced atrial 
tachycardia/fibrillation. In Chapter 3 Cx40 deficient and Cx43G60S/+ mutant mice, with an 
80% reduction in atrial phospho-Cx43, were studied to determine the role of altered connexin 
content in promoting myogenic AF.  Based on a comparative analysis of literature, it was 
hypothesized that Cx40 deficient mice would be protected from AF while the Cx43G60S/+ 
mutant would have severe AF.  By identifying a model of AF promoted by structural 
alterations in gap junctions, the role of the ICANS in myogenic AF could be studied.  
Finally, by utilizing the threshold Model of arrhythmogenesis, the relative role or interface of 
disparate neurogenic (role of M3 muscarinic receptors) and myogenic factors (role of altered 
connexin content) in promoting AF were analyzed in the reasonably controlled context of 
induced pre-arrhythmia substrate remodelling.  In Chapter 4 I identified another atrial 
arrhythmia which is inducible in the mouse that involves the ICANS, junctional tachycardia. 
Junctional tachycardia is most prevalent among children following cardiac surgery (~10%) 
and can increase the risk of mortality up to 15%, however the mechanism of the arrhythmia 
is unknown. I tested the hypothesis that JT is caused inappropriate activation of the AV node 
pacemaker initiated by abnormal autonomic influences. The final objective of this thesis was 
to develop the proposed "Threshold Model" of arrhythmogenesis and use it to analyze results 
and make relative comparisons of observations obtained from the different experiments 
performed in Chapters 2-4. In Chapter 5, the discussion section of this thesis, the Threshold 
Model will be used to explain the role of the ICANS in studies examining the neuro-
myogenic interface of atrial arrhythmia. I will also present this simple relative comparison 
Threshold Model as a useful tool to make predictions of the outcomes of clinical arrhythmia 
interventions. 
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1.8 SUMMARY OF HYPOTHESES AND OBJECTIVES 
1.8.1 Hypotheses 
1. There is an interface of neuro-myogenic influences on arrhythmia mechanism. Therefore 
the intrinsic cardiac autonomic nervous system has a role in most atrial arrhythmias. 
2.  RGS2-/- mice have enhanced M3 muscarinic receptor signalling and an increased 
susceptibility to electrically induced atrial tachycardia/fibrillation. 
3. Cx40 deficient mice will be protected from, but the Cx43G60S/+ mutant will have severe 
AT/F.  
4. Junctional tachycardia is caused inappropriate activation of the AV nodal pacemaker 
initiated by abnormal autonomics. 
1.8.2 Objectives 
1. To determine what atrial arrhythmias are inducible in the mouse and how to systematically 
elicit and study those arrhythmias. 
2. Determine the mechanisms of the induced atrial arrhythmias in the mouse to provide the 
basis for future investigations of potential therapeutic options for patients. 
3. Develop the proposed "Threshold Model" of arrhythmogenesis and use it to analyze results 
and make relative comparisons of observations obtained from the different 
experiments performed in this thesis. 
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CHAPTER 2: Evidence for enhanced M3 muscarinic receptor function and sensitivity 
to atrial arrhythmia in the RGS2 deficient mouse 
 
A version of this chapter has been published: 
Tuomi JM, Chidiac P, Jones DL. Evidence for enhanced M3 muscarinic receptor function 
and sensitivity to atrial arrhythmia in the RGS2 deficient mouse. Am J Physiol Heart Circ 
Physiol. 2010 Feb;298(2):H554-61. Epub 2009 Dec 4. 
2.0 CHAPTER SUMMARY 
 The role of the intrinsic cardiac autonomic nervous system in promoting neurogenic AF 
is well recognized, especially in patients with lone AF that develops nocturnally.  Nocturnal 
AF in particular highlights an important vagal parasympathetic component of AF 
mechanisms. Studies in vagally mediated AF commonly focus on acetylcholine 
concentration dependence and the expression profiles of receptors and downstream effectors 
while ignoring the important regulators of the G protein signalling cascades. The amplitude 
of G protein effector signalling is strongly regulated by GTP hydrolysis, a process greatly 
accelerated (1000 fold) by GTPase activating proteins, such as the regulator of G protein 
signalling.  The studies performed in this chapter attempts to address this issue by studying 
neurogenic atrial tachycardia/fibrillation in the RGS2 deficient mouse.  These studies have 
also identified important anatomical and methodological considerations that must be adhered 
to in order to obtain systematic and reproducible data on arrhythmia susceptibility in the 
mouse.  By using His bundle electrograms as a landmark of catheter positioning I have 
determined that AF induction in the mouse requires pacing in the Mid-Right Septal atrium 
(MRA).  Also, I suggest that AF induction with single premature extra stimuli during 
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programmed electrical stimulation is more physiologically relevant than high frequency burst 
pacing (50Hz) with important mechanistic implications (re-entry).  Overall, these studies find 
for the first time, a role for RGS proteins in atrial arrhythmia, showing that RGS2 deficiency 
in the mouse raises the substrate above the threshold for AF induction.   
2.1 INTRODUCTION 
 Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in general clinical 
practice5. It is characterized by abnormal, disorganized and very rapid atrial electrical 
activation. AF is a common health problem in the developed world35, and its prevalence 
increases from about 0.5% of people in their 50s to nearly 10% of those over 80 years of 
age5. As the population ages, AF thus will place an increasing burden on health care 
resources, not only for its treatment and ongoing therapeutic management, but also because 
of the two most serious complications of AF, heart failure and stroke10. The generation of AF 
requires two critical components: 1) a trigger that initiates the event, and 2) a susceptible or 
vulnerable substrate that maintains the arrhythmia once initiated. AF can be triggered by 
ectopic foci firing15 from areas such as the pulmonary vein region13 or posterior left atrium29. 
Maintenance of AF may depend on rotor formation, which is the organizing source (driver) 
of functional re-entrant activity (spiral waves). Rotors form when a propagating electrical 
wave “breaks” on an anatomical or electrophysiological heterogeneity, and under appropriate 
conditions of excitability, begins to rotate17, 41. The wavelength of excitation (which is equal 
to the product of the conduction velocity and the refractory period), is also important in re-
entry, with shorter wavelengths resulting in more stable rotors. For a review of rotors in 
cardiac fibrillation see Vaquero 200841.  
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 The pathogenesis of AF is complex, involving not only remodelling of the atrium, but 
also effects mediated via the intrinsic cardiac autonomic nervous system (ICANS)25. 
Subpopulations of intrinsic cardiac neurons express multiple neurotransmitters14; however, in 
Guinea pig posterior ganglia, choline acetyltransferase immunostaining of all neurons 
indicates major parasympathetic cholinergic input to the myocardium28. Rhythm 
management after catheter ablation of arrhythmogenic tissue in the pulmonary veins tends to 
be more successful when these autonomic ganglia are knowingly or inadvertently modified36. 
Recently, we demonstrated that selective surgical left atrial neuroablation blocked the ability 
to electrically induce AF in the anaesthetized pig20. The abrogation of parasympathetic 
signals may underlie the anti-arrhythmogenic effects of ICANS manipulation, since the 
development of AF can be promoted by cholinergic input to the atrium. ICANS-derived ACh 
activates multiple muscarinic receptor subtypes present in the atria including Gαi/o-coupled 
M2 receptors (M2R) as well as Gαq-coupled M3 muscarinic receptors (M3R). These receptor 
subtypes activate distinct potassium currents including the G protein activated inward 
rectifier potassium current (GIRK3.1/3.4 or IK, ACh) by M2R, and delayed rectifier potassium 
(I K,M3) channels via the M3R38. 
 Muscarinic receptors are GPCRs (G-protein coupled receptors), and as such they activate 
heterotrimeric G proteins by catalyzing GDP dissociation from the Gα subunit and 
consequently promoting GTP binding. This activating step leads to conformational changes 
and possibly also subunit dissociation within the G protein, thus enabling both Gα-GTP and 
the Gβγ dimer to regulate downstream effectors44. Gα proteins are turned off by their 
intrinsic ability to hydrolyze GTP, however in vivo this step may be facilitated by an RGS  
(Regulator of G protein signalling) protein, thus shortening the duration of G protein 
activation. Most RGS proteins appear to be expressed in cardiac tissue32and 7 distinct 
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isoforms (RGS2, RGS3, RGS4, RGS6, RGS10, RGS19 (GAIP) and RGS17 (RGSZ2) have 
been specifically localized to atrial myocytes9. Nearly all RGS proteins are GAPs for Gαi/o, 
and about half also act on Gαq/111. RGS2 is one of the most highly expressed RGS proteins 
in the heart24, and it is a uniquely selective GAP for Gαq with limited potency on Gαi/o1, 7. 
Thus, RGS2 is potentially an important regulator of atrial Gαq-coupled M3 receptors  
 Since RGS proteins limit GPCR signalling, we hypothesized that they may limit atrial 
arrhythmogenesis by keeping in check parasympathetic signals mediated via atrial 
muscarinic receptors. To test this, I compared RGS2-/- and wild type mice for atrial 
electrophysiological properties and susceptibility to the induction of atrial tachyarrhythmias. 
To determine if the loss of RGS2 would enhance susceptibility to tachyarrhythmia induction, 
we performed in vivo electrophysiological pacing and recording studies in both strains. 
Overall, our results suggest that removing the inhibitory effect of RGS2 on M3-activated 
Gαq renders the knockout mice more susceptible to electrically-induced atrial 
tachyarrhythmia. 
2.2 METHODS 
2.2.1 Animals And Preoperative Procedures  
 The generation and genotyping of RGS2 knock out (RGS2-/-) mice have been described 
(Oliviera-Dos-Santos30). Mice were provided with ad libitum food and water and held on a 
standard (12h:12h) light:dark cycle. The studies were approved by the Animal Use and Care 
Committee of the University of Western Ontario (protocol #2006-121-12) and complied with 
the guidelines of the Canadian Council on Animal Care and the Guide to the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (Institution #A5527-
01). One month old male RGS2-/- and control C57BL/6 wild type (WT) mice were 
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anaesthetized with an i.p injection of a mixture of ketamine (150 mg/kg) and xylazine (10 
mg/kg), and fixed in a supine position over a heated water blanket. Body temperature was 
monitored with a YSI-402 (Yellow Springs Instruments, Yellow Springs, Ohio) small animal 
rectal probe inserted approximately 1 cm past the anal sphincter, and maintained within the 
normal physiological range (36.5-38oC)8. Hair was removed from the neck with Nair® cream 
hair remover (Church & Dwight, Co, Inc., Mississauga, ON). With a cut down approach, a 
23 ga Teflon endotracheal tube was inserted and ligated in place to keep the airway dry and 
open. 
2.2.2 Surface Limb Lead Electrocardiograms (ECG) 
 Measurements were obtained using 4 subcutaneous 25 ga platinum electrodes (Grass 
Instrument Inc., Quincy, Mass.) placed at the base of each limb. ECG tracings were filtered 
between 0.05 to 100 Hz, digitized and sampled at 1.5 kHz, with an ECG 100 preamplifier 
connected to a MP100 recording system (BIOPAC Systems, Biolynx, Montreal, PQ).  
2.2.3 In Vivo Intracardiac Electrophysiology Studies 
 A 2F octapolar stimulation / recording / drug infusion catheter (CIB’ER Mouse®, 
NuMED Inc., Hopkinton, NY) was inserted through the right jugular vein and advanced into 
the right atrium and ventricle (Fig. 1). Intracardiac electrograms were sampled at 1.5 kHz, 
and filtered at 100 to 5000 Hz (DA 100 amplifier, BIOPAC Systems). All data were recorded 
using Acknowledge software (BIOPAC Systems). 
2.2.4 Catheter Positioning 
 Stimulation sites within the heart is known to influence the effective refractory period 
(ERP)27. In the present study we used His bundle potential recordings (Fig. 1) to establish 
catheter positioning within the right atrium (RA) and ventricle (RV). Based on the size of the 
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RA and the spacing of the catheter electrodes, the two pairs of bipolar RA electrodes were 
located at the mid right atrium (MRA) and the high right atrium / superior vena cava region 
(HRA) above the crista terminalis.  
2.2.5 Pacing Protocols 
 Bipolar pacing used 2 ms pulses at twice the diastolic threshold, delivered through a 
Grass SIU5 stimulus isolation unit, connected to a Grass S99 stimulator, programmed with a 
custom-built timer. Atrial (AERP), ventricular (VERP), and AV nodal (AVNERP) effective 
refractory periods were assessed with programmed electrical stimulation (PES)27 using a 
drive train of 9 stimuli (S1) at cycle lengths of 150 and 100 ms followed by delivery of an 
extra stimulus (S2). Atrial pacing with 1 ms decrements were used to determine the 
Wenkebach cycle length (WCL). 
2.2.6 Arrhythmia Induction 
 Both PES19 and burst pacing18 (2 ms pulses at 50 Hz, 400 ms burst duration) were used to 
determine susceptibility to atrial arrhythmia induction. Burst pacing used up to 30 bursts of 
pacing in both atrial locations. Atrial fibrillation in the mouse was implied to be 
distinguishable from atrial tachycardia based on the surface electrograms: lack of regular P 
waves, irregularly irregular ventricular responses, in combination with intracardiac  
electrograms having fractionation and/or intracardiac activation heterogeneities between the 
mid- and high-right atrium.   
2.2.7 Effects of muscarinic receptor drugs 
 Pharmacological agents were purchased from Sigma, (Mississauga, ON), unless 
otherwise stated. Muscarinic receptor drugs, including the nonselective agonist carbachol 
(0.5 mg/kg), and the nonselective antagonist atropine (1 mg/kg) were injected  
 55 
 
 
 
Figure 2.1: A. Photograph of the 2F octapolar stimulation / recording / drug infusion 
catheter (CIB’ER Mouse®, NuMED Inc., Hopkinton, NY) used for intracardiac 
electrophysiological studies in the mouse. Note the 0.5 mm spacing of the electrodes. Each 
bracketed electrode pair was used for recording and electrical stimulation. Numbers indicates 
the position within the heart: 1=right ventricle, 2=His bundle, 3=mid right atrium, 4=high 
right atrium / superior vena cava. B. Representative recording from electrode pair 2 showing 
the atrial, ventricular and His deflections. 
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intraperitoneally. The M3R-selective antagonist darifenacin hydrobromide (Cedar Lane labs, 
Markham, ON, 1 mg/kg) was administered intravenously. Electrophysiological 
measurements were made sequentially in the absence of drug, and then in the presence of 
carbachol, followed either by atropine or by darifenacin and then atropine. Effects of vagal 
stimulation (10V, 30 Hz, 3 s) on heart rate were measured prior to and after darifenacin and 
atropine administration. 
2.2.8 RNA Isolation And Real Time RT-PCR 
 RNA was isolated using a Trizol kit (Qiagen Inc., Invitrogen, Burlington, ON). RNA 
concentration was determined using a spectrophotometer (Beckman Coulter, Mississauga, 
ON). Isolated RNA was converted to cDNA using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems Inc., Carlsbad, CA). Real time analyses were carried 
out using Taqman gene expression Assays-on-Demand from Applied Biosystems and 
normalized to levels of the endogenous control, GAPDH. Relative expression of M2R, M3R, 
M4R, RGS2 and RGS4 mRNA were determined using 40 cycles on the ABI Prism 7900 HT 
sequence detector (Perkin Elmer Life Sciences, Woodbridge, ON). All samples were 
amplified in 3 parallel reactions per trial. To determine real time amplification efficiencies 
(E) and starting concentration (N0) of the amplicon, non-baseline corrected raw input data 
from the ABI Prism 7900 HT sequence detector was analyzed by linear regression analysis 
with LinRegPCR (2009) software34. 
2.2.9 Statistical Analysis 
 Group wise comparison of gene expression ratios were calculated using the relative 
expression REST software31, with efficiency and Ct deviations calculated by LinRegPCR. 
Discrete data were analyzed using Chi Square analysis39. Drug and strain comparisons used 
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2-way ANOVA and the Bonferoni post-hoc test with GraphPad Prism 4 software. A P-value 
of <0.05 was be considered statistically significant. 
2.3 RESULTS 
2.3.1 Atrial Effective Refractory Periods 
 PES revealed a regional heterogeneity in refractory period, with longer AERPs in the 
HRA region compared to the MRA, and this difference was observed in both RGS2-/- and 
WT mice (Table 2.1). AERPs were significantly lower in the RGS2-/- mice in both the HRA 
(34±2 vs 30±1 ms, P<0.05) and MRA (23±1 vs. 21±1 ms, P<0.05) regions compared to WT 
mice (Table 2.1). Strain-related differences remained after carbachol administration, which 
reduced AERPs in both strains. In contrast, the  
nonselective muscarinic antagonist atropine increased AERPs to similar levels in both strains 
(Table 2.1). To determine the role of the M3R in the RGS2-/- mouse we used the selective 
M3R blocker darifenacin hydrobromide (Fig. 2.2). Darifenacin increased the AERP from 
20±2 to 30±1 of the MRA in the RGS2-/- mouse (P<0.05, n=5) and from 25±1 to 30±1, in 
WT mice (n=6, P<0.05), which eliminated the strain-related differences. Two-way ANOVA 
revealed a significant interaction between strain and drug (darifenacin), suggesting that  
increased signalling through the M3 receptor may underlie the lower AERPs measured in 
animals lacking RGS2. 
 Since it has been established that vagally-induced bradycardia is mediated via M2R 
but not M3R11, we compared the effects of darifenacin and atropine on heart rate changes 
following vagus nerve stimulation. Stimulating the vagus (10V, 30 Hz, 3 s) decreased heart 
rate by 386.8% in WT animals. This decrease was abolished by atropine but was unaltered 
in the presence of darifenacin (354.5%, n=4, P>0.5). This provided evidence that this dose  
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Table 2.1: Intracardiac electrophysiological values recorded in the absence and presence of 
carbachol and atropine in 1 month old male RGS2-/- and wild type mice.  
 
Values are means ± SE; n (no. of mice) indicated beside value. AhERP, high atrial effective 
refractory period; AmERP, mid atrial effective refractory period; VERP, ventricular effective 
refractory period; AVNERP, atrial-ventricular effective refractory period; WCL, Wenkebach 
cycle length. Subscripts 100 and 150 refer to drive cycle lengths of 100 and 150 ms, 
respectively.  
* 95% Confidence interval (CI) and  
† 99% CI for difference in RGS2-/- vs. wild type within drug group.  
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of darifenacin did not affect M2R signalling. 
2.3.2 Atrial Tachyarrhythmia Induction 
 Atrial burst pacing (Fig. 2.3), and PES (Fig. 2.4)18 induced atrial tachyarrhythmias 
which demonstrated properties of AF; however, validating AF would require high density 
mapping and recording from the left atrium which often is the driver of regular rhythms 
recorded from the right atrium29. Thus these have generally been labelled AT/F. PES- 
induction is thought to mimic physiological initiations of AF, as premature atrial beats often 
precede AF episodes15. On the other hand, burst pacing, although thought to be a non-
physiological provocation, will reliably induce AF via cardiac electrical instability18. AF is 
very rarely induced by single extrastimuli in large animal and human studies and was thus 
anticipated to be even less provocable in mice, due to their small size. Thus AT/F sensitivity 
to single extrastimuli in the mouse implies a highly vulnerable myocardial substrate. The 
duration of induced arrhythmia is also important with “sustained” AF being defined in large 
animal and human electrophysiological studies as lasting >30 s. Hence, AT/F data were 
analyzed based on susceptibility to both pacing modalities and grouped into duration of the 
induced arrhythmia lasting <10 s, between 10-30 s and >30 s. As expected, one month old   
WT mice were mostly insensitive to single stimulus-induced AT/F (4%, 1/25) compared to 
burst pacing (40%, 10/25, P<0.05) (Fig.2.3, Top). Carbachol increased the susceptibility to 
both single extrastimulus (33%, 4/12) and burst pacing (58%, 7/12). Muscarinic receptor 
activation also prolonged the duration of AT/F episodes with only 2 of 12 untreated mice 
having sustained AT/F, while 5 of the 12 had sustained AT/F after carbachol administration. 
The site of stimulation within the atrium also affected susceptibility to AT/F induction. For 
WT mice, burst pacing more readily induced AT/F from the MRA (40%, 10/25) compared to 
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Figure 2.2: Atrial effective refractory period (AERP) was measured using programmed 
electrical stimulation (PES) with a 100ms drive train in 1 month old male wild type 
compared RGS2-/- mice. AERP was measure in both the high right atrium (HRA) and mid 
right atrium (MRA) in the absence (A. Vehicle) and presence of darifenacin (B. Darifenacin). 
The AERP of the RGS2-/- was significantly lower than that of wild type mice with vehicle 
control, but was normalized with darifenacin. * P<0.05, ** P<0.01. 
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Figure 2.3: A. Atrial tachycardia/fibrillation (AT/F) induced with burst pacing (Burst) of the 
mid right atrium (MRA) in a 1 month old wild-type (WT) mouse. B. AT/F induced with 
burst pacing (Burst) of the MRA in a 1 month old RGS2-/- mouse. Note the different 
tachycardia rates between the His bundle region electrogram (HBE) and the high right atrial 
electrogram ( HRA) as well as the irregularly irregular ventricular response seen on limb lead 
I (LL1) and  right ventricular electrogram (RV). 
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the HRA (8%, 2/25, P<0.05) region. This is likely related to the relative AERPs, which were 
significantly shorter in the MRA compared to the HRA (Table 2.1). This electrical 
heterogeneity may be an important factor in providing a permissive substrate for wave break 
and re-entry initiation in the right atrium. 
 RGS2-/- mice were more susceptible to PES induction of AT/F from the MRA (50%, 
11/22) compared to the WT mice (4%, 1/25, P<0.05) (Table 2.2). There was a  
trend for a greater percentage of RGS2-/- mice to have sustained AT/F (>30 sec) with either 
pacing modality, but this did not reach significance (0.1>P>0.05) (Table 2.2). 
2.3.3 Mechanism Of Arrhythmia (Evidence For Re-Entry) 
 Rapid focal activity has the potential to initiate rotors due to the interaction of a high 
frequency propagating wave fronts with the refractory tail of the previous wave17, 41. 
Immediately after PES-initiated arrhythmia, local cycle lengths were often identical in the 
HRA and His bundle regions. However, sometimes at arrhythmia onset, heterogeneities in 
refractory periods were accompanied by a regional conduction block into the HRA (Fig. 2.4, 
Top). Also, heterogeneity in local cycle lengths were observed between the HRA and His 
bundle regions immediately following initiation of AT/F in an RGS2-/- mouse (Fig. 2.4, 
Bottom). Immediately after induction, the local atrial electrogram from the His bundle region 
was shorter (22 ms) than that of the HRA (27 ms) region. However, 173 ms after initiation, 
local cycle length of the His bundle region converged with that of the HRA (25ms). This 
pattern suggests a drifting rotor that rapidly became anchored. However, this pattern may 
also indicate a tachycardia with a rapid rate at onset that slows down as the driving 
mechanism stabilizes.  The rapid onset may combine with the regional ERP heterogeneity to 
produce a functional conduction block/slowing that recovers at a slower rate. In this and 
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Table 2.2: Incidence of AT/F induced by PES or burst pacing and maximum duration of 
induced AT/F with either PES or burst pacing induction. 
 
χ2 Analysis of discrete values revealed significant differences in atrial tachycardia/fibrillation 
(AT/F) susceptibility with programmed electrical stimulation (PES) (P < 0.05).  
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other mice (n=4) the cycle length during AT/F (27ms) was faster than the intrinsic AERP in 
the HRA region (32ms), suggesting the possibility of electronic interactions from a rotor core 
causing reduced refractoriness41.  
2.3.4 Expression Of M2, M3 And M4 Receptors And RGS2 And RGS4 mRNA 
 Regional heterogeneity (left vs right atrium) in the expression of muscarinic receptors 
and/or their associated RGS proteins may contribute to arrhythmia. Therefore, we compared 
regional levels of mRNA encoding M2, M3 and M4 receptors, as well as RGS2 and RGS4, 
in 1 month old WT mice using the Relative Expression Software Tool (REST)31. There was 
no difference in M2, M3 and M4 receptor expression in WT compared to RGS2-/- mice (data 
not shown). However, M2 receptor expression in WT mice was higher in the RA compared 
to the LA (P<0.05, ratio=0.763), while M3 receptor was higher in the LA (P<0.05, 
ratio=1.188) (Fig. 2.5). M4R, RGS2 and RGS4 did not differ between the two atria. In order 
to compare the expression levels of M2, M3 and M4 muscarinic receptors LinRegPCR 
analysis was used to determine both the PCR reaction efficiencies and the starting 
concentration of the amplicon (N0). As expected, the M2 receptor expression was 
substantially higher than both M3 and M4 receptors in atria and ventricles (Fig2.6, Bottom). 
RGS2 was more highly expressed than RGS4 in both right and left atria, while there was 
greater expression of RGS2 in the atrium than the ventricle (Fig. 2.6, Top). 
2.3.5 Effects Of Body Temperature 
 Previously, with the exception of QTc, all electrophysiological parameters were found to 
be prolonged at lower body temperatures3. We extended these results to determine the effect 
of low body temperature (33.5 ºC) on AERP and AT/F susceptibility. At 33.5 ºC, AERPs 
were prolonged in both the HRA (34±3 vs 41±3, P<0.05) and MRA (24±3 vs 29±3, P<0.05) 
regions. The prolongation of AERP’s reduced the susceptibility to AT/F induction.  
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Figure 2.4: A. Programmed electrical stimulation (PES)-induced atrial 
tachycardia/fibrillation (AT/F) with a single extrastimulus (S2) in a 1 month old RGS2-/- 
mouse. Note the conduction block into the high right atrial (HRA) region seen as far-field 
(low amplitude) potentials during block. The duration of the arrhythmia was >200 sec with 
an average atrial rate of ~1600 bpm. B. PES-induced AT/F using a single extrastimulus (S2) 
in a 1 month old RGS2-/- mouse. Note the tachycardia cycle length variations between the 
high right atrial (HRA) and His bundle electrogram (HBE) regions, which regularize 173 ms 
after induction (anchoring point). LL1 limb lead 1. RV, right ventricular electrogram. HBE, 
electrogram from the His bundle region. HRA, recording from the high right atrium. 
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Figure 2.5: Quantitative real time reverse transcriptase polymerase chain reaction (qRT-
PCR) determination of M2 and M3 receptor mRNA content in the atria of 1-month-old wild-
type (WT) mice. Left vs right atrial mRNA expression ratios of were determined using the 
Relative Expression Software Tool (REST).  There was greater expression of M2R in the 
RA, and greater M3R in the LA.  * P<0.05. 
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Maintenance of body temperature is important as previous studies have stated that AT/F 
cannot be induced in mice without carbachol22. Our studies clearly show that AT/F can be 
induced without carbachol administration, and this difference is likely due to having 
maintained body temperature constant at 37 oC throughout the previous studies. 
2.4 DISCUSSION 
 This study, to my knowledge, demonstrates for the first time a role for RGS proteins in 
atrial arrhythmia. The RGS2-/- mice were more susceptible to PES-induced AT/F, and there 
was a greater percentage of RGS2-/- mice with sustained AT/F. The greater susceptibility to 
AT/F was likely due to the abbreviated AERP in RGS2-/- mice. This strain dependent 
difference was maintained in the presence of carbachol, while atropine abolished the strain 
dependent differences. These findings suggest an alteration in muscarinic receptor- 
gated K+ flux evidently due to an increase in muscarinic receptor response per se. The 
observed phenotypic difference cannot easily be attributed to increased parasympathetic 
release of acetylcholine, as chronic telemetry showed that while mean arterial pressure was 
increased by ~10 mm Hg in RGS2-/- animals, heart rate was unchanged, indicating a resetting 
of the baroreceptor reflex12. It follows that any observed cardiac electrophysiological 
phenotype would be due to the direct effect of RGS2 loss in the atria, rather than a 
baroreflex-mediated enhancement of vagal activity. Consistent with other studies, I found 
that RGS2 was highly expressed in the atria of mice. As RGS2 is a selective GAP for Gαq, 
while having limited potency on Gαi/o1, I hypothesized that Gαq-coupled M3Rs and not 
Gαi/o-coupled M2Rs were involved in RGS2-/- mediated reductions in AERP. The M3 
muscarinic receptor activates a delayed rectifier potassium channel (I K, M3) in the atrium38. 
To date I K, M3 is the only identified atrial K+ channel activated by Gαq which is blocked by 
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Figure 2.6: Relative mRNA expression as a ratio of the normalized gene of interest (GOI) 
relative to a house keeper gene (GAPDH) compared to either RGS4 (A) or M3R (B) in the 
left atrium, using the following equation: [N0(GOI)/N0(GAPDH)]/[N0(M3R or RGS4)]. 
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atropine43 and the M3 selective antagonist, darifenacin42. I K, M3 has only been observed in 
canine atrial cells in the presence of 10 mM choline. However, while M2 deficient mice had 
a positive inotropic response to carbachol, M2/M3 double knockout mice were devoid of any 
inotropic response21. As the heart has been classically considered a “pure M2” organ23, I 
examined the levels of M2, M3 and M4 muscarinic receptor mRNA in the RA, LA and 
ventricle. M2R expression was ~70 times higher than M3R with very little M4R detected in 
either atria or ventricle. To confirm the participation of M3R, I determined AERP in the 
absence and presence of darifenacin. This selective antagonist eliminated AERP differences 
between strains, confirming an M3R mediated phenotype. 
 AF can be maintained by either rapidly firing ectopic foci (e.g. from the pulmonary 
veins) or a functional re-entrant circuit (mother rotor). Reduced AERP in RGS2-/- mice 
would be expected to provide a vulnerable substrate for reentry by proportionally decreasing 
the wavelength of excitation. While it can be difficult to distinguish between AF mechanisms 
using whole animal intracardiac electrophysiological studies in animals the size of the 
mouse, I have made a number of observations that suggest a re-entrant mechanism of AT/F 
in the RGS2-/- mouse. 1) RGS2-/- mice were susceptible PES-induced AT/F, which, while not 
diagnostic in itself, is thought to more readily induced reentry than triggered activity16. 2) 
Myocardial regions with large heterogeneities in electrical properties are often more 
vulnerable to reentry2, which can result from unidirectional conduction block in regions with 
longer refractoriness4. In the present study the atrial ERP was significantly longer in the 
HRA compared to the MRA region, and AT/F was more easily induced by pacing the MRA. 
3) Computer modelling has been used to determine electrical and structural heterogeneities 
between the crista terminalis and right atrium as being key mechanisms underlying the 
initiation of reentry4. Rapid pacing in this area results in unidirectional conduction blockage 
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towards the crista terminalis and the initiation of reentry4. Consistent with this concept, I 
observed activation heterogeneities between the MRA and HRA region during and at the 
onset of AT/F (Fig.2.4 Top).  
 Initiation of rotors are suggested to be key in maintaining AF41.  Once initiated, rotors 
have the potential to drift until they anchor around tissue heterogeneities (i.e. scars, coronary 
arteries, bands of connective tissue etc)41. Drifting rotors exhibit Doppler-like shifts in 
tachycardia cycle lengths such that the coupling interval is shorter in an area it drifts towards 
and longer in regions from which it moves away16. After anchoring, cycle lengths in the two 
regions should be identical. Due to the small size of the mouse heart, and the left atrial 
predominance of AF mechanisms, one could speculate that anchoring should occur rapidly 
with Doppler shifts observed relatively infrequently in the RA. However, I observed this 
complex activation pattern in an RGS2-/- mouse (Fig.4 bottom). Rotors also enhance the 
repolarization of excited myocardium (reducing AERP) up to 1cm away due to a strong 
electrotonic current flow into the unexcited core16, 41. For this mouse, the local cycle length in 
the HRA during arrhythmia was faster than what would be allowed by the intrinsic ERP 
(32ms) further strengthening the argument for a re-entrant mechanism in AF in the RGS2-/- 
mouse. Nevertheless, the suggestion of reentry supporting AF in the mouse requires 
techniques such as optical mapping to document the mechanism.  
 Both M2 and M3 muscarinic receptor-mediated K+ currents may be involved in the 
development of AF. In the canine heart, M2R-regulated I K, ACh comprises >60 % of the total 
muscarinic mediated outward K+ current37. However, with AF due to ventricular 
tachypacing-induced congestive heart failure, the contribution of IK, M3 increased to ~50% of 
the total outward K+ current37. IK, ACh channels also can participate in AF, as GIRK3.4 
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knockout (GIRK4-/-) mice, which lack functional IK, ACh channels, appear to be completely 
resistant to carbachol-induced AF22. 
 RGS protein regulation of M2R function likely contributes to AF. RGS4 was identified 
as an important regulator of IK, ACh channels in the SA node; however, little RGS4 was 
detected in the surrounding right atrium6. Consistent with this observation, I found >150 fold 
higher expression of RGS2 than RGS4 in the mouse atria. Future studies may reveal a role 
for other RGS proteins in atrial arrhythmia. 
2.5 CLINICAL RELEVANCE 
 With the aging of the population there is an increasing drive to identify novel treatments 
for AF. This will require increased understanding of the signalling pathways and molecular 
regulators involved in arrhythmia induction, perpetuation, and atrial remodelling. The 
clinical relevance is highlighted by the success of ACE inhibitors in preventing fibrosis and 
development of an AF substrate26. Mutations in, or altered expression/function of a variety of 
RGS proteins could be involved in AF mechanisms in patients, and indeed changes in RGS2 
have been identified in several human cardiovascular phenotypes. Targeting RGS proteins 
may be important for drug development33. Also, our data suggests that selective M3R 
blockade, alone or in combination with other anti-arrhythmic agents, may be useful for 
patients with AF.  However, in mice oral darifenacin exerted only transient binding to 
cardiac muscarinic receptors45, its use may be limited.   
2.6 LIMITATIONS 
 While these results indicate a role for RGS2 and the M3 muscarinic receptor in 
promoting AF in the mouse, additional studies will need to directly determine the role of  
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IK, M3 activity. In the mouse, it may be difficult to distinguish atrial fibrillation from atrial 
tachycardia, particularly with an arrhythmia of short duration. However, using standard 
clinical criteria for atrial fibrillation: lack of regular P waves, irregularly irregular ventricular 
responses often it was possible to demonstrate characteristics of atrial fibrillation in the 
mouse. Nevertheless, this is difficult particularly with arrhythmias of short duration.  Atrial 
vulnerability may also be due to a balance of autonomics 20, 36. RGS2-/- mice have also been 
shown to have reduced renal sympathetic nerve activity compared to WT mice40. Although, 
the lack of a heart rate difference between RGS2-/- and WT mice found in their earlier study12 
does not assist in establishing the role of the sympathetic nervous system in atrial 
susceptibility, the role of the balance between sympathetics and M3 responses remains to be 
determined. RNA expression provides an index of the relative importance of the proteins but 
may or may not parallel Bmax values of radioligand assessment of M2, M3 or M4 protein 
expression, distribution and function. One month old mice were chosen to avoid potential 
complexity due to the chronic effects of the hypertensive phenotype associated with RGS2-/- 
in the mouse. It is also recognized that it may not be possible to directly extrapolate from 
mouse experiments to the human. 
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CHAPTER 3:  Atrial Tachycardia/Fibrillation in the Connexin 43 G60S Mutant 
(Oculodentodigital Dysplasia) Mouse 
A version of this chapter has been published: 
Tuomi JM, Tyml K, Jones DL. Atrial Tachycardia/Fibrillation in the Connexin 43 G60S 
Mutant (Oculodentodigital Dysplasia) Mouse. ” Am J Physiol Heart Circ Physiol. 2011 
Apr;300(4):H1402-11. (Epub 2011 Jan 14) 
3.0 CHAPTER SUMMARY 
 One of the greatest challenges in studying AF has been the impossibility of dissociating 
fibrillatory activation from its mechanism. Due to this most molecular data is  correlative and 
does not describe the initial substrate state that lead to AF development.  Studies in 
genetically manipulated mice may address both issues as induced pre-arrhythmia substrate 
remodelling allows for investigations of the initial state dissociated from fibrillatory 
activation thus yielding causative mechanistic insights.  One particular challenge has been 
determining the role of altered connexins (Cx40 and Cx43) in promoting myogenic AF.  
Increases, decreases and no change in the expression of Cx40 and Cx43 have been observed 
in different patients and large animal models of AF.  In each case, a change in Cx expression 
may be compensatory, lowering the substrate closer to threshold, or may promote permanent 
AF, raising the substrate further above threshold.  In this chapter Cx40 deficient and 
Cx43G60S/+ mutant mice, with an 80% reduction in atrial phospho-Cx43, are studied to 
determine the role of altered connexin content in myogenic AF. Identification of a model of 
myogenic AF would allow testing of the hypothesis that "tonic autonomic influences play a 
role in all atrial arrhythmias".  I found that while Cx40 deficient mice are protected from 
carbachol induced AF, the Cx43G60S/+ mutant mouse, is highly susceptible to AF that can be 
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terminated by darifenacin hydrobromide (a M3R blocker).  Detailed electrogram analysis 
show disturbed right atrial conduction, while epicardial recordings found left to right atrial 
activation patterns consistent with clinical AF.  Overall, these studies determined a role for 
the ICANS in myogenic AF while electrical recordings indicate that AF in the mouse is 
highly similar to that observed in the human. 
3.1 INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia seen by the general 
practitioner 3. It is characterized by disorganized and rapid atrial electrical activation, which 
can drive rapid and irregular ventricular activation. AF requires a trigger for initiation, 
together with a dynamic susceptible or vulnerable substrate for maintenance. It has been 
shown to be triggered by either wavebreak 24 or ectopic foci 22 arising from regions such as 
the pulmonary veins 20 or the posterior left or right atrium 20, 36. Triggers combined with 
dynamic substrates of structural heterogeneities, reduced refractoriness, enhanced spatial 
dispersion of refractoriness and abnormal impulse conduction, to initiate and perpetuate the 
arrhythmia 38. 
Gap junction channels are critical for the conduction of electrical impulses in the heart 
and may be involved in arrhythmia. They are composed of 4 transmembrane domain 
proteins, connexins (Cxs), which oligomerize in the Golgi apparatus to form hexamers called 
connexons31. Connexons from adjacent cells dock, primarily at intercalated disc, to form low 
resistance channels that allow rapid propagation of electrical signals 7. While 4 primary 
isoforms of Cxs are found in the heart (mouse Cx30.2/ human Cx31.9, Cx40, Cx43, Cx45), 
only Cx40 and Cx43 are abundant in the working myocardium. The atrium expresses similar 
amounts of Cx40 and Cx43 33. 
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Remodelling of connexins can be functional (altered conductance) and structural (altered 
content/distribution) 14. The role of connexins in AF has been studied in animal models and 
patients with AF; however, the exact role of Cx40 and Cx43 is not clear 14. In wild type 
(WT) mice following the administration of carbachol, 7 of 8 mice were susceptible to atrial 
tachycardia/fibrillation (AT/F) lasting 139.2±402.1 seconds 51. However, studies in Cx40-/- 
mice have reported that AT/F was not detected 1, occurred infrequently (5 of 19) 4, had no 
difference in susceptibility compared to WT mice 42, or was short lived (5/10, <1 second) 4, 19, 
49. These reports demonstrate that relative to wild type (WT) mice in the presence of 
carbachol 51, Cx40-/- mice have little susceptibility to sustained AT/F. However, somatic 
mutations in Cx40 17 and Cx43 44 have been reported in patients with idiopathic AF. When 
expressed in N2A cell pairs, similarly mutated Cx40 had reduced junctional conductance (gj) 
and inhibited wild type (WT) Cx43 gj. These observations highlight an important distinction 
between functional and structural alterations of gap junction channels. 
Arrhythmia studies in transgenic mice have primarily focused on Cx40 deficient (Cx40-/-) 
mice as Cx43 deficient (Cx43-/-) mice die peri-natally 40. The cardiac selective Cx43 
knockout mouse has only been used in studies of ventricular arrhythmia 18. To date, 62 
mutations in Cx43 have been linked to Oculodentodigital dysplasia (ODDD), a pleiotropic, 
autosomal dominant disorder in humans 39, 44 primarily affecting the eye, dentition, and digits 
of the hands and feet. Cardiac defects were reported in 177 individuals from 54 families with 
ODDD 39. Both G138R 13 and I130T 27 Cx43 mutant mice with the ODDD phenotype have 
increased susceptibility to ventricular arrhythmia; however, atrial arrhythmia susceptibility 
was not determined. The Cx43 G60S (Cx43G60S/+) mutation in mice 39 is dominant negative, 
causing connexons with mutant and WT Cx43 to be retained in the Golgi and targeted for 
degradation 35. Cx43G60S/+ mutant mice have a 60% reduction in total atrial Cx43 protein 
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content, with a preferential down-regulation (~80%) of the highly phosphorylated form of 
Cx43 35. The Cx43G60S/+ mutation did not alter Cx40 or Cx45 expression. We took advantage 
of this well characterized Cx43G60S/+ mouse model to determine the role of Cx43 reductions 
in AT/F. Intracardiac electrophysiological pacing determined AT/F susceptibility in 6 month 
old male mice. As no atrial arrhythmias were reported in WT mice and a relatively low 
frequency of AT/F in Cx40-/- mice, we compared Cx43G60S/+ mutant to age-matched Cx40-/- 
mice to determine the role of reduced Cx43 and total loss of Cx40 in AT/F. 
3.2. METHODS 
3.2.1 Animals And Preoperative Procedures 
 Animal studies were approved by the Animal Use Committee of the University of 
Western Ontario (protocol #2006-121-12) and complied with the Guidelines of the Canadian 
Council on Animal Care and the Guide to the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Six 
month old male Cx43G60S/+ mice were obtained from the colony maintained by Dr. Gerald 
Kidder which were originally developed by Dr. Janet Rossant (Centre for Modeling Human 
Disease, Toronto, ON, Canada) 16. Comparisons were made to age matched male C57BL/6 
littermate (Cx43+/+), wild-type (WT) and Cx40−/− mice originally derived from male mice 
provided by Dr. David Paul (Harvard University, Boston, MA) 43. 
 Mice were anesthetized with an intraperitoneal injection mixture of ketamine (150 
mg/kg) and xylazine (10 mg/kg). Body temperature was monitored with a YSI-402 (Yellow 
Springs Instruments, Yellow Springs, Ohio) rectal probe inserted 1-1.5 cm beyond the anal 
sphincter, and maintained at 36.5-38 oC 45. A 23 ga Teflon® endotracheal tube was inserted 
and ligated in place to keep the airway open. 
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3.2.2 Surface Limb Lead Electrocardiograms (ECG) 
 Surface ECGs were obtained using 4 subcutaneous, 25 ga platinum electrodes (Grass 
Instrument Inc., Quincy, Mass.) placed at the base of each limb. ECG tracings were filtered 
between 0.05 to 100 Hz, digitized and sampled at 1.5 kHz, with an ECG100 preamplifier 
connected to a MP100 recording system (BIOPAC Systems, Biolynx, Montréal, PQ).  
3.2.3 Blood Pressure And Conscious Restrained Heart Rates 
 Blood pressure and simultaneous heart rate was assessed non-invasively in conscious WT 
and Cx40-/- mice using the CODA system 15.  
3.2.4 In Vivo Intracardiac Electrophysiology Studies 
 A 2F octapolar stimulation / recording / drug infusion catheter (CIB’ER Mouse®, 
NuMED Inc., Hopkinton, NY) was inserted through the right jugular vein and advanced into 
the right atrium and ventricle. Intracardiac electrograms were filtered between 100 to 5000 
Hz (DA100 amplifier, BIOPAC Systems) and sampled at 1.5 kHz. All data was recorded 
using a personal computer running Acknowledge software (BIOPAC Systems). His bundle 
potentials were used to establish catheter positioning within the right atrium (RA) and 
ventricle (RV) with 2 pairs of bipolar electrodes located at the posterior septal mid right 
atrium (MRA) and high right atrial/superior vena cava region (HRA) 45.  
3.2.5 Pacing Protocols 
 Bipolar pacing used 1 ms pulses at twice the diastolic threshold, delivered through a 
Grass stimulus isolation unit (SIU5), connected to a Grass SD9 stimulator, driven by a 
custom-built timer 45. Effective refractory periods (ERPs) from the right atrium (AERP), 
right ventricle (VERP), and AV node (AVNERP) were assessed with programmed electrical 
stimulation (PES) 45 using a drive train of 9 stimuli (S1) at a cycle length of 100 ms followed 
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by a progressively premature extra stimulus (S2). Atrial pacing with 1 ms decrements was 
used to determine the Wenkebach cycle length (WCL). 
3.2.6 Arrhythmia Induction Protocols 
 Three pacing protocols were used to evaluate the susceptibility to electrically-induced 
AT/F: 1) a single atrial stimuli (SAS) delivered during sinus rhythm, timed to follow the P-
wave (Fig. 3.1A); 2) programmed electrical stimulation (PES), with an increasingly 
premature extra stimulus (S2, Fig. 3.1B) 26, and 3) atrial burst pacing (1 ms pulses, 50Hz, 
400 ms train) 25, 45. AT/F was characterized based on the susceptibility to the pacing modality 
and the arrhythmia duration: a) no response; b) lasting <10 s; c) lasting from 10 to 60 s, and 
d) >120 s.  We previously determined that AT/F, when inducible in WT mice, is dependent 
on the pacing location in the right atrium, validated by using the His bundle potential as a 
landmark of catheter positioning 45.  Previous murine studies of atrial arrhythmia frequently 
report low susceptibility to AT/F in WT mice in the absence of carbachol (CCh) 51. As 
electrically-induced arrhythmia was rare in Cx40-/- mice, additional provocation used the 
nonselective cholinergic agonist, carbachol (CCh, 50ng/g, intraperitoneal, Sigma, 
Mississauga, ON) in WT and Cx40-/- mice 45.   
3.2.7 Epicardial Left Atrial Recordings 
 A subgroup of Cx43G60S/+ mice were mechanically ventilated at a respiratory rate of 100 
breaths per minute. The chest was open via a lateral thoracotomy between the first and 
second ribs. For epicardial recordings, Teflon insulated silver bipolar electrodes (0.2 mm 
spacing) were positioned on the surface of the left and right atrial appendages or the posterior 
left atrium 23. 
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Figure 3.1 A: Induction of atrial fibrillation (AT/F) with a single atrial stimulus (SAS) 
delivered during sinus rhythm in a 6-mo-old male Cx43G60S/+ mouse. Susceptibility to SAS 
induced AT/F indicates Cx43G60S/+ mouse have an extremely vulnerable atrial substrate. B: 
Programmed electrical stimulation (PES)-induced AT/F with a single extrastimulus (S2) in a 
6-mo-old male Cx43G60S/+ mouse. LL1, limb lead I; RV, right ventricular electrogram; HBE, 
electrogram from the His bundle region; HRA, recording from the high right atrium. 
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3.2.8 Statistical Analysis 
 Drug and strain comparisons were analyzed with 2-way ANOVA, and the Bonferoni 
post-hoc test (Prism 4.0, GraphPad Software, La Jolla, CA). The Chi Square test was used to 
analyze discrete data. A probability of P<0.05 was considered statistically significant. All 
data was expressed as the mean ±SEM. 
3.3 RESULTS 
3.3.1 Standard Electrophysiological Parameters 
 Cx40-/- mouse ECGs had prolonged P-wave and QRS durations, and QT and PQ intervals 
compared to age-matched WT mice (Table 3.1). Atrial-Hisian (AH) intervals were shorter 
during sinus rhythm and at a drive cycle length of 100 ms (AH100), while His-ventricular 
(HV) intervals were prolonged compared to WT mice (Table 3.1). WCLs were also shorter 
in Cx40-/- mice. Cx43G60S/+ mice had no differences in P-wave durations or PQ intervals 
compared to age matched littermates (Cx43+/+); however, QRS durations and QT intervals 
were  prolonged (Table 3.2). AH intervals recorded during sinus rhythm did not differ 
significantly, but with pacing, AH100 was lower in the Cx43G60S/+ mice compared to Cx43+/+ 
mice. HV intervals were also shorter in the in Cx43G60S/+ mice (Table 3.2). 
3.3.2 Effective Refractory Periods 
PES consistently revealed regional heterogeneity in AERPs: longer in the high right 
(AHERP) than the mid right atrium (AMERP) (Tables 3.1 & 3.2), but did not differ between 
strains. CCh reduced sinus rate (~20%) and AERPs in Cx40-/- and WT mice (Table 3.1). 
Interestingly, the ventricular ERP (VERP100) was lower in Cx43G60S/+ compared to Cx43+/+ 
mice, consistent with results from isolated right ventricular myocytes of the conditional Cx43 
knockout mouse, which was found to have enhanced IK1 activity 10. For Cx40-/- mice, VERP 
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did not differ from those of WT mice; however, following CCh administration, VERP100 in 
WT were even higher than those of Cx40-/- mice (Table 3.1).  
3.3.3 Cardiac Hypertrophy/Hypertension 
 Cardiac hypertrophy 29 and hypertension 50 were reported in Cx40-/- mice. As both 
hypertension and heart failure are risk factors for developing AF, we documented these 
phenotypes in our mice. Cx40-/- mouse hearts were visibly hypertrophic with a 54% increase 
in the ventricular weight to tibial length ratio (10.8 ± 0.8 vs. 7.0 ± 0.4 mg/mm, P<0.05), 
while Cx43G60S/+ mouse hearts were normal (6.9 ± 0.5 vs. 7.2 ± 0.7 mg/mm, P=N.S.). Using 
tail cuff measurement, conscious Cx40-/- mice had higher systolic (179.3 ± 4.8 vs 123.1 ± 5.6 
mmHg, P<0.001) and diastolic (140 ±7.3 vs 94.3 ± 5.8 mmHg, P<0.001) blood pressures and 
lower heart rates (594.1 ± 28 vs 701.2 ±36 bpm, P<0.05)  compared to age matched WT 
mice. One Cx40-/- animal died suddenly from unknown causes during tail cuff measurement. 
This death may have resulted from restraint stress-induced ventricular arrhythmia 37, as no 
WT but 2 Cx40-/- mice had burst pacing induced ventricular tachycardia lasting ~13 seconds. 
Of note, atrial standstill was reported in patients that co-inherit a novel SCN5A mutation 
along with a Cx40  polymorphism 34. Blood pressures in Cx43G60S/+ mice were not 
determined.  
3.3.4 Atrial Tachyarrhythmia Induction 
 Pacing-induced atrial arrhythmia had electrophysiological characteristics of AF 25, 
although distinguishing from rapid atrial tachycardia and validation of AF would require 
high density mapping. Thus, we labeled all atrial arrhythmias as AT/F 45.  
 C57BL/6 WT Mice were relatively insensitive to any duration of AT/F induction (0.1 sec 
to >120 sec) with PES (4 of 12, 17%), while they were inducible with burst pacing (9 of 12, 
75%; Fig. 2A). CCh injection (50ng/g, I.P) caused a trend to increase susceptibility to AT/F  
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Table 3.1. Intracardiac electrophysiological values recorded in the absence and presence of 
carbachol in 6-mo-old male Cx40-/- and C57BL/6 wild-type mice 
 
 
Values are means ± SE; n, number of mice. AHERP, high right atrial effective refractory 
period; AMERP, mid-right atrial effective refractory period; WCL, Wenkebach cycle length; 
AVNERP, atrial-ventricular effective refractory period; AH, atrial-Hisian interval; HV, His-
ventricular interval; VERP, right ventricular effective refractory period. Subscripts (100) 
indicate drive cycle lengths of 100 ms. *P < 0.05; †P <0.01; ‡P <0.001 for Cx40-/- vs. wild-
type mice within drug group. 
 
 
 
 
Table 3.2. Intracardiac electrophysiological values recorded from 6-mo-old male Cx43G60S/+ 
and Cx43+/+ mice. 
 
 
Values are means ± SE; n, number of mice. *P<0.05 for Cx43G60S/+ vs. Cx43+/+ mice. 
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induction with both PES (7 of 10, 70%, Χ2=2.93, P=0.08) and burst pacing (9 of 10, 90%, 
Χ2=0.83, P=0.36). SAS induction protocol was not performed in WT mice. However, CCh 
injection prolonged the duration of AT/F with only 1 of 12 untreated WT mice having 
sustained AT/F (>2 min) before, while 7 of 10 had sustained AT/F after CCh administration 
(Χ2=8.96, P=0.003, Fig. 3.2B). Consistent with our previous studies 45, the site of stimulation 
within the atrium also influenced AT/F inducibility. In WT mice, CCh induced AT/F was 
more readily initiated from the mid-right septal atrium (MRA) (7 of 10, 70%) compared to 
the high right atrium/superior vena cava region (HRA) (1 of 10, 10%, Χ2=7.5, P=0.006). This 
may have been due to the respective AERPs, which were shorter in the MRA compared to 
the HRA (Table 3.1). The requirement for pacing of the MRA to induce AT/F was consistent 
in all Cx40-/-, Cx43G60S/+, Cx43+/+ and WT mice. 
 Cx40-/- mice were less susceptible to AT/F induction of all durations (0.1 sec to >120 sec) 
with burst pacing in the absence of CCh (2 of 13, 15%) compared to WT animals (9 of 12, 
75%, Χ2=9.0, P=0.003, Fig. 2A). In the absence of CCh, more WT mice were susceptible to 
short lived, non-sustained AT/F (<10 sec), compared to Cx40-/- mice (9 of 12 vs. 1 of 13, 
Χ2=11.78, P<0.001, Fig 3.2B & C). However, there was no difference between WT and 
Cx40-/- mice in the susceptibility to sustained AT/F (>120 sec) (1 of 12 vs. 1 of 13, Χ2=0.003, 
P=0.95, Fig 3.2B & C). Of note, the single Cx40-/- mouse with sustained AT/F had a much 
shorter AERP in both HRA (14 ms) and MRA (12 ms) relative to average values (Table I). 
While the results of this and other studies indicate that Cx40-/- mice do not appear to have an 
increase in susceptibility to AT/F compared to WT mice, it is possible that Cx40 deficiency 
would alter the substrate sufficiently to increase the susceptibility and sustainability of CCh-
induced AT/F. As such we used CCh, to evaluate potentially increased susceptibility to AT/F  
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Figure 3.2. Incidence of AT/F-induced PES or burst pacing in 6-mo-old male wild-type 
(WT) and Cx40-/- mice. AT/F was classified based on susceptibility (A) to each pacing 
protocol and the duration (B and C) of induced arrhythmias in both the absence and presence 
of carbachol.   
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in Cx40-/- mice. However, unlike WT mice where CCh substantially increased susceptibility 
to sustained AT/F (Fig. 2B), administration of CCh did not increase susceptibility to 
sustained AT/F in Cx40-/- mice (1 of 13 without vs 2 of 9 with CCh, Χ2=0.95, P=0.32, Fig. 
3.2C). 
 Cx43+/+ littermate mice were used as controls instead of WT mice to ensure strain 
background control for the G60S mutant strain. Similar to WT mice, Cx43+/+ mice were 
relatively insensitive to AT/F induction of any duration (0.1 sec to >120 sec) by either single 
atrial stimulation (SAS) (1 of 11) or PES (4 of 11), while 8 of 11 were inducible using burst 
pacing (Fig. 3.3A). Of those which were inducible, 3 had sustained AT/F (>120 sec), 1 was 
had AT/F of an intermediate duration (10 to 60 sec) while the other 4 were not sustained 
(<10sec, Fig. 3.3B). 
 Cx43G60S/+ mice were highly susceptible to the induction of AT/F with all 3 pacing 
modalities: SAS (12 of 12, Fig. 3A); PES (12 of 12, Fig. 3A), and burst pacing (12 of 12, 
Fig. 3A). Of these, 9 of 12 had sustained AT/F, while 3 of 12 had intermediate durations (10-
60 sec, Fig. 3B). Cx43G60S/+ mice were more sensitive to induction of sustained AT/F 
compared to Cx43+/+ mice (Χ2=5.24, P=0.02, Fig. 3B). Of the Cx43G60S/+ mice with sustained 
AT/F, the maximum arrhythmia duration allowed was >35 minutes before the arrhythmia 
was terminated using burst pacing; however, the majority were electrically terminated after 2 
minutes in order to proceed with the electrophysiological studies. In a subset of the 
Cx43G60S/+ mice AT/F could be terminated using a single atrial stimulus delivered to the mid 
right atrium (n=5). In our previous study we found that RGS2-/- mice had AT/F associated 
with enhanced M3 muscarinic receptor 45. Thus, we determined the efficacy of intravenous 
darifenacin hydrobromide (1 mg/kg), a selective M3 muscarinic receptor antagonist, to 
terminate the “new onset” sustained AT/F in 5 Cx43G60S/+  
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Figure 3.3. Incidence of AT/F induced by a SAS, PES, and burst pacing in 6-mo-old male 
Cx43+/+ littermate and Cx43G60S/+ mice. AT/F was classified based on susceptibility (A) to 
each pacing protocol and the duration (B) of induced arrhythmias. 
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mice. Intravenous  injection of darifenacin terminated sustained AT/F in all 5 mice. Of note, 
AT/F was re-inducible with burst pacing 5 minutes after drug treatment.  
3.3.5 Electrogram Analysis 
The morphology of bipolar electrograms has been extensively studied in patients and 
animal models of AF 11, 30. Normal unfractionated bipolar electrograms usually have a single  
monophasic or biphasic potentials, the morphology of which depends on the orientation of 
the electrode poles relative to the vector of the propagating electrical wave. Fractionated 
electrograms (FE) have multiple deflections within one cardiac cycle. As the study of 
electrogram fractionation in AT/F, to our knowledge, has not previously been performed in 
the mouse, we present the spectrum of electrograms that we have observed (Fig. 3.4). The 
simplest FE was a double potential, in which the time between peaks could be short (short 
double), or long (long double) (Fig. 3.4). Complex fractionated atrial electrograms (CFAE) 
have multiple peaks or may have continuous electrical activity throughout the entire cardiac 
cycle (Fig. 3.4). In humans, fractionated electrograms may be found: 1) in areas with slow 
conduction, such as the border zone of an infarct; 2) associated with a line of block (short/ 
long double) 11; 3) around the pivot point of a micro re-entrant circuit, or 4) where waves 
collide 30. CFAEs have also been observed in myocyte monolayers, at sites of migrating 
rotors and wave break 46. As an index of conduction disturbance in-vivo, bipolar right atrial 
activation patterns observed in the MRA and HRA during AT/F were used, since optical 
mapping is not available in our laboratory, and in mice, optical mapping usually requires ex-
vivo studies. We devised an index of electrogram patterns during AT/F, based on the degree 
of conduction disturbance: a) the lowest level was designated “fractionation only”, without a 
variable HRA cycle length compared to that recorded from the MRA; b) the intermediate had 
a variable HRA cycle length (CL) compared to the MRA CL, with or without intermittent  
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Figure 3.4. Morphology of fractionated bipolar electrograms (FEs) in mice recorded 
during sinus rhythm and electrically induced AT/F. Normal electrogram 
morphology had single sharp potentials. The simplest FEs had double 
potentials in which the time between peaks could be short (short double) or 
long (long double). Complex FEs had multiple peaks or continuous electrical 
activity throughout the entire cycle. 
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activation failure in the HRA, and c) the highest level had a pattern of 2:1 activation failure 
in the HRA compared to that recorded in the MRA. WT and Cx43+/+ mice commonly had 
unfractionated single potentials recorded from both the MRA and HRA electrodes during 
both sinus rhythm and AT/F. Fractionated double potentials, and complex electrograms were 
observed during AT/F in Cx43G60S/+ mice, commonly with double potential morphologies, 
which may have been due to functional conduction block along a zone of poor conduction.  
In order to determine if the Cx43 G60S mutation-induced reduction in Cx43 was 
associated with disturbed conduction during AT/F (short cycle lengths or high rates), we 
compared electrograms recorded from Cx43G60S/+ to both Cx43+/+ and WT mice with induced 
AT/F. As there were no significant differences in the absence of carbachol, in the 
susceptibility to sustained AT/F between WT and Cx43+/+ mice (1 of 12 vs. 3 of 11, X2=1.43, 
P=0.23), their responses to CCh-induced AT/F were grouped and compared to those of the 
Cx43G60S/+mice. During AT/F, Cx43G60S/+ mice had a higher instance of disturbed RA 
conduction compared to Cx43+/+ and WT mice (X2=8.37, P=0.004, Fig. 3.5). Importantly, 
tachycardia cycle lengths did not differ between the two groups (WT/Cx43+/+, 33.2 ±2 ms 
and Cx43G60S/+, 35.9 ±2.1 ms,  P=0.36). The atrial activation rate during AT/F ranged from 
1154 to 2609 per minute; an 8 fold maximal increase over the sinus rate of the anaesthetized 
mouse (325 ±35 bpm) and a 4 fold increase over the sinus rate of the conscious “restrained” 
WT mouse (701.2 ±36 bpm).  
3.3.6 Left Atrial Recordings 
 As AF in patients frequently originates from the left atrium/pulmonary vein region, we 
performed epicardial left and right atrial appendage recording in a subset of mechanically 
ventilated Cx43G60S/+ mice (n=4). In all mice, atrial activation followed a left leading right 
atrial pattern, indicating that the arrhythmia driver was in the left atrium (n=4) (Fig. 3.6A).  
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Figure 3.5. Classification of electrogram activation patterns during AT/F in Cx43G60S/+, 
Cx43+/+, and WT mice with carbachol-induced AT/F. Electrograms were grouped based on 
the degree of conduction disturbance, the least severe being “fractionation only”; 
intermediate being “variable HRA CL,” with or without intermittent activation failure in the 
HRA; and most severe being a pattern of “2:1 activation failure” of the HRA relative to the 
MRA. 
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Figure 3.6. Recording from epicardial electrodes during AT/F in mechanically ventilated 
Cx43G60S/+ mice. A: activation patterns recorded from the left (LAA) and right atrial 
appendages (RAA) demonstrating a left leading right activation pattern. B: recording from 
the left atrial posterior wall (LAPW) during AT/F demonstrating a complex fractionated left 
atrial electrogram pattern, while there is no fractionation in the right. 
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Spontaneous termination, when observed, occurred in the left with the last area of activation 
in the right atrium. Recordings from the posterior left atrium also revealed zones of high 
frequency complex fractionation (Fig. 3.6B), consistent with AF. 
 
3.4 DISCUSSION 
 This main purpose of this study was to investigate the role of the Cx43 G60S 
mutation on the susceptibility to atrial tachy-arrhythmias in the mouse. Studies in the Cx40-/- 
mouse also allowed direct comparisons on the role of reductions in each Cx isoform in AT/F. 
The results indicate that Cx43G60S/+ mice have increased susceptibility to AT/F while Cx40-/- 
mice do not. 
As gap junctions are critically important for cardiac impulse propagation it is not 
surprising that alterations of Cxs would be important in atrial arrhythmia. However, as Cx43 
deficient mice die prematurely, comparative in vivo studies on the role of Cx40 and Cx43 in 
AT/F have not been performed. Interpretations of the significance of the results of past 
studies in Cx40-/- mice have been hindered by the lack of definition of what constitutes a 
sustained atrial tachy-arrhythmia in the mouse. In the presence of CCh, WT mice had AT/F, 
averaging >139 s 51. In the present study, we found long lasting (>2 min, and as long as 35 
min), readily inducible (100% susceptibility) AT/F in Cx43G60S/+ mice. These observations 
provide a bench mark to define “sustained AT/F” in the mouse, allowing differentiation from 
transient arrhythmias.  
 We observed infrequent, primarily short runs of rapid atrial activity following burst 
pacing in the Cx40-/- mice with only 1 incident of sustained AT/F, consistent with previous 
findings. After observing AT/F lasting >35 min in the Cx43G60S/+ mutant mice, it has become 
clear that short duration (<1 second) events are likely of limited physiological significance. 
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To evaluate if Cx40 deficiency could make the atrium more susceptible to AT/F in the 
presence of another provocative agent, we determined the susceptibility to CCh-induced 
AT/F in the Cx40-/- mouse. However, we found that CCh did not significantly enhance 
inducibility of sustained AT/F in Cx40-/- mice (>120 sec, Fig. 3C). This finding is consistent 
with those of dogs treated with n3-polyunsaturated fatty acids (PUFA) which had a reduced 
incidence of vagally induced AF, where protection was related to PUFA induced reductions 
in Cx40 protein expression 41. 
Three different pacing protocols were used to induce AT/F: burst pacing; PES with a 
single premature extra stimulus; and SAS with single atrial stimuli delivered during sinus 
rhythm timed to follow the p-wave and interact with the heterogeneous refractoriness of the 
atrial tissue. Both PES and SAS were thought to mimic physiological initiation of AT/F, as 
premature atrial beats often precede AT/F episodes 22. Burst pacing, perhaps a non-
physiological provocation, was found to more reliably induce AT/F by promoting cardiac 
electrical instability 25. Susceptibility to AT/F in the mouse induced by single stimuli 
delivered in sinus rhythm, an extremely mild pacing protocol, has not previously been 
reported in the mouse.  AT/F induction with the SAS protocol indicates that the Cx43G60S/+ 
mice are extremely vulnerable to atrial arrhythmia. Detailed electrogram analysis showed 
that underlying heterogeneities in AERPs (in MRA vs HRA) on a background of reduced 
Cx43 content were associated with fibrillatory conduction with short cycle lengths (Fig. 5). 
Mechanistically, AF may result from a single source (mother rotor) resulting in fibrillation 
due to the breakup of high frequency wavefronts interacting with tissue heterogeneities 24. 
Thus reductions in Cx43 could promote AF initiation by promoting a wavebreak, coupled 
with conduction disturbances 48 to perpetuate AF. In an effort to compare murine AT/F to 
human AT/F, we determined if the mouse had left atrial predominance in AT/F mechanisms 
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as had been observed in man. Epicardial left atrial recordings in mechanically ventilated 
Cx43G60S/+ mice during AT/F had a left preceding right atrial activation pattern, and 
displayed zones of complex fractionation in the posterior left atrium. This result is consistent 
with clinical findings where the driver of AF is commonly observed in the posterior left 
atrium/pulmonary vein region 20, 36. While sustained AT/F occurred infrequently in the Cx40-
/- mice, genetic polymorphisms in Cx40 are associated with AF 6, 8. While a functional 
change in gap junctions caused by retaining mutant Cx40 at the intercalated disc may 
promote AF 17, the present data show that complete removal of Cx40 (structural change) 
appears to provide resistance to CCh-induced AT/F. However, a large reduction (~80%) of 
phospho-Cx43 promotes enhanced AT/F susceptibility. While these results warrant further 
study, they are consistent with previously published results.                  
 The atrium has equivalent expressions of Cx40 and Cx43. Thus atrial gap junctions may 
have varying stoichiometry (homomeric, heteromeric, homotypic or heterotypic), with 
unique gating and conductance properties 9. In A7r5/Rin cell pairs, Cx40 and Cx43 can form 
homomeric/heterotypic and heteromeric/heterotypic gap junctions with unique gating and 
conductance properties 9; however, junctional conductance is reduced relative to 
homomeric/homotypic channels. HeLa cell pairs co-expressing Cx40 and Cx43 also were 
reported to have substantial reductions (~56-66%) in junctional conductance compared to 
homotypic cell pairs 47. In addition, another study suggests that Cx40 and Cx43 
hemichannels are potentially incompatible, as conduction was not detected 21. It is reasonable 
to assume that Cx40-/- and Cx43G60S/+ mice would have altered stoichiometry of connexon 
oligomerization which would alter conduction properties. However, the presence of, and 
functional consequence of gap junctions of mixed stoichiometry in the atrium has been 
reported to be uncertain 12.  
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A functional consequence of coexpression of Cx40 and Cx43 on junctional conductance 
(gj) in the mouse atrium has been studied using spermine, a compound that is reported to 
dose-dependently and selectively block Cx40 containing gap junctions 33. Spermine blockade 
in Cx40-/- and Cx40+/+ atrial cell pairs indicated that Cx40 contributes to ~40% of wild type 
gj 33. Susceptibility to spermine inhibition also suggested that ~10-20% of atrial junctional 
conductance might be due to gap junctions of mixed stoichiometry 33. Also, junctional 
conductance was unaltered in myocyte pairs from Cx40-/- mice (WT = 6.031.09 nS vs Cx40-
/- = 6.101.14 nS) (see Supplementary Material in Lu et al 33), suggesting an important role 
for channels of mixed stoichiometry or that Cx43 may compensate for the lack of Cx40. 
Cx43G60S/+ mice have an ~80% reduction in ventricular phosphorylated Cx43 but only a 
~50% decrease in ventricular myocyte gj. This suggests that myocytes biosynthesize larger 
amounts of Cx43 than is necessary to maintain normal cardiac gj function 35. This idea is 
consistent with the observation that in ventricular myocytes only 10% of the available 
cardiac gj channels are open to conduct current during a given action potential 52. Both 
phosphorylation and pH are well known to regulate functional properties of gap junction 
channels. Ischemia results in acidification and closure of homomeric Cx40 and Cx43 
containing gap junctions. However, coexpression of Cx40 and Cx43 in xenopus oocytes 
enhances the pH sensitivity of the channel, a phenomenon that requires the carboxy termni of 
both connexins 5. Reductions in either Cx40 or Cx43 (reducing heterogeneity) would then 
likely decrease the pH sensitivity of the remaining gap junction channels. 
In synthetic strands of neonatal atrial myocytes from Cx40-/- and Cx43-/- mice, 
conduction velocity was increased in Cx40-/- strands, but was reduced in Cx43-/- strands 2. 
The percent cell area occupied by the Cx40 immunosignal was smaller (2.0 ± 1.6% vs 1.0 ± 
0.2%) in Cx43-/- cultures, while the area of Cx43 immunosignal was larger (1.2 ± 0.9% vs 3.1 
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± 3.6%) in Cx40-/- cultures 2. This suggests that Cx40 may sterically limit the number of 
Cx43 containing gap junctions at the intercalated disc in WT atria. Removal of Cx40 would 
allow an increased insertion of Cx43 containing gap junctions into the intercalated disc 
region, to compensate for the reduced Cx40. Compensation may not be limited to those of 
neonatal myocytes, as optical mapping from adult Cx40-/- mice revealed that morphologically 
normal hearts have no change in atrial conduction velocity 32. Similar observations have been 
made in human myocardium, where there is a positive correlation between conduction 
velocity and the relative quantity of Cx immunolabelling (expressed as Cx40/[Cx40 + 
Cx43]), when Cx40 signal was higher or Cx43 signal was lower, conduction velocity was 
lower 28. 
Taken together, these observations suggest the following theoretical model of the role of 
alterations of connexins in the atrium. As stated above, Cx40 may sterically limit Cx43 
content at the intercalated disc region, thus loss of Cx40 would lead to compensatory 
increased Cx43 insertion; however, the reverse seems not to occur. Atrial gap junction 
channel conductance follows a hierarchy where Cx40/Cx40 > Cx43/Cx43 > Cx40/Cx43.  
Therefore, homogenous loss of Cx40 leads to increased junctional conductance (plus 
decreasing pH sensitivity of channels) and reduced heterogeneity as only Cx43/Cx43 gap 
junctions remain. As such increased heterogeneity of coupling might then promote AT/F. On 
the other hand, somatic mosaic mutation in either Cx40 or Cx43 in patients leads to AF. This 
is likely due to the resultant enhanced heterogeneity of the atrial tissue accentuated by the 
mosaic nature of the functional changes, whether or not there is an accompanying 
localization in the intercalated disc.  
In conclusion, it is clear that alterations in gap junctions can have a role in AF 
mechanisms. However that role may not simply be due to reductions in Cx content 14. Proper 
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interpretation of the role of Cxs in AT/F should consider the functional alterations, structural 
alterations, stoichimetric alterations, and the potential for compensation 14. In this study we 
found that the Cx43G60S/+ mutant mouse had sustained AT/F. We also noted that Cx40-/- mice 
were resistant to CCh-induced AT/F despite severe hypertension and cardiac hypertrophy; 
both risk factors for development of AF. As AF can be a silent disease, observed only after 
diagnostic (ECG) testing, it may be wise to monitor patients with Cx43 mutations causing 
Oculodentodigital Dysplasia as there are reports of cardiac phenotypes 39 in these patients 
and they may have additional age-related risk for developing AF.  
3.5 LIMITATIONS 
It may be difficult to distinguish AF from atrial tachycardia, when evaluating recordings 
from the mouse heart, particularly with arrhythmia of short duration 45. However, using the 
standard clinical criteria for identification of AF, lack of regular P waves on ECGs and 
irregularly irregular ventricular responses, often with left atrial predominance of AF 
mechanisms, in this study it was often possible to demonstrate these classical characteristics 
of AF in the mouse. In addition, it may not always be possible to extrapolate data obtained 
from the mouse to explain arrhythmia mechanisms in the human.  
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CHAPTER 4: Junctional Tachycardia in the Mouse is Prevented by Pacemaker 
Channel (If) Blockade 
 
4.0 CHAPTER SUMMARY 
 A central objective of this thesis was to determine how to systematically elicit and 
study atrial arrhythmia in the mouse.  Here I investigate AV nodal conduction properties and 
two supraventricular arrhythmias, AV nodal reentry and Junctional Tachycardia (JT).  
Histological studies indicate that the mouse AV junction is highly similar to the human.  I 
determined that the mouse and human AV junction also have similar electrophysiological 
properties including: dual AV nodal physiology; nodal reentry; functional longitudinal 
dissociation of the bundle of His; and susceptibility to JT.  JT occurs in approximately 10% 
of children following cardiac surgery and increases the risk of mortality by 5.6-14%. I found 
that rapid ventricular pacing (RVP) induced JT in the mouse, which was distinguished from 
AVNRT using diagnostic pacing studies.  RVP caused decreases (46±2.6%) in the minimal 
end-diastolic blood pressure and enhanced nodal conduction following 10 bursts (pre-pacing 
AH=31±1ms vs post-pacing AH=28±1ms, P<0.001, n=14) prior to JT initiation, suggesting 
involvement of a baroreflex response. Vagal nerve stimulation (5/5) and propranolol (7/7) 
prevented JT induction, confirming a role for the autonomics.  These observations provide 
evidence for the hypothesis that there is a role for the autonomics in most atrial arrhythmias.  
Due to the impaired ventricular function in neonates following cardiac surgery, use of 
negative inotropic drugs for JT, such as propranolol, is counter indicated.  Thus, there is a 
need for a novel antiarrhytmic for the treatment of JT.  In this chapter I found that Ivabradine 
hydrochloride, a selective If channel blocker, with no negative inotropic effects, prevented JT 
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in 8 of 9 mice  (X2=14.4, P<0.001).  As such ivabradine might be useful in patients with post-
operative JT. 
 
4.1 INTRODUCTION  
The heart’s atrioventricular node (AVN) plays 2 important functions; cardiac impulse 
conduction and impulse initiation.  The AVN is normally the only electrical route for 
activation from the atria to the ventricles and acts to shield the ventricles from excessively 
fast atrial rates. Dysfunction of AV nodal conduction results in AV block or re-entrant 
tachycardia (AVNRT). The mechanism of AVNRT is well defined, involving the conversion 
of multiple non-discrete input pathways to the compact AV node, (the “fast” (FP), 
“intermediate” (IP), and “slow” (SP) pathways), into functional dual pathways allowing for 
reentrant conduction (Fig. 4.1)49. Normal antegrade conduction to the ventricles is through 
the FP. The SP, which is composed of the posterior peripheral or inferior nodal extension 
(PNE or INE) of the compact AVN, is present in all normal hearts49.  However, differential 
refractoriness, local negative balances of current source and current sink along with 
increasing electrical load at the transition zone of the AVN are thought to results in the 
development of a "line of block" in one pathway and thus initiate reentry49. The AV node is 
tightly regulated by the autonomic nervous system32, explaining why vagal manoeuvres are 
successful in terminating AVNRT47. Knowledge of the mechanism of AVNRT has resulted 
in development of successful curative interventions using radiofrequency ablation of the SP. 
The AVN is also an oscillator, acting as a backup pacemaker during sinoatrial nodal 
(SAN) failure. The SAN is the dominant pacemaker of the heart. Normally the AVN  
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Figure 4.1: A diagrammatic representation of the structure of the atrial inputs to the AV 
node from optical mapping data adapted from Wu & Zipes49. FP, fast pathway. IP, 
intermediate pathway. SP, slow pathway. AVN, compact AV node. Dashed lines 
represent the borders of the triangle of Koch. 
 
 
 
 
 
 
 
 109 
pacemaker is much slower, thus it is kept quiescent by continual overdrive suppression by 
the faster SAN. In the heart, 2 pacemaking mechanisms have been proposed: that involve the 
activity of the hyperpolarization activated cyclic nucleotide gated (HCN4) pacemaker funny 
channel (If)26, which produces a diastolic depolarization; and a "calcium clock", where 
oscillations in local Ca2+ release from the ryanodine receptor activate the electrogenic Na+-
Ca2+ exchanger to accelerate the upstroke of the late diastolic depolarization24. Genetic 
markers of pacemaking tissue (high: Cx30.2/Cx45/ HCN4/Tbx3, low: Cx40/Cx43/SCN5a) 
are expressed in both the mouse SA and AV node8. The If channel density is much greater in 
the SAN6, than the dominant AVN pacemaker region26, located in the posterior nodal 
extension13. This indicates that If channel expression density correlates with intrinsic 
pacemaker rate. The human AVN also contains HCN4, with little HCN4 detected in the 
surrounding atrium52.  
Dysfunction of AVN impulse initiation results in junctional tachycardia (JT, also called 
junctional "ectopic" tachycardia). JT is frequently observed in neonates following cardiac 
surgery4, 11, 19, 34; although, a rare congenital form exists50. The rapid rate and hemodynamic 
dysfunction during JT following cardiac surgery can be problematic, increasing the risk of 
mortality by 5.6%-14% 4, 11, 19, 34. It is suggested that the arrhythmia may be generated by 
injury to the AVN during surgery; however, JT can occur in patients where the AV node is 
not harmed. Thus, the mechanism(s) of JT have not yet been fully elucidated. Numerous 
clinical observations suggest a role for the autonomics. During JT the atria contract against 
closed AV valves, reducing the atrial component of ventricular filling, thus reducing cardiac 
output. This reduction coupled with the already reduced cardiac output due to post-surgical 
stunning, produces dangerous hypotension which may drive a positive feedback-like 
baroreflex response, potentiating the arrhythmia. Pre-operative treatment with propranolol, a 
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β-adrenergic receptor inverse agonist, can reduce the incidence of post-operative JT (control 
group (38%) vs. propranolol group (21%) P<0.042)28. Consistent with this finding, 
dopamine, an adrenergic agonist used for inotropic support after cardiac surgery in neonates4, 
19, is a risk factor for JT4. Amiodarone (generally considered a class III antiarrhythmic), used 
for treatment of JT, also has anti-sympathetic actions. Atrial sympathetic noradrenalin release 
is inhibited by pre-synaptic α-2 adrenergic receptor stimulation18. Post-operative use of 
Dexmedetomidine, a sedative and α-2 adrenergic receptor agonist, decreased JT rate from 
197±22 to 165±17 bpm within 67±75 min of administration9. Pacemaker function is tightly 
regulated by autonomic responses. Activation of β-adrenergic receptors (stimulatory) and M2 
muscarinic receptors (inhibitory) regulate the formation of the cyclic AMP (cAMP) that 
directly regulates pacemaker channel and PKA activation. Cyclic AMP binding directly 
regulates If channels, causing a shift towards depolarization in the channel’s activation curve. 
This coupled with the phosphorylation of various intracellular Ca2+ handling proteins (L-
Type Ca+ channels, RyR, Phospholamban) by PKA and CAMKII are also proposed to 
enhance the periodicity of the local Ca2+ release events of the "Calcium Clock" and 
pacemaker rate.  
 The development and 3-D architecture of the mouse atrioventricular conduction axis has 
high similarity to the human conduction system1. Thus, I hypothesized that the mouse and 
human AV junction would have similar electrophysiological properties including: dual AV 
nodal physiology; nodal reentry; and functional longitudinal dissociation of the bundle of 
His.  In addition, the mouse has been used for the study of AV nodal properties27, 37, 46 and 
arrhythmia29 and as such may provide insights into the mechanisms of JT.  I hypothesize that 
JT is caused by inappropriate (enhanced) AV nodal pacemaker activity initiated by abnormal 
autonomic (baroreflex) activity. In this chapter I determine normal AV nodal conduction 
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properties; determine the susceptibility of the mouse to induced JT; distinguish JT from 
AVNRT using diagnostic pacing studies; and study the mechanisms of JT pharmacologically 
in the mouse. 
4.2 METHODS 
4.2.1 Animals 
 Studies used 3-6 month old C57BL/6 mice from Charles River, unless otherwise stated. 
All studies were approved by the Animal Care and Use Committee of the University of 
Western Ontario (protocol #2006-121-12) and complied with the guidelines of the Canadian 
Council on Animal Care and the Guide to the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (Institution #A5527-01).  RGS2-/- mice were provided 
by Dr. Peter Chidiac from his breeding colony. 
 Using routine procedures42, 44, mice were anesthetized with an i.p. injection mixture of 
ketamine (150 mg/kg) and xylazine (10 mg/kg). Body temperature was monitored with an 
YSI-402 (Yellow Springs Instruments, Yellow Springs, Ohio) rectal probe and maintained at 
36.5 - 38 oC42. Through a cut-down, a 23 ga Teflon endotracheal tube was inserted and 
ligated in place to keep saliva and blood from the trachea and maintain it open. Limb lead 
ECGs were obtained using 4 subcutaneous 25 ga platinum electrodes (Grass Instrument Inc., 
Quincy, Mass.) placed at the base of each limb. ECG tracings were filtered between 0.05 to 
100 Hz, digitized and sampled at 1.5 kHz, with an ECG100 preamplifier connected to an 
MP1000 recording system (BIOPAC Systems, Biolynx, Montréal, PQ).  
4.2.2 In Vivo Intracardiac Electrophysiology Studies 
 A 2F octapolar stimulation / recording / drug infusion catheter (CIB’ER Mouse®, 
NuMED Inc., Hopkinton, NY) (Fig. 4.2a) was inserted through the right jugular vein and 
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advanced into the right atrium and ventricle. Intracardiac electrograms were filtered between 
100 to 5000 Hz (DA100 amplifier, BIOPAC Systems) and sampled at 1.5 kHz. All data were 
recorded using a personal computer running Acknowledge software (BIOPAC Systems). His 
bundle potentials (Fig. 4.2b) were used to establish catheter positioning within the right 
atrium (RA) and ventricle (RV) with 2 pairs of bipolar electrodes located at the mid right 
atrium (MRA) and the high right atrium region (HRA)42.  The catheter positioning was 
verified using Computerized Tomography (CT, Fig. 4.2c).  
 Bipolar pacing used 1 ms pulses at twice the diastolic threshold, delivered through a 
Grass stimulus isolation unit (SIU5, Grass Equipment Ltd., Quincy, Mass), connected to a 
Grass S99 stimulator, driven by a custom-built timer42. Effective refractory periods (ERPs) 
from the right atrium (AERP), right ventricle (VERP), and AV node (AVNERP) were 
assessed with programmed electrical stimulation (PES)25 using a drive train of 9 stimuli (S1) 
at a cycle length of 100 ms and150 ms, followed by a progressively premature extra stimulus 
(S2). Atrial pacing with 1 ms decrements was used to determine the Wenkebach cycle length 
(WCL). Junctional Tachycardia was induced by repetitive (10-40) trains of ventricular burst 
pacing (train duration: 400ms, S1S1 coupling interval: 20ms). Single atrial stimuli delivered 
to the high right atrium at various phases of the tachycardia cycle were used to distinguish JT 
from AVNRT. 
4.2.3 Blood Pressure  
 Blood pressure changes in response to ventricular burst pacing were assessed by 
cannulating the carotid artery with PE-10 tubing filled with heparinized saline. The tubing 
was connected to a COBE pressure transducer and recorded on the BioPac system.  
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4.2.4 Pharmacological Tests 
 Responses to cholinergic stimulation were determined using i.p. injections of the non-
selective cholinergic agonist, carbamyl choline chloride, (carbachol, CCh, 0.05 mg/kg), and 
the non-selective cholinergic antagonist, atropine (1 mg/kg). Sympathetic blockade used i.v. 
injection of propranolol (1mg/kg) via a cannula inserted into the left jugular vein.  
Ganglionic blockade used the nicotinic acetylcholine receptor blocker Hexamethonium 
bromide (30mg/kg, i.v.). Low dose Ivabradine hydrochloride (1 mg/kg, i.v.) examined the 
role of the pacemaker funny channel (If). Ruthenium Red (1 mg/kg, i.v.), a potent inhibitor of 
Ca2+ release from the ryanodine receptor and Caffeine (10mg/kg, i.v.) to stimulate Ca2+ 
release examined the function of the intracellular Ca2+  clock. DPCPX35 (8-cyclopentyl-1, 3-
dipropylxanthine, 100ug/kg, i.v.), a selective A1 adenosine receptor antagonist, tested the 
adenosine effect in the Caffeine response. Forskolin (1 mg/kg, i.v.), a direct activator of 
Adenylyl Cyclase, IBMX (0.5 mg/kg, i.v.) a nonselective phosphodiesterase inhibitor and 
Milrinone (1 mg/kg, i.v.) a selective PDE3 inhibition, investigated the role of cAMP in JT. 
4.2.5 Statistical analysis 
 The Chi Square test was used to analyze discrete data. Student’s t Test analyzed non-
discrete data. A probability of P<0.05 was considered statistically significant. All data was 
expressed as the mean ± SEM. 
4.3 RESULTS 
4.3.1 Antegrade AV nodal conduction  
 Antegrade AV nodal conduction curves were examined for the presence of 
discontinuous conduction, an indication of functional dual AV nodal pathways27. 
Determination of what constitutes an adequate "jump" or sudden increase in A2H2 interval 
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with a decrease in A1A2 coupling interval, during programmed electrical stimulation, was 
made by examining for the presence of re-entrant atrial beats. Evidence for discontinuous 
conduction was taken as a >9 ms increase in A2H2 interval with a <5 ms decrease in A1A2  
 
 
 
 
 
 
Figure 4.2. A) Photograph of the 2F octapolar recording catheter used for intracardiac pacing 
and recording experiments in the mouse.  Numbers represent the bipolar electrode 
pairs used for recording sites within the heart: 1) ventricle 2) His bundle 3) mid-right 
atrium 4) high right atrium/superior vena cava. B) A representative electrogram from 
His bundle region. Electrode pair # 2 was the landmark used for determining of 
catheter position in the right atrium. C) Validation of catheter position using 
Computed Tomography (CT) imaging with the dots indicating the position of the 
electrode poles within the heart.   
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coupling interval. Using this criterion, discontinuous antegrade AVN conduction was 
observed in 8 of 19 mice (Fig. 4.3), with single re-entrant beats observed 3 of 19 (Fig. 4.4), 
but only one incidence multiple re-entrant events (1 of 19). 
4.3.2 Functional Longitudinal Dissociation Of The His Bundle (FP vs SP conduction) 
 Functional longitudinal dissociation of the bundle of His has previously been observed 
during optical mapping studies in rabbit51 and human20, 23AV junction preparations.  This 
phenomenon was used to explain the His bundle electrogram (HBE) amplitude alterations2, 40 
observed during SP vs FP activation of the His bundle. I examined mouse HBEs from 
antegrade conduction curves during discontinuous conduction (SP activation) and compared 
those electrograms to those recorded in the zone of continuous conduction (FP activation) on 
the same curve (Fig.4.3b/Fig.4.4, A1A2=59ms for FP vs A1A2=57ms for SP).  His 
amplitudes during defined "slow pathway" conduction (0.15±0.03 mV) was higher than 
during "fast pathway" conduction (0.12±0.03 mV, n=7, P<0.02). This pattern of His 
amplitude alterations is indicative of functional longitudinal dissociation of the His. His 
amplitudes recorded during "Slow pathway" conduction were also significantly greater 
compared to those recorded during sinus rhythm (0.15±0.03mV vs 0.10±0.02 mV, n=7, 
P=0.01) (Fig 4.4).  As a control for motion artefact due to pacing rate during programmed 
electrical stimulation, HBE amplitudes from the continuous antegrade conduction curves 
were analyzed just prior to conduction failure (the AV node effective refractory period).  
There was no significant differences in HBE amplitudes from the last His bundle activation 
on the continuous conduction curves vs the His amplitude in the preceding cycle (0.10±0.01 
vs 0.10±0.01 mV, n=11, P=0.93) or when compared to sinus rhythm (0.10±0.01 vs 
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0.10±0.02, n=11, P=0.82). There was also no difference in HBE amplitudes recorded during 
sinus activation of the His for mice with discontinuous conduction curves (8/19) compared to 
the continuous conduction curves (11/19) (0.10±0.01 vs 0.10±0.02 mV, P=0.98). Detection 
of HBE amplitude alterations on antegrade conduction curves may be a useful diagnostic test 
for the presence of slow pathway conduction.  The average change in HBE amplitude during 
SP activation was 0.04±0.01 mV. Therefore, a >0.03 mV change in HBE amplitude was set 
as an independent criterion for detection of SP conduction. To ensure there was no sample 
bias, raw data from individual antegrade conduction experiments were number coded, and 
randomized before re-analysis for HBE amplitude changes by an independent blinded 
observer.  A >0.03mV change in HBE amplitude was detected in 1 of 11 animals with 
continuous conduction and 7 of 8 animals with discontinuous conduction curves.  
4.3.3 Junctional arrhythmia  
 Junctional arrhythmia (His-V-A activation pattern) lasting 1-60 seconds, was 
consistently induced following repetitive (10-40) trains of ventricular burst pacing (50 Hz, 
400ms). The burst pacing protocol did not follow 1-1 with the pacing rate, but caused 
ventricular rate accelerations over 950 bpm. Junctional arrhythmia was induced in 74% of 
mice (14/19) producing a 32% increase in heart rate (325±15 vs 429±19 bpm, P<0.001). 
Spontaneous termination of the junctional arrhythmia was either sudden or occurred after the 
junctional rate arrhythmia slowed to a point that the arrhythmia was suppressed by a faster 
intrinsic SA nodal rate. 
4.3.4 Diagnostic Pacing Studies  
 Diagnostic pacing studies were performed to determine the mechanism of the induced 
junctional arrhythmia and distinguish AVNRT from JT. A premature atrial stimulus 
delivered >30 ms before the next His activation, consistently advanced His activation   
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Figure 4.3. A) An antegrade AV nodal conduction curve in a mouse with apparent 
continuous (no Jump) AV nodal conduction. B) An antegrade AV nodal conduction 
curve in a mouse with discontinuous AV nodal conduction.  An increase (jump) in 
A2H2 of >10 ms with a <4 ms decrease in A1A2 suggests conversion from the Fast 
to the Slow AV nodal pathway.   
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Figure 4.4.  Single AV nodal reentrant beats were observed during recording of antegrade 
AV nodal conduction. A) An electrogram with normal fast pathway (FP) conduction 
to the His bundle during antegrade AV nodal conduction.  B) After a 1 ms decrease in 
the A1A2 coupling interval, there was a 10 ms increase in A2H2 that initiated a 
reentrant atrial beat. C) With a further 1 ms decrease in A1A2, A2H2 increased 15 
ms, and a reentrant atrial beat was recorded. Note, the HA interval (retrograde FP) 
during reentry in “C” is shorter (22ms) than in “B” (33ms), due to the prolonged SP 
conduction, allowing recovery of the FP. LLI, limb lead 1. HBE, His bundle 
electrogram. MRA, mid-right atrium. ** P<0.01. 
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(through the FP) without terminating the arrhythmia (0/14 were terminated, Fig 4.5a). 
Occasionally, premature FP activation transiently suppressed the junctional rhythm, but it 
resumed a few cycles later. Also, His-synchronous atrial activation did not advance the 
following ventricular cycle (0/14 were advanced). Both findings strongly indicate that the 
observed arrhythmia was JT and not AVNRT. Atrial effective refractory periods were 
commonly longer than the retrograde His to Atrium cycle length. Therefore, during His 
synchronous stimulation, retrograde activation of the atrium was blocked as the atrium was 
still refractory following the His synchronous stimulation. The mechanism of AVNRT 
involves the atrium as a critical component of the circuit, indicating this junctional 
arrhythmia is likely not AVNRT49. In one mouse, retrograde Wenkebach block to the atrium 
that did not affect the V to V or His to His cycle length was observed, indicating that the 
atrium and retrograde pathway were not involved in the arrhythmia mechanism. These 
observations strongly suggest JT as the mechanism of the arrhythmia.  Similarly, the 
induction using rapid ventricular pacing, and failure of AVNRT initiation in most animals 
using standard programmed electrical stimulation, also support JT as the arrhythmia 
mechanism.  
4.3.5 Blood Pressure Measurements  
 Blood pressure measurements were obtained from the carotid artery cannula to determine 
a potential involvement of an autonomic baroreflex response in JT initiation. Ventricular rate 
during burst pacing produced transient 46±2.6 % (n=4) reductions in the minimum end-
diastolic blood pressure (Fig 4.5b). During JT, minimum end-diastolic blood pressure was 
also lower 22±4 % (Fig 4.5b) than that during sinus rhythm, as the atria contracted against 
closed AV valves, decreasing the atrial component of ventricular filling. This was not a rate  
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Figure 4.5. A) Top: Ventricular Burst Pacing induced Junctional Arrhythmia in a mouse.  A 
single early atrial stimulus prematurely activated the fast pathway (FP).  The junctional 
arrhythmia was not terminated by the atrial stimulus, demonstrating that the FP was not 
involved and confirming the arrhythmia was junctional tachycardia (JT). Bottom: A ladder 
diagram illustrating the hypothesized cardiac activation sequence during JT.  B) Ventricular 
burst pacing (1 ms pulses at 50 Hz, 400 ms burst) induced junctional tachycardia (JT) in the 
mouse indicated by the His, then V, then A activation pattern. Diastolic blood pressure (BP), 
measured from the carotid artery, decreased 41% during burst pacing, suggesting that 
baroreflex sympathetic activation is involved in the arrhythmia. During JT, the atria and 
ventricles contract in synchrony associated with a 21 % reduced diastolic blood pressure. 
CN-compact node, ** P<0.05 
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Table 4.1: Basic electrophysiological values (in ms) in 6 month old male C57BL/6 mice 
recorded in the absence and presence of: Carbachol; Atropine, and Propranolol. 
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dependent effect during JT as blood pressure increased when the atrium was paced at the 
same rate.   
 
4.3.6 AV Nodal Conduction Times  
 AV nodal conduction times (AH interval) were analyzed before and after 10 rounds of 
burst pacing for evidence of a positive dromotropic response which would be indicative of a 
baroreflex response (withdrawal of parasympathetic and enhanced sympathetic drive).  AV 
nodal conduction times were significantly decreased following 10 rounds of ventricular burst 
pacing (pre-pacing AH=31±1ms vs post-pacing AH=28±1ms, P<0.001, n=14) while there 
were no changes in sinus cycle length (185±12vs 188±10ms, P=0.39, n=14). However, 
following additional cycles of burst pacing, increased sinus rate was also observed.   
4.3.7 Subthreshold Stimulation  
 Subthreshold stimulation of the slow pathway region has been shown to activate local 
autonomic nerves and produce transient accelerations in junctional rate21, 22.  Subthreshold 
stimulation of the right ventricle and His bundle region did not induce JT or alter nodal 
conduction times. Also, rapid atrial pacing (50Hz, 400 ms, 10-40 bursts) failed to induce JT. 
This argues against the possibility of JT induction due to time/voltage dependent effects on 
AV nodal autonomic nerves and sarcolemmal ion channel function. 
4.3.8 Vagal Nerve Stimulation  
 Vagal nerve stimulation (20 Hz, 5 V, 10 ms pulse) was done simultaneously with 
ventricular burst pacing to further test the involvement of a baroreflex response in JT 
induction.  Vagal nerve stimulation caused reductions in sinus rate and suppressed JT 
induction in 5 of 5 mice.  Interestingly, JT initiated immediately following cessation of vagal 
nerve stimulation in all 5 mice.  
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4.3.9 Pharmacological Tests Of Baroreflex Involvement 
 Pharmacological tests using Carbachol (a parasympathetic agonist, 50ng/g i.p), atropine 
(a parasympathetic antagonist, 1mg/kg i.p) and propranolol (a sympathetic β-receptor inverse 
agonist, 1mg/kg i.v.) and hexamethonium (a nicotinic acetylcholine receptor (ganglionic) 
blocker, 30mg/kg, i.v.3) further examined the role of a baroreflex response in the induction of 
JT.  While 8/10 mice were susceptible to JT at baseline, Carbachol reduced JT susceptibility 
(2/10) and atropine following carbachol restored, and slightly enhanced JT susceptibility 
(9/10).  Propranolol completely abolished susceptibility to JT induction (0/7). It was initially 
hypothesized that hexamethonium would suppress JT susceptibility due to its sympathetic 
blockade; however i.v. administration mildly enhanced JT susceptibility (pre:5/8 vs post:7/8) 
and prolonged JT duration (6.1±2.6 vs 14.8±2.4, P<0.05), as well as promoting JT in 2 
animals that were not previously susceptible. This suggests that parasympathetic withdrawal 
may have the more prominent role in JT initiation. 
4.3.10 His Bundle Electrograms Amplitude Alterations During JT vs Sinus Rhythm 
 His bundle electrograms were analyzed during JT and sinus rhythm for evidence of His 
amplitude alterations which would be indicative of functional longitudinal dissociation of the 
bundle of His51. Optical mapping studies of the AV junction have determined that the 
dominant site of junctional pacemaking activity is in the posterior nodal extension (the slow 
pathway region). Thus, His amplitude alterations might be observable when comparing JT 
(SP activation of the His) to sinus rhythm (FP activation of the His). His bundle electrogram 
amplitudes during JT were significantly greater compared to those of sinus rhythm (JT: 0.13± 
0.01mV vs sinus rhythm: 0.09± 0.01 mV, n=14, P<0.05). This pattern of activation was also 
observed during diagnostic pacing studies, where a premature atrial stimulus would activate 
the FP and His amplitude decreased to that observed during sinus rhythm activation (Fig. 
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4.5a). This result is consistent with His amplitude alteration observed during discontinuous 
antegrade AV nodal conduction curves and suggests that JT originated from the SP region.  
4.3.11 Activation Patterns During JT  
 Activation patterns during JT were observed to shift from an “A-His-V” pattern with a 
short (5-10ms) AH interval and an inverted P wave morphology (2 of 14), to that of the more 
commonly observed “His-V-A” activation pattern (Fig. 4.6).  This suggests that the dominant 
site of the focal arrhythmia could shift within the SP region, similar to how the dominant site 
of SA nodal pacemaking can shift along the crista terminalis in response to β-adrenergic 
stimulation12. The A-His-V pattern of JT had a longer cycle length than the His-V-A pattern.  
This suggests that the dominant junctional pacemaker site of the His-V-A pattern was located 
closer to the compact AV node than the retrograde atrial exit site of the SP, while during the 
A-His-V pattern the site shifted closer to the retrograde exit site. This seems to be a likely 
interpretation however there are other explanations of this pattern. 
4.3.12 Pharmacological Tests Of Pacemaking 
 To examine the role of the If channel in the induced JT, low dose Ivabradine 
Hydrochloride (1 mg/kg, i.v.41), a selective If channel blocker was used.  Ivabradine produced 
a 12±2 % decrease in heart rate and suppressed JT induction in 7 of 9 mice examined. 
Interestingly, in 2 mice, JT was not immediately suppressed, and activation patterns were 
observed to shift from the His-V-A to the A-His-V (short AH) pattern of JT. To examine the 
potential role of the Ca2+ clock in JT, Caffeine (10mg/kg, i.v.) and Ruthenium Red (1 mg/kg, 
i.v.) were used. Caffeine, known to stimulate the release of Ca2+ from intracellular stores, 
enhanced the rate of the induced JT in 5 of 5 mice. Caffeine also blocks A1 adenosine 
receptors, inhibits adenylyl cyclase activity, and A3 adenosine receptors which stimulate 
adenylyl cyclase activity.  To differentiate the role of these two apparently antagonistic  
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Figure 4.6. Evidence for a shifting junctional pacemaker locus along the slow pathway 
region in the mouse with burst pacing induced JT. A) The conversion from normal sinus 
activation of the His (AH = 19 ms) to a junctional arrhythmia with a short AH interval (AH = 
10ms).  B) The pacemaker locus shifts along the SP region to a more centralized location, 
converting the activation pattern from an A-His-V to a His-V-A pattern with an abbreviated 
cycle length (153 ms vs 204 ms). C) Reversion back to an A-His-V activation pattern of JT 
before D) the arrhythmia terminates and sinus rhythm resumes. Note: the isoelectric P-wave 
and altered forces in the mid-right atrial (MRA) electrogram in “A” and “D” during 
junctional rhythm indicating a low to high atrial activation.  
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actions, DPCPX (100µg/kg, i.v.) a selective A1 adenosine receptor antagonist was used.  
DPCPX had no effect on the rate or frequency of JT induction (3 of 3 mice). Ruthenium red 
binds ryanodine receptors and potently inhibits intracellular Ca2+ release. Ruthenium red 
(1mg/kg, i.v.) prevented JT induction in 5 of 5 mice. The coupled clock pacemaker system 
proposed by Lakatta et al. 24 suggests important interactions between sarcolemmal and 
intracellular events.  Adenylyl cyclase produces cAMP which directly activates If channels 
but also activates PKA, which, through phosphorylation, affects intracellular Ca2+ handling.  
Regulation of cAMP compartmentalization by phosphodiesterases may also have a role in 
pacemaking24 and JT; however, both IBMX, a non-selective PDE inhibitor, and Milrinone, a 
selective PDE3 inhibitor, suppressed JT (3 of 3 mice). This may have resulted from non-
selective actions, which enhanced the sinus rate, suppressing the slower junctional rate. 
These compounds may also enhance contractility which could suppress JT by blunting the 
baroreflex response. Similarly, Forskolin (1mg/kg, i.v.), a direct activator of AC produced an 
enhancement of sinus rate and reduced JT susceptibility (4 of 4 mice).  However, in 5, 12 
month old C57BL/6 mice, Forskolin followed by caffeine caused spontaneous JT (not 
requiring rapid ventricular pacing) lasting >2 minutes. In all cases, the spontaneous JT was 
terminated by Ivabradine (1 mg/kg, i.v.).   
4.3.13 RGS2 Deficient Mice  
 In biochemical assays, RGS2 has been found to interact with the C1 catalytic loop of 
adenylyl cyclase and inhibit its activity. RGS2 also inhibits forskolin-induced cAMP 
accumulation. The presence or absence of RGS2 in the AV node has not been determined, 
and is beyond this investigation. However, in the regulator of G-protein signalling 2 protein 
deficient (RGS2-/-) mouse41, there was no difference in susceptibility to JT compared to age 
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matched littermates (unpublished). This suggests that RGS2 is either not present in the AV 
node or is not important in regulating JT susceptibility. 
4.4 DISCUSSION 
 The objectives of this chapter were two-fold: first I examined normal AV conduction 
properties in the mouse and determine if the mouse AV junction had similar 
electrophysiological properties as the human, and second, I determined if junctional 
tachycardia (JT) could be induced and studied in the mouse. We found evidence of 
discontinuous antegrade conduction in 41%, reentrant nodal echo beats in 17%, and multiple 
reentrant events in 5% of the mice examined. These results were consistent to previous 
findings for the mouse27. His bundle electrogram amplitude alterations during SP vs FP 
activation of the His suggests the presence of functional longitudinal dissociation of the 
mouse His bundle. This is a novel observation in the mouse. These electrophysiological 
findings are consistent with the histological observations suggesting the mouse AV 
conduction axis is highly similar to that of the human1. As such, the mouse appears to be a 
suitable model to study AV nodal conduction properties and arrhythmia. Thus, we studied 
the mechanisms of JT in the mouse. Based on the literature, we proposed that JT is caused, in 
part, by inappropriate (enhanced) AV nodal pacemaker activity initiated by abnormal 
autonomic (baroreflex) activity. 
I found that transient repetitive decreases in blood pressure induced JT in 74% of mice 
examined. The induced arrhythmia was prevented by parasympathetic activation (through 
vagal nerve stimulation or carbachol) and sympathetic blockade (propranolol).  JT can often 
be difficult to distinguish from AVNRT during electrophysiological studies. However, it is 
possible to distinguish JT from AVNRT based on the response to single premature atrial 
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stimuli (SAS) delivered during different phases of the tachycardia cycle31. A SAS just before 
the His that advances the His without terminating the tachycardia indicates that the 
retrograde fast pathway is not essential for the circuit and confirms a diagnosis of JT. But any 
perturbation in His refractoriness following a His synchronous SAS indicates that 
anterograde slow pathway conduction is involved and confirms a diagnosis of AVNRT. This 
protocol has been used to distinguish JT from AVNRT with 100% specificity in adult 
patients31, and was successfully used to confirm JT in this study (Fig 4.5a). 
Optical mapping observed junctional beats following administration of 1 µmol/L 
isoproterenol in 9 of 347 (2.6%) of embryonic mouse hearts45. However, to my knowledge, 
induction of JT has not been reported in the adult mouse. To further study the role of the 
autonomics I used both hexamethonium, a ganglionic blocker, and electrical vagal nerve 
stimulation. JT duration was mildly enhanced by hexamethonium and was blocked by, and 
then initiated immediately following removal of vagal nerve stimulation. Thus, I speculate 
that an imbalance in autonomic input to the AV node contributes to JT susceptibility. This 
hypothesis is supported by the literature where differential intracardiac sympathetic and 
parasympathetic innervation to the SA and AV nodes was observed in dogs15, 16. AV 
junctional rhythm was observed by stimulating discrete autonomic nerves in the canine heart 
preparations14. Treatment with atropine and propranolol during nerve stimulation suggested 
that AV junctional rhythm was produced by sympathetic-parasympathetic imbalance. High 
level atrioventricular stimulation induced a junctional rhythm in the dog16. This is 
reminiscent of junctional rhythm observed clinically during SP ablations for AVNRT. 
Interestingly, it has also been observed that disruption of antegrade SP conduction is not 
necessary for termination of AVNRT17. In humans, stimulation of the fat pad which contains 
the parasympathetic ganglia supply of the AV node can alter right atrial effective refractory 
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periods up to 2 cm from the fat pad32. In another study, SP ablation decreased vulnerability to 
pacing induced AF, indicating SP ablation may modify parasympathetic inputs to the AV 
node and atrium33. Frequently, there is also an improvement in FP conduction following SP 
ablation suggesting modification of the autonomic inputs5, 30.  It has been hypothesized that 
that focal beats originating from the SP region may initiate AVNRT in patients21. Thus 
modifying the nervous inputs to the AVN may be important for successful AVNRT ablation, 
initially stimulating a junctional rhythm by a transiently suppressing parasympathetic inputs 
and then suppressing junctional beats which could initiate AVNRT by a complete ablation of 
the autonomic influence on pacemaker activity. 
There are parallels in nodal function between species. Following removal of the SA node 
in the rabbit, AV junctional rhythm was initiated in the posterior nodal extension (the slow 
pathway region), which then spread to the compact node22.  Based on the pattern of His 
amplitude alterations during JT compared to sinus rhythm and then comparing that of defined 
SP conduction compared to FP conduction, we suggest that JT in the mouse also originates 
from the SP region. As shown by optical mapping, the dominant site of the SA nodal 
pacemaker can shift along the crista terminalis in response to β-adrenergic stimulation12, and 
in response to subthreshold pacing; the AVN pacemaker also shifted in 5% of cases22. I 
observed a similar pattern of shifting the AV nodal pacemaker along the SP region (Fig. 4.6) 
in JT during the conversion of an A-His-V (short AH:10 ms) to a His-V-A activation pattern 
in 2 of 19 mice examined (10%). Conversion to this A-His-V pattern occurred in 2 additional 
mice following the administration of Ivabradine. While these observation lack the 
sophistication of optical mapping, their consistency supports the hypothesis that JT is caused 
by enhanced junctional pacemaker activity initiated by autonomic influences. 
 130 
The rapid rate of JT can be problematic and difficulty to treat pharmacologically. In 
neonates following cardiac surgery, JT is associated with a mortality risk of 5.6 to 14%4, 11, 19, 
34. Pre-operative treatment with propranolol reduced the incidence of post-operative JET 
from 38 % without drug to 21 % in patients with propranolol28. However, after surgery, 
patients may have reduced cardiac output requiring positive inotropic support to maintain 
blood pressure, often provided with dopamine, epinephrine or dobutamine7. Thus, β-
adrenergic receptor blockade may be contra-indicated due to its negative inotropic effects. In 
addition, patients treated with propranolol to reduce the incidence of JT required more 
dopamine and dobutamine for inotropic support than non-blocked patients28. Amiodarone has 
been used successfully to treat JT; however, it was found to have an 87% risk of adverse 
events in children including mortality, hypotension, and AV block38. Thus, a novel non-
inotropic treatment is required for the treatment/prevention of post-operative JT based on 
understanding its underlying mechanisms. 
I propose that JT was caused by inappropriate junction pacemaker activity. Two central 
mechanism of pacemaking in the heart have been proposed: diastolic depolarization's 
produced by the hyperpolarization activated cyclic nucleotide gated (HCN4) pacemaker 
funny channel (If); and rhythmic oscillations in local Ca2+  release from the ryanodine 
receptor which activates the electrogenic Na+-Ca2+ exchanger to accelerate the upstroke of 
the late diastolic depolarization (Ca2+ clock). Both these proposed mechanisms have been 
observed in isolated nodal preparations.  In the mouse, the intrinsic cycle length of the SA 
and AV node are 179±2.7 ms and 258±18.7ms. Blocking If with 1 µmol/L ZD7288 increased 
the cycle length of both the SA (258±18.7) and AV (447±92.4ms26).  This indicates that If 
channel is important component of AV junctional pacemaking. The rate of the JT observed 
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(429±19 BPM) was 1.8 times that of the intrinsic rate of the AV nodal pacemaker observed 
in the previously discussed study26.  
The role of the Ca2+ clock has been investigated in the isolated rabbit junctional 
preparations36. The rate of spontaneous activity was decreased by ryanodine and increased by 
isoprenaline. These changes were accompanied by respective changes in the slope of the 
preceding Ca2+ ramp. To determine the involvement of these mechanisms in the observed JT 
in our studies, I used Ivabradine hydrochloride (a selective If channel blocker), caffeine (to 
stimulate Ca2+ release), and ruthenium red (a potent inhibitor of intracellular Ca2+ release). 
Ryanodine, which depletes sarcoplasmic calcium stores by holding the Ryanodine receptor in 
a sub-conductance state, was not used due to the biphasic nature of the response, which 
would make the distinction between the effects difficult in whole animal studies. Both 
Ivabradine (8 of 9) and Ruthenium Red (5 of 5) prevented JT, while caffeine mildly 
potentiated the rate of the arrhythmia. To further investigate mechanisms I used Forskolin 
(an adenylyl cyclase activator), caffeine, DPCPX (an A1 adenosine receptor blocker), IBMX 
(a non-selective PDE inhibitor), and Milrinone (a selective PDE3 inhibitor) 39. The results of 
these studies are difficult to interpret as a number of competing and non-specific factors 
occur during in-vivo investigations. Despite this limitation, or perhaps as a result, I found in 
a subset of mice that Forskolin and caffeine together could induce a prolonged (>2 min) 
spontaneous (occurring without V burst pacing) junctional tachycardia. While the nature of 
this spontaneous JT is unknown, I speculate the involvement of an inappropriate 
phosphorylation cascade of various sarcolemmal ion channels and intracellular calcium 
handling proteins (RyR, Phospholamban) by PKA and CAMKII involved in pacemaking. 
This concept is an important component of the coupled-clock pacemaker system proposed by 
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Lakatta. In all cases (5 of 5) the spontaneous JT could be terminated by intravenous 
Ivabradine hydrochloride. 
Ivabradine hydrochloride, blocks the intracellular side of the If channel in a use dependent 
manner10, a beneficial property for an anti-arrhythmic drug. Ivabradine has recently received 
FDA approval for the treatment of stable angina due to its pure heart rate reducing effects 
without compromising cardiac output (no negative inotropic effect). The fact that JT in the 
mouse could be prevented by Ivabradine suggests its potential therapeutic use in patients.  
This presumption is strengthened by clinical reports of successful termination of 
inappropriate sinus tachycardia with Ivabradine39, 48; although the mechanisms of junctional 
and sinus tachycardia may differ. Nevertheless, Ivabradine may be a beneficial therapeutic 
agent even if it merely slows the rate of JT, as the arrhythmia in post-surgical patients 
typically last no longer than 2 days and rate reducing strategies have previously been 
beneficial9.  
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CHAPTER 5: DISCUSSION  
This thesis set out to test the hypotheses and achieve objectives listed below.  These goals 
were achieved as outlined in the following summary section of the major finding of this 
thesis. 
Hypotheses 
1. There is an interface of neuro-myogenic influences on arrhythmia mechanism. Therefore 
there is a role for the autonomics in most atrial arrhythmias. 
2.  RGS2-/- mice have enhanced M3 muscarinic receptor signalling and an increased 
susceptibility to electrically induced atrial tachycardia/fibrillation. 
3. Cx40 deficient mice will be protected from, but the Cx43G60S/+ mutant will have severe 
AT/F.  
4. Junctional tachycardia is caused inappropriate activation of the AV nodal pacemaker 
initiated by abnormal autonomics. 
 
Objectives 
1. To determine what atrial arrhythmias are inducible in the mouse and how to systematically 
elicit and study those arrhythmias. 
2. Determine the mechanisms of the induced atrial arrhythmias in the mouse to provide the 
basis for future investigations of potential therapeutic options for patients. 
3. Develop the proposed "Threshold Model" of arrhythmogenesis and use it to analyze results 
and make relative comparisons of observations obtained from the different experiments 
performed in this thesis. 
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5.1 SUMMARY AND MAJOR FINDINGS  
There were multiple objectives in this thesis. I sought to determine how to systematically 
elicit atrial arrhythmia in the mouse to study various molecular factors involved in 
arrhythmogenesis in the controlled context of "induced pre-arrhythmia substrate 
remodelling". As outlined in Chapter 1, a central goal of this discussion section is to develop 
the proposed "Threshold Model" of arrhythmogenesis and use it to put the results into 
perspective and make relative comparisons of observations from the different experiments in 
this thesis. Briefly, the Threshold Model proposes that a myocardial substrate that is 
susceptible to arrhythmia initiation by an appropriate trigger would be said to be above the 
threshold. If the atrial substrate is well below threshold a single arrhythmogenic perturbation 
would not initiate an arrhythmia. If the atrial substrate is well above the threshold, then an 
antiarrhythmic treatment might be ineffective in terminating the arrhythmia. This concept 
will be developed throughout this discussion and summary of the major findings of this 
thesis. In this discussion, I have summarized the importance of the various methodological 
considerations revealed during my investigations. I have also examined the central 
hypothesis of this thesis "that there is an interface of neuro-myogenic influences on 
arrhythmia mechanisms", and as such there is a role for the autonomics in most atrial 
arrhythmias. Finally, I present the Threshold Model as a useful tool to make predictions of 
clinical outcomes. 
 The first objective of this thesis was to determine how to systematically and 
reproducibly elicit and study atrial arrhythmia in the mouse. I found that atrial 
tachycardia/fibrillation (AT/F) as well as AV nodal reentry and junctional tachycardia (JT) 
are inducible in the mouse. Both AF and JT pose significant clinical challenges as there are 
many patients who do not respond to current clinical management strategies14, 22. Also, as the 
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population ages, AF will place an increasing burden on health care resources, not only for its 
treatment and ongoing therapeutic management, but also because of the 2 most serious 
complications of AF, heart failure and stroke6. JT results in a risk of death of 5.6 – 14 %2, 5, 8, 
15 in neonates following cardiac surgery. AF is equally problematic with an increased risk of 
all-cause mortality (1.5-1.9 fold) compared to those without AF, regardless of the presence of 
symptoms3. This is suggested to be due to the effects of AF itself, drug toxicities associated 
with treatment, or co-morbidities such as hypertension, heart failure, and valvular disease14, 
22. Clearly, there is a great need for uncovering the mechanisms of these arrhythmias, so that 
novel targets for intervention can be identified. 
While both AT/F and nodal re-entry have previously been studied in the adult mouse, the 
inducibility of JT is a novel observation. In this thesis, experimental description of AT/F was 
based on 2 criteria: the susceptibility to induction with different pacing methods (triggers), 
and its duration which describes a substrate susceptible to AT/F maintenance. The induction 
of AT/F required pacing of the mid-right septal atrium (MRA) validated by using His bundle 
electrograms as a landmark of catheter location. This may have been due to the observed 
electrical heterogeneity between the MRA and the high right atrium (HRA), as effective 
refractory periods were consistently shorter in the MRA than the HRA.  The catheter 
placement may also allow for trans-septal pacing of the left atrium.  This finding was 
independent of the strain of mouse used.  This was a novel anatomical and methodological 
finding that allowed for the systematic and reproducible initiation of AT/F among groups of 
mice. The induction of AT/F requires a trigger and a substrate susceptible to arrhythmia 
maintenance. In this thesis, I used 3 different electrophysiological pacing methods (triggers) 
to induce AT/F including: burst pacing; programmed electrical stimulation (PES) with 1 
extra stimulus, and a single atrial stimulus (SAS) timed to follow the P-wave and interact 
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with the heterogeneous refractoriness of the normal sinus depolarization. These pacing 
protocols can be subdivided based on their ability to modify the substrate.  The drive train 
during PES can affect both action potential duration and amplitude as the pacing rate is 
greater than the intrinsic rate along the cardiac restitution curve.  Burst pacing would have a 
similar substrate modifying effect, however the high frequency pacing (50 Hz) may also 
activate intrinsic nerves.  The most physiological of these "triggers" may be the SAS protocol 
as premature beats often precede AF episodes9 and the SAS protocol would have no substrate 
modifying effects. Burst pacing is the least physiological as it not only acts as a trigger but 
contributes to substrate formation by promoting cardiac electrical instability10. The induction 
of AT/F with burst pacing only but not PES or SAS implies that the substrate is near the 
arrhythmia threshold and required the added substrate modifying effect of burst pacing 
induced electrical instability for arrhythmia initiation. This concept has important 
implications as in Chapter 2.  I found that 1 month old RGS2-/- mice had a greater 
susceptibility to PES induced AT/F but no difference in susceptibility to burst pacing induced 
AT/F when compared to wild type littermates.  These results also provide evidence for the 
hypothesis that functional M3 muscarinic receptors are present in the atria and are involved 
in arrhythmogenesis.   
The use of 3 different triggers to elicit AT/F is proposed to allow the examination of the 
degree of substrate vulnerability to arrhythmia initiation. In Chapter 3, all 3 pacing protocols 
were used to examine AT/F susceptibility in the 6 month old Cx43G60S/+ mutant and Cx43+/+ 
littermate mice (Figure 3.3A). While the Cx43G60S/+ mutant mouse was 100% susceptible to 
AT/F induction with each trigger, susceptibility in the Cx43+/+ littermates followed a pattern 
of burst pacing> PES>SAS induction.  As such, a substrate vulnerable to SAS induction is 
very close to the Threshold for arrhythmia initiation, followed by PES induction, while, as 
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discussed before, susceptibility to burst pacing only implies a substrate that is further from 
the threshold. 
The duration of the induced arrhythmia is also of critical importance as it defines a 
substrates ability to maintain an arrhythmia once initiated. Clinically, a duration of greater 
than 30 seconds is used to indicate sustained arrhythmia. This classification appears to be 
relatively arbitrary; however, it is a standard value and was used in Chapter 2 to define 
sustained AT/F. It was found that the RGS2-/- mouse had a greater propensity to sustain AT/F 
with any induction protocol; however, this was not significant. In Chapter 3, AT/F in the 
Cx43G60S/+ mutant mouse lasted longer than 35 minutes; however, I expanded on this 
standard (in agreement with other published findings) and defined severe sustained AT/F in 
the mouse as lasting longer than 2 minutes. Figure 3.3B shows that 75% of the Cx43G60S/+ 
mutant mice had AT/F lasting longer than 2 minutes which was significantly greater than the 
Cx43+/+ littermate mice. These results indicate that Cx43G60S/+ mutant mice have a substrate 
which is more susceptible to the maintenance of AT/F than the RGS2-/- mice.  This suggests 
that RGS2 and M3 muscarinic receptors are more limited contributors to substrate formation 
while Cx43 reduction is a major contributor. This interpretation is consistent with findings in 
section 3.3.4 showing that while darifenacin (a selective M3 receptor antagonist) could 
terminate new onset sustained AT/F in Cx43G60S/+ mutant mice, AT/F was reinducible 5 
minutes after termination. It may be that darifenacin only destabilized arrhythmia 
maintenance while not lowering the substrate very far below threshold for arrhythmia 
induction. However, it has also been reported that darifenacin exerted only transient binding 
to cardiac muscarinic receptors in mice 21, which could also explain the reinduction. These 
observations also provide evidence that there is a nervous component to AT/F in Cx43G60S/+ 
mutant mice. In Chapter 4, I found that junctional tachycardia (JT) was caused by 
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inappropriate (enhanced) AV nodal pacemaker function initiated by abnormal autonomic 
(baroreflex) influences. I presented evidence for a role of both enhanced calcium clock and 
membrane clock function by utilizing ruthenium red (a potent inhibitor of intracellular 
calcium release) and ivabradine hydrochloride (a selective If channel blocker). However, it 
must be recognized that ruthenium red binds and inhibits many ion channels in addition to 
the L-Type Ca2+ channel.  Both ruthenium red and ivabradine prevented JT induction, 
indicating that interference with either pacemaking mechanism lowered the substrate below 
the threshold for arrhythmogenesis.    
The study of arrhythmia mechanisms in the mouse and development of novel 
antiarrhythmic interventions was an objective of this thesis. I found that both darifenacin 
hydrobromide and ivabradine hydrochloride may be useful antiarrhythmics given that they 
are currently used clinically for other purposes. Darifenacin is used to treat overactive 
bladder syndrome while ivabradine is used in the treatment of stable angina due to its pure 
heart rate reducing effects. Darifenacin’s use may be limited, although it was found to 
destabilize AT/F causing termination in Cx43G60S/+ mutant mice, it did not prevent 
reinduction by burst pacing. Nevertheless, it may still be of use clinically, either alone, or in 
combination with current antiarrhythmics utilizing a single dose "pill in the pocket" anti-
arrhythmic drug for rhythm control14, 22. On the other hand, ivabradine has great potential for 
clinical application for JT management. Not only was low dose ivabradine found to terminate 
JT in 8 of 9 mice, it has no negative inotropic effects 17, 19 and is currently FDA approved for 
other purposes.  
The current clinical management of AF uses 2 strategies, controlling the ventricular rate 
during AF (rate control) and preventing AF from recurring (rhythm control). Rate control 
utilizes β blockers, Ca2+ channel blockers and digoxin to reduce AV nodal conduction and 
 143 
slow the ventricular rate. Anticoagulation therapy with warfarin is necessary as AF is 
associated with a high rate of thromboembolic events. Rate control utilizes various Na+ 
channel and K+ channel blocking drugs to maintain sinus rhythm. Studies comparing the 2 
strategies (AFFIRM1) showed no difference in overall mortality between the rhythm and rate 
control arms. This may have been due to the fact that patients in the rhythm control arm were 
not always in sinus rhythm and patients in the rate control arm were not always in AF. There 
was also an increase in stroke in the rhythm control arm as patients stopped taking warfarin.  
The risk of stroke persists in high risk patients even after restoration of sinus rhythm.  It is 
suggested that AF may cause, or be a marker of biochemical alteration at the endothelial and 
intra-atrial level that may increase stroke risk independent of mechanical considerations4. 
These observations highlight an increased need for the understanding of AF mechanisms 
which was a goal of this thesis. To this end, I have developed a novel Threshold Model of 
arrhythmogenesis that allows the relative comparison of the role of multiple physiological 
factors in promoting AF. I have also investigated the neuro-myogenic interface of arrhythmia 
mechanism and suggest that the intrinsic cardiac autonomic nervous system (ICANS) is 
involved in most atrial arrhythmias.  
Both pharmacological and electrical atrial defibrillation are used to restore sinus rhythm 
(cardioversion). Some patients are refractory (not susceptible) to restoration of sinus rhythm 
using electrical cardioversion. The Threshold Model would suggest that the substrate is too 
far above threshold for electrical cardioversion to terminate AF. If the ICANS is involved in 
most atrial arrhythmias as suggested, then it is predicted that muscarinic receptor blockade 
would lower the substrate sufficiently close to threshold to allow electrical cardioversion to 
terminate AF in these refractory patients. Following this, a search of PubMed revealed a 
clinical study12  demonstrating atropine facilitated electrical cardioversion of AF, consistent 
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with the previous predictions. In this study, 49 of 364 patients (13.5%) with persistent AF did 
not respond to electrical cardioversion. However, following 2 mg of atropine, 40 of 49 
previously refractory patients were successfully restored to normal sinus rhythm. Other 
standard antiarrhythmic drugs are also successful in facilitating electrical cardioversion13.  
As proposed in Chapter 1, a 2 media (physiological and electrical) perspective of the 
heart, where many dependent or independent physiological factors can promote the same 
electrical phenomena, yields a physiological substrate Threshold Model of arrhythmogenesis.  
The Threshold Model is useful as it allows the simple comparison of results of different 
investigations relative to each other and the basal substrate state.  Relative comparison is 
used to normalize and compare the results of many studies using advanced techniques such 
as quantitative real time PCR.  While not informative of the actual mechanism of arrhythmia 
(abnormal impulse initiation/propagation), it allows a simple analysis of the physiological 
substrate state that can promote abnormal rhythm in the electrical media, regardless of the 
electrical mechanism.  As the results of different investigations in the intact mouse 
accumulate, this form of relative comparison will aid in distinguishing between major and 
minor contributors to arrhythmia susceptibility.  The Threshold Model is not proposed to 
overthrow a previous theory of arrhythmogenesis, only add to the arsenal of tools used to 
conceptualize the importance of results of various investigations.  Any model or scientific 
theory allows for testing of hypotheses generated from its use.  As discussed above this 
seems to be the case with the Threshold Model which begins to demonstrate it as a robust 
tool for arrhythmia research. 
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5.2 LIMITATIONS 
The use of mice to investigate human disease is a common tool allowing the study of 
various genetic causes of disease, in isolation, and potential therapeutic options for patients.  
However, as discussed in detail in Chapter 1 Section 1.0, utilizing the mouse for arrhythmia 
investigation has limitations including differences in the intrinsic rate of the SA node, ion 
channels and differences in action potential morphology and duration.  It is recognized that 
the  mouse is not a human; however, comparative analysis of the mouse and human genome 
have revealed that approximately 99% of all mouse genes can be linked with a human 
homologue20.   
In Chapter 2, the role of RGS2 in arrhythmogenesis was investigated.  The results of 
these studies indicated a role for RGS2 and the M3 muscarinic receptor in promoting AT/F in 
the mouse; however, the potential role for other Gq coupled receptors influencing 
arrhythmogenesis was not determined.  Also, direct patch clamp investigation of currents to 
directly determine if there was a role for the IK, M3 channel in this phenotype was not 
performed. It is recognized that atrial vulnerability may also be due to the balance between 
autonomics, which were not explored in these studies11, 16. This may be an important 
consideration as RGS2-/-  mice have been shown to have reduced renal sympathetic nerve 
activity compared to WT mice18. However, the lack of a heart rate difference between RGS2-
/-
 and WT mice found in their earlier study7does not assist in establishing the role of the 
sympathetic nervous system in atrial susceptibility, therefore the role of the balance between 
sympathetics and M3 responses remains to be determined. Also in Chapter 2, RNA 
expression profiles were determined for the muscarinic receptors.  While RNA expression 
provides an index of the relative importance of the proteins, it may not parallel Bmax values 
of radioligand assessment of M2, M3 or M4 protein expression, distribution and function.  
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Furthermore, AF propensity increases with aging. However in Chapter 2, one month old 
mice were chosen to avoid potential complexity due to the effects of the chronic hypertensive 
phenotype with RGS2-/-.  
 The investigation of atrial fibrillation was the focus of both Chapter 2 and Chapter 3.  
However, in the mouse, it may be difficult to distinguish atrial fibrillation from atrial 
tachycardia, particularly with an arrhythmia of short duration. However, with the use of the 
standard clinical criteria for identification of AF, lack of regular P waves on ECGs and 
irregularly irregular ventricular responses, and left atrial predominance, it was often possible 
to demonstrate these classical characteristics of AF in the mouse.  In Chapter 3 I sought to 
make a direct comparison of the role of Cx40 and Cx43 in AT/F susceptibility.  This 
comparison has not been previously done and is of importance in understanding the role of 
the various connexin isoforms in atrial arrhythmia vulnerability.  However, this investigation 
had complications as Cx40-/- is associated with cardiac morphological changes, hypertension, 
cardiac hypertrophy and altered kidney function.  The Cx43G60S/+ mouse was used as the 
Cx43-/- mouse dies perinatally.  This G60S mutation produces a phenotype of 
ocluodentodigital dysplasia in the mouse and may potentially have unforeseen systemic 
influences on cardiac function.  While these studies were quite informative on the role Cx40 
and Cx43 in atrial arrhythmogenesis, future analyses should be performed on cardiac 
selective knockout animals in order to avoid these non-specific effects.   
 In Chapter 4, AV nodal arrhythmia was investigated in the normal wild type mouse.  
Programmed electrical stimulation was used to map antegrade AV nodal conduction curves 
in order to observe slow pathway conduction.  While the presence of an atrial echo beat when 
presence, was helpful as it could be used as an index to determine when the minimal jump in 
A2H2 interval occurred revealing slow pathway conduction. It is recognized the absence of 
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an echo beat may not be indicative of a lack of slow pathway conduction which could 
sometimes be observed with an obvious jump.  It is also recognized that the study of 
Junctional Tachycardia in the 6 month old mouse may not be indicative of human neonatal 
arrhythmia. 
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APPENDIX I: Bias in the Cq value observed with hydrolysis probe based quantitative 
PCR can be corrected with the estimated PCR efficiency value. 
 
A version of this appendix has been published: Tuomi, J. M., F. Voorbraak, D.L. Jones, J.M. 
Ruijter. "Bias in the Cq value observed with hydrolysis probe based quantitative PCR can be 
corrected with the estimated PCR efficiency value." Methods. 2010 Apr;50(4):313-22. Epub 
2010 Feb 6. 
 
1.0 SUMMARY 
 For real-time monitoring of PCR amplification of DNA, quantitative PCR (qPCR) assays 
use various fluorescent reporters. DNA binding molecules and hybridization reporters 
(primers and probes) only fluoresce when bound to DNA and result in the non-cumulative 
increase in observed fluorescence. Hydrolysis reporters (TaqMan® probes and QZyme™ 
primers) become fluorescent during DNA elongation and the released fluorophore remains 
fluorescent during further cycles; this results in a cumulative increase in observed 
fluorescence. Although the quantification threshold is reached at a lower number of cycles 
when fluorescence accumulates, in qPCR analysis no distinction is made between the two 
types of data sets. Mathematical modeling shows that ignoring the cumulative nature of the 
data leaves the estimated PCR efficiency practically unaffected but will lead to at least 1 
cycle underestimation of the quantification cycle (Cq value), corresponding to a 2-fold 
overestimation of target quantity. The effect on the target-reference ratio depends on the PCR 
efficiency of the target and reference amplicons. The leftward shift of the Cq value is 
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dependent on the PCR efficiency and with sufficiently large Cq values, this shift is constant. 
This allows the Cq to be corrected and unbiased target quantities to be obtained.  
 
1.1 INTRODUCTION 
 The fluorescence-based quantitative real time PCR (qPCR) has become the gold standard 
technique for analysis of nucleic acids in medical diagnostics and life sciences. The 
proliferation of qPCR over the last decade has resulted in a diversity of reagents, protocols, 
analysis methods and reporting formats [1-3]. To promote consistency, increase 
transparency, and ensure the integrity of scientific literature, guidelines for the minimum 
information required for publication of qPCR experiments were formulated (MIQE) [4]. 
Quantitative PCR data analysis is based on the principle that the more copies of template that 
are present at the start, the fewer cycles of amplification it takes to make a specified amount 
of product [5]. The implementation of this principle involves setting of a fluorescence 
threshold (Nq) and determining the fractional cycle number (Cq) that is required to reach this 
quantification threshold [6-8]. Using the inverse of Eq. 1 (section 4), an estimate of the target 
quantity (expressed in arbitrary fluorescence units) can be calculated from the observed Cq 
value, using the amplification efficiency and this threshold [9-11]. Almost all qPCR analyses 
are based on the exponential nature of PCR kinetics (Eq. 1), and rely on the determination of 
the PCR efficiency per assay and Cq values per sample. However, the chemistries available 
for qPCR result in different kinetics of fluorescent reporter increases, which can be either 
non-cumulative (e.g SYBR green) or cumulative (e.g. TaqMan® probes). Apart from the 
illustration of typical amplification curves obtained for amplicons detected using SYBR 
Green I and TaqMan chemistries [3] the cumulative nature of some monitoring chemistries is 
commonly ignored in qPCR data analysis.  
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 In this paper, we outline how the cumulative nature of some reagents impacts on qPCR 
data analysis choices, the way the data is analyzed and the results. In short, mathematical 
modeling shows that ignoring the cumulative nature of the data leaves the estimated PCR 
efficiency practically unaffected but will lead to at least 1 cycle underestimation of the Cq 
value, corresponding to 2-fold overestimation of the target quantity. The effect on the target-
reference ratio depends on the PCR efficiency of the target and reference amplicons. The 
leftward shift of the Cq value is dependent on the PCR efficiency and with sufficiently large 
Cq values, this shift is constant. This allows the Cq to be corrected and unbiased target 
quantities to be obtained. 
 
1.2 STRUCTURE OF THIS PAPER 
 This paper will follow the different steps of qPCR analysis from the choice of the assay 
to the presentation of the final results (Fig. 1). The main stream of qPCR analysis is based on 
determination of the PCR efficiency from standard curves (section 2.3.1). Alternatively, PCR 
efficiency values can be derived from individual amplification curves (section 2.3.2). The 
calculation steps in the flow chart explicitly separate the calculation of the target quantity of 
the gene of interest and reference genes from the calculation of the gene expression ratio. 
Many qPCR algorithms immediately calculate the expression ratio, thereby simplifying the 
equations by leaving out the quantification threshold and the PCR efficiency values. These 
equations inadvertently suggest that differences in PCR efficiency values do not play a role 
and can be ignored. It should be kept in mind that such simplification of the equations can 
only be done when the PCR efficiencies are equal [11]. Even small differences in efficiency 
can have a large effect on gene expression ratios [7].  
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 Each section of the text will focus on a step, review the aspects relevant in the 
comparison of cumulative and non-cumulative chemistries and detail how the chosen 
detection chemistry will impact on the procedure and affect the result.  
Most steps will be illustrated with experimental or simulated data and graphs showing the 
biasing effect of the use of accumulated fluorescence data. Recommendations or correction 
methods will be presented where possible. These sections will refer to a Methods section 
describing the qPCR experiment of which the data are shown to illustrate certain steps and to 
a Theory / Calculations section describing the basic and derived equations used in qPCR data 
analysis and in the correction of the biasing effects of cumulative fluorescence data. 
 
1.3. Methods  
1.3.1 Tissue samples 
 The tissue samples used in this study were taken from the hearts of three, one month old 
C57BL/6 mice. Atria were isolated, flash frozen in liquid nitrogen and stored at -80 C for no 
more than 6 months prior to RNA isolation using a Trizol kit (Qiagen Inc., Invitrogen, 
Burlington, ON). RNA concentration was determined using a spectrophotometer (NanoDrop; 
Thermo Scientific), and quality was assessed by gel electrophoresis. A total of 500 ng of 
RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit 
with random primers (Applied Biosystems Inc., Carlsbad, CA). 
 
 154 
 
Figure 1. Flow chart. 
Graphical illustration of the six decision and calculation steps in a quantitative PCR 
experiment that are described in this paper. The choice for a PCR monitoring chemistry 
results in the use of a non-cumulative or a cumulative reporter-fluorescence increase during 
PCR which has implications for the baseline subtraction. A second choice has to be made 
between PCR efficiency estimation with a standard curve or estimation from the 
amplification curves. Both methods can be applied to non-cumulative as well as cumulative 
fluorescence data. After determination of the Cq values and calculation of the target 
quantities, all data streams come together in the calculation of the gene expression ratio 
which is the final result of a qPCR experiment. 
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1.3.2 PCR reactions 
 C57BL/6 mouse atrial samples were amplified in 384-well plates on a BioRad cycler.  
The qPCR was performed using 15 µl reaction volumes. Specific primers for SYBR-green 
qPCR were developed using Primer-BLAST (NCBI) and examined for secondary structures 
using the oligonucleotide calculator [62].  Custom oligo (Invitrogen) primers for β-actin 
reference (Forward: CTGGAACGGTGAAGGCGACAG; Reverse: 
GCTTTTGGGAGGGTGAGGGAC; product: 182 bp), M2 Muscarinic Receptor (M2R) 
(Forward: TAGCACCATCAACCCTGCCTGC; Reverse: 
TCCCCAAGACACACTCGACCAC; product: 151 bp), M3 Muscarinic Receptor (M3R) 
(Forward: CACAAGCGAGTGCCTGAGC; Reverse: GAATGGCCTCCCACCTGC; 
product: 115 bp) were used at a 1 µmol/l concentration in SYBR green Mastermix (Quanta).  
The amplification protocol was identical for all primer sets: 10 min 95C, 50x (15 s 95C, 
30s 60C, 30s 72C). Hydrolysis probe-based studies used TaqMan® gene expression 
Assays-on-Demand from Applied Biosystems and AmpliTaq Gold® 360 PCR Master Mix 
(ABI).  Sequence information for primer and probe assays are proprietary to ABI and thus 
not available for publication.  β-actin, M2 muscarinic receptor and M3 muscarinic receptor 
used a FAM reporter (excitation=495 nm, emission=515 nm) and TAMRA quencher 
(excitation=565 nm, emission=580 nm).  These samples were measured in 3 parallel 
reactions using the following amplification protocol: 10 min 95C, 50x (15 s 95C, 30 s 
60C, 30 s 72C).   
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1.3.3 Mathematical modeling 
The basic equation for the kinetics of the exponential phase of PCR amplification (Eq. 1; 
section 4) was used to derive an equation of the kinetics that would be observed when the 
fluorescence accumulates from cycle to cycle (Eq. 2). These two models served to derive an 
equation for the distance between the cumulative and non-cumulative amplification curves 
on a log (fluorescence) scale. These equations were used in a spreadsheet program to 
calculate PCR efficiency values, target gene quantities and gene expression ratios. In these 
calculations, the PCR efficiency was derived from the slope of 4 data points (window-of-
linearity method) [34]. A quantification threshold (Nq) was set at 1 cycle below the upper 
limit of this window. PCR efficiency and Cq values were then used to calculate the target 
quantity, N0 [24]. The calculations were done with windows resulting in Cq values ranging 
from 10 to 40 cycles. 
1.3.4 Theory / Calculations 
The basic equation for PCR kinetics is:  
   CC ENN  0       [Eq. 1]  
where the amount of amplicon after C cycles (Nc) is the starting concentration of the 
amplicon (N0) times the PCR efficiency (E) to the power C. The PCR efficiency in this 
equation is defined as fold increase per cycle (2 indicates 100% efficiency). Because the 
fluorescence is linearly related to the amount of the amplicon, Eq. 1 also describes the 
increase in fluorescence for a non-cumulative DNA binding fluorochrome or hybridization 
reporter. When the fluorescent reporter of a hydrolysis probe is released during elongation, it 
remains fluorescent in subsequent cycles and accumulates. Because the amount of 
fluorescence released per cycle depends on the amount of amplicon present at the start of 
each cycle, cumulative fluorescence increases according to:  
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The practically constant vertical distance between Eq. 1 and Eq. 2 at large cycle numbers, 
when plotted on a logarithmic axis (Fig. 2A), is written as N, which can be calculated by: 
   )))/1(1/(1log()(lim ENNN CCC    [Eq. 3] 
Appendix A shows the derivation of Eq. 3. The horizontal distance, Cshift, between the 
cumulative and non-cumulative amplification curves then follows from the fact that on a 
logarithmic axis the slope of both lines can be considered to be given by log(E):  
   )log(ENCshift       [Eq. 4]  
When the accumulation of fluorescence is ignored, biases will occur in the estimation of the 
starting target quantity (N0) or target / reference ratios in starting quantities. The bias in the 
target quantity, calculated as qCq /ENN 0 , is given by: 
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and the bias in the gene expression ratio by: 
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Derivation of the latter two equations is shown in Appendices B and C.  
 
1.4 QUANTITATIVE PCR ANALYSIS STEPS 
1.4.1 Choice of detection chemistry  
An impressive variety of monitoring chemistries are available for qPCR. The 
available non-cumulative fluorescent detection technologies depend on 2 principle 
mechanisms: 1) where a dye fluoresces upon binding with double stranded DNA (e.g SYBR 
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green), and 2) where fluorescence increases upon hybridization of the reporter to a specific 
oligonucleotide sequence.  Examples of the latter include hairpin probe hybridization (LUX, 
Light Upon eXtension, Invitrogen), hairpin loop hybridization (Molecular beacons [12], 
Sigma Aldrich/IDT), and dual probe hybridization (Light Cycler, Roche) [2]. As the structure 
of these fluorescent reporters remains intact during the PCR reaction, the resulting increase 
in signal intensity is directly proportional to the amount of amplification product.  
 Cumulative reporter technologies depend on a hydrolysis step that irreversibly 
separates a fluorescent reporter from a quencher molecule. The close proximity of reporter 
and quencher, maintained until hydrolysis, results in suppression of the reporter molecule 
fluorescence (see Section 2.2). Examples of hydrolysis based chemistries include TaqMan® 
probes (Applied Biosystems), and the QZyme™ assay (Clontech laboratories, Inc.).  As of 
Dec 2009, a PubMed search for TaqMan® probe-based assays yielded 4180 hits, while 
application of the QZyme™ assay has not yet gained popularity yielding only 2 PubMed hits.  
During the annealing/extension phase of PCR, the TaqMan® probe hybridizes to the 
template and the double stranded DNA-specific 5’-3’exonuclease activity of thermostable 
Taq or Tth polymerase degrades the probe and releases the reporter.  The increased 
specificity due to the requirement for matching 3 independent nucleotide sequences (forward 
and reverse primers and probe), and the ability to multiplex reactions using different 
fluorophores in TaqMan® assays underlies the popularity of this system [2,13].   
 The cumulative fluorescence of hydrolysis reporters leads to observed fluorescence 
values that are higher than the kinetic equation of PCR predicts. Assuming the same 
fluorescence characteristics for a cumulative and a non-cumulative signal, Fig. 2A shows a 
simulation of the amplification curves of the same target, monitored with non-cumulative 
fluorescent dye binding (Eq. 1) and with a cumulative fluorescent probe (Eq. 2). The PCR 
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efficiency and target quantity N0 was the same for both lines. At high cycle numbers, the 
lines become practically parallel on a logarithmic scale. The almost constant distance 
between the lines approximates a limit, written as N. The mathematical derivation (see 
Appendix A) of this limit leads to Eq. 3, showing that N is only dependent on the PCR 
efficiency. The distance between the non-cumulative and cumulative fluorescence curves for 
different PCR efficiency values is plotted in Fig. 2B. The horizontal lines represent the 
respective N values calculated with Eq. 3. The graph shows that for a PCR efficiency of 
1.4, parallelism can be considered to be reached after 20 cycles whereas at maximum PCR 
efficiency as little as 11 cycles are sufficient to reach parallelism. This means that for most 
quantitative PCR applications, on a semi-logarithmic plot the curves can be considered to be 
parallel at the level of the quantification threshold.  
 
1.4.2 Baseline correction 
Baseline fluorescence is defined as the level of fluorescence measured before any specific 
amplification can be detected. The word ‘baseline’ is used to avoid confusion with the 
‘background’ which in PCR systems is often used to address the fluorescence of the internal 
reference dye (e.g. ROX or Fluorescein) or the signal observed outside the reaction wells. 
Similarly, the fluorescence baseline should not be confused with background defined as the 
amplification resulting from a ‘non-template’, ‘minus RT’ or ‘water’ control samples [14]. 
Fluorescence baseline has been described as constant, linearly dependent on cycle number 
[15-17] or as a non-linear saturation curve [18,19]. The definition of a constant baseline 
ranges from the minimum observed fluorescence [20], the mean of the 5 lowest observations 
[21], the mean of a fixed set of cycles [22,23] and the mean value of a dynamically 
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Figure 2. PCR efficiencies derived from non-cumulative and cumulative fluorescence 
curves. 
 
A. Graphical representation of Eq. 1 and Eq. 2 (section 4) showing that on a logarithmic 
fluorescence axis, the curves resulting from a non-cumulative and a cumulative monitoring 
chemistry become virtually parallel. The inset shows the same data on a normal Y-axis. 
Parameters: N0: 0.000001, PCR Efficiency: 1.9 for both curves. 
B. Demonstration that the vertical distance between the logarithmic curves closely 
approaches N after a number of cycles that depends on the PCR efficiency. For each 
efficiency value, the black diamond indicates when the actual distance is less than 0.001 from 
N. 
C. PCR efficiencies derived from a subset of 4 cumulative fluorescence data points according 
to the window-of-linearity approach [34]. The PCR efficiencies are plotted against a Cq value 
obtained by placing a quantification threshold one cycle below the upper limit of the data 
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window. In windows that include early cycles the observed PCR efficiencies show a positive 
bias. The large black squares and diamonds indicate the Cq cycles above which this bias is 
less than 1% and 0.1%, respectively. Parameters: N0: 0.000001, PCR Efficiency: 1.4 - 2.0. 
D. Bias in observed quantification cycle (Cq) for cumulative fluorescence data. Cq values in 
the simulated cumulative dataset were determined for quantification thresholds that lead to 
integer Cq values in a simulated non-cumulative data set. The large diamonds indicate the 
cycles at which the biases differ less than 0.001 from the Cshift predicted by Eq. 4 for each of 
the included PCR efficiency values. Parameters: N0: 0.000001, PCR Efficiency: 1.4 - 2.0. 
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 determined set of ground phase cycles [15]. Most qPCR systems currently use a linear 
baseline trend.  
 It was described previously that a 2% underestimation of the baseline leads to a 2% 
underestimation of the PCR efficiency determined from the amplification curves whereas a 
similar overestimation of the baseline leads to such an overestimation of the PCR efficiency. 
Because of the exponential nature of PCR, such errors in the PCR efficiency can lead to a 10 
fold error in reported gene expression ratios. To avoid these baseline estimation errors a new 
estimation algorithm was described [24].This baseline estimation algorithm is based on the 
kinetic model of PCR amplification (Eq. 1) and assumes that the observed fluorescence at 
each data point up till the start of the plateau phase is the sum of baseline fluorescence and an 
exponential increasing amplicon concentration dependent fluorescence. The constant PCR 
efficiency in the exponential phase means that, in a semi-logarithmic plot, the data points in 
the exponential phase of the PCR reaction are on a straight line. The correct baseline value 
isolates the exponentially increasing part of the observed fluorescence values and results in 
the longest straight line of data points downwards from the plateau phase [24].  
 Experimental data from mouse atrium samples were analyzed using both SYBR green 
as well as TaqMan® assays (see section 3). The raw fluorescence data show that the 
baseline-to-plateau distance in SYBR green fluorescence data is larger than in Taqman® data 
(Fig. 3A). A similar difference in baseline-to-plateau distance between the two monitoring 
chemistries has been illustrated in other papers [3]. After baseline correction [24], both data 
sets show an exponential phase ranging over approximately 10 cycles (Fig. 3B).  
 An important factor influencing the baseline estimation is the baseline-to-plateau 
distance (∆Rn) in the raw, i.e. not baseline corrected, data. This distance is determined by 
intrinsic properties of the fluorescent reporter and on the primer and probe concentrations 
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[24]. For non-cumulative fluorescence data, a large part of the baseline fluorescence results 
from the fluorescence of the unbound fluorochrome or fluorescent probe. For example, the 
unbound molecule of the DNA binding dye SYBR green is already fluorescent but at only 
1/1000 of the fluorescence of the bound molecule [25]. High ∆Rn values are typical of 
SYBR green chemistry [3]. ∆Rn values recorded with hydrolysis probes, however, are 
reported to be significantly lower due to the use of FRET based chemistries that display 
inefficient quenching. For these chemistries it is important to choose a reporter/quencher pair 
that gives the largest baseline-to-plateau difference. This will facilitate the estimation of the 
correct baseline value and thus reduce the variation in observed PCR efficiency values (Fig. 
3F) [24].  
Criteria for selection of reporter/quencher pairs that display efficient quenching have been 
described. Briefly, 3 mechanisms of quenching reporter fluorescence include; 1) fluorescent 
resonance energy transfer (FRET); 2) static or contact quenching, and 3) quenching by the 
nucleotide proximal to the fluorophore (Guanine for FAM, Adenine for Alexa-488 dyes) 
[26]. In order to achieve efficient FRET, the reporter and quencher must be close to one 
another, and the absorption spectrum of the quencher must overlap the emission spectrum of 
the reporter fluorophore [27,28]. Reporter and quencher molecules can bind to form a 
ground-state complex [29].  Such coupling of the reporter and quencher’s excited-state 
energy levels results in different electronic properties of the ground state complex that 
inhibits fluorescence [29]. The efficiency of contact quenching was revealed to always be 
greater than the efficiency of quenching by FRET [27,29].  
 Conventional TaqMan® probes use the reporter fluorophore, fluoroscein (FAM), and 
a quencher, tetramethylrhodamine (TAMRA), which is also fluorescent.  FAM/TAMRA 
based probes display relatively efficient quenching, over 90% [29]; however, the remaining  
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Figure 3. qPCR analysis with SYBR green and TaqMan® hydrolysis probe assays. 
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Amplification curves resulting from an experiment in which 3 amplicons (β-actin, M2 
muscarinic receptor and M3 muscarinic receptor) were amplified with a non-cumulative 
SYBR green assay and a cumulative TaqMan® hydrolysis probe assay. Details on biological 
samples, experimental design and reaction conditions are given in the Methods section. 
A. Raw fluorescence data resulting from PCR amplification of the M2 muscarinic receptor. 
The data are plotted on a logarithmic fluorescence axis and show that SYBR green 
fluorescence results in a larger baseline-to-plateau distance than TaqMan®.   
B. Data from panel A were baseline corrected [24] and plotted on a logarithmic fluorescence 
axis.  
C. Detail of the part of the TaqMan® amplification curves that is used for determination of 
the PCR efficiency per sample. The horizontal lines indicate the window-of 
-linearity [24]. Note that, although the window is at the top of the exponential phase, the 
amplification curves at the bottom of the window are diverging. 
D. As C but for SYBR green amplification curves. Within the window virtually all 
amplification curves are parallel.  
E. PCR efficiencies and Cq values determined for both assays and the 3 amplicons. The plot 
of PCR efficiency against Cq value shows no correlation between these two parameters. 
F. Mean PCR efficiency (with 1 times standard deviation; N=12 per amplicon per sample) 
observed for a SYBR green and a TaqMan® hydrolysis probe assay. The graph shows that 
PCR efficiencies per sample overlap per amplicon, indicating the PCR efficiency is not 
sample dependent. Although the PCR distributions overlap for all amplicons in the SYBR 
Green assay and between β-actin and the M2 muscarinic receptor for the TaqMan® assay, 
those of the M3 muscarinic receptor in the TaqMan® assay are significantly higher. 
Therefore, PCR efficiencies should be considered to differ between amplicons and between 
monitoring chemistries. 
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unquenched FAM and fluorescent TAMRA contribute significantly to baseline fluorescence 
and decrease ∆Rn. Non-fluorescent ‘dark’ quenchers absorb light and emit only heat [30]. 
These dark quenchers, trademarked black hole quenchers (BHQ®; Biosearch Technologies) 
can greatly increase signal to noise ratios in qPCR. 
 
1.5 PCR EFFICIENCY ESTIMATION   
 For the transformation of qPCR data into (relative) target gene quantity, almost all 
qPCR data analyses are based on estimating PCR efficiencies, setting an Nq threshold and 
determining the Cq value per sample [17,31]. The calculation of the target gene quantity N0, 
uses the inverse of Eq. 1 (N0 = Nq/E^Cq) and a PCR efficiency E, for which several 
estimation methods have been proposed in the literature.  
 Some qPCR data analysis algorithms, such as the comparative Cq method [32], use 
equations that do not account for specific PCR efficiency values. However, the derivation of 
these equations requires the efficiency values for all amplicons to be equal or even equal to 2. 
The MIQE guidelines do not mention an acceptable range of PCR efficiency values [4]. For 
the comparative Cq method a validation method to test the equality of target and reference 
efficiency was described [6]; at a PCR efficiency of 1.8, an observed efficiency up to 1.83 
meets this criterion. Recently a range of 1.93 to 2.05 for the standard curve derived efficiency 
was described to reflect an optimized assay [3]. Note, however, that at a Cq of 30 cycles, 
treating an actual PCR efficiency of 1.9 as if maximal amplification was reached leads to an 
approximately 5-times overestimation of the target quantity [7]. When a small over-or 
underestimation of the PCR efficiency occurs independently in the target and reference 
genes, a 10-fold error in the gene expression ratio can easily result [24]. It may be for this 
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reason that the comparative Cq method is described as the most popular but not necessarily 
the most appropriate method [4]. 
 Several reports showed that the assumption that the amplification efficiencies of the 
amplicon of interest and the reference gene were similar enough to ignore the differences, 
resulted in over- as well as under estimations of the biological effects [11,24,32-35]. To 
avoid this bias analysis should be based on a PCR efficiency value per amplicon [9-
11,36,37].  
 
1.5.1 PCR efficiency derived from a standard curve 
The PCR efficiency per amplicon is most often derived from a dilution series, also 
known as standard curve [38] which is a plot of Cq values versus the known Log-
concentration of a series of known concentrations or a serial dilution of a standard sample 
[3,6,32,36,39,40]. The simplicity and general use of the standard curve has led to its 
implementation in qPCR software which has obscured the mathematical principles upon 
which the analysis is based [8]. The regression line fitted to the data points is described by 
the equation Cq = Log(Nq)/Log(E) - 1/Log(E).Log(N0) which is the Log-transformed Eq. 1, 
rearranged to show the linear dependence of Cq on Log(N0).  
Determining the efficiency value from a standard curve has been described as 
simplified because the PCR efficiency may vary with input concentration [15]. The 
requirement that the efficiency is constant for each included sample is rarely achieved and 
verified [41]. Studies on the reproducibility of the standard curve derived PCR efficiency 
with replicate standard curves show a large variation in values derived from these data sets 
[8,11,24,34].  
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The Cq values used to construct the standard curve result from a dilution series. For a 
typical dilution series (10 times dilution per step; 4 steps) the expected Cq values, at a PCR 
efficiency of 2, range over approximately 14 cycles. As will be shown in section 2.4, at high 
Cq values, all Cq are negatively biased when the observed fluorescence is cumulative. The 
resulting standard curve will be parallel and the slope of the curve will result in the same 
PCR efficiency as when the amplification was monitored with a non-cumulative reporter. 
 However, when the Cq values for the least diluted samples are too low, the negative 
bias in these samples is less (see section 2.4). These slightly overestimated Cq values will 
lead to a standard curve with a steeper slope and the derived efficiency will be too low. 
Because only the lowest Cq value of a dilution series will be affected, and Cq values below 10 
cycles are very rarely used in a standard curve, this bias will have had minimal effects. In 
practice, the standard curve-derived efficiency can, therefore, be considered to be 
independent of the fluorescent chemistry used to monitor the PCR reaction. Similarly, the use 
of a concentration series as calibration curve to look-up the concentration of an unknown 
sample from its Cq is not affected because both calibration curve and sample Cq are similarly 
biased.  
 
1.5.2 PCR efficiency derived from amplification curves 
Alternatively, the PCR efficiency can be derived from a subset of data points in the 
exponential phase of the amplification curve of each individual sample. Such an efficiency 
value was used in the first radioactively monitored quantitative PCR experiments [42]. For 
data obtained by fluorescent monitoring of PCR amplification [43], several authors 
advocated the determination of the PCR efficiency from the slopes of individual 
amplification curves on a semi-logarithmic scale [34,44,45] or by non-linear fit of Eq. 1 to 
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data points in the exponential phase [15,41,46]. Similarly, mean efficiency values per 
amplicon can be estimated by calculating the common slope of the data points in the 
exponential phase for a group of samples [47]. Although good agreement between results 
obtained with a standard curve derived efficiency value and the mean of the efficiencies 
derived from individual amplification curves has been reported [48] other studies show that 
PCR analysis with the comparative Cq method or with standard curve derived efficiency 
values give precise (low within group variation) but significantly biased results [9,11,49]. In 
contrast, qPCR analysis based on the PCR efficiencies derived from individual amplification 
curves per sample resulted in unbiased target quantities but gave high variation within groups 
[9,49]. The average of these efficiency value for all samples per amplicon was shown to 
result in unbiased gene expression results with low variation [9,11,24,45,50]. The estimation 
of the PCR efficiency from the slope of the exponential phase of the amplification curve, 
plotted on a log (fluorescence) scale is directly derived from the logarithmic transformation 
of the basic kinetic equation of PCR (Eq. 1) [34]. The application of this method seems, 
therefore, to be limited to non-cumulative fluorescence data [24]. 
 However, the simulation of the estimation of the PCR efficiency from cumulative 
fluorescence data shows that the estimated PCR efficiencies are only positively biased when 
they are derived from subsets with low cycle numbers (Fig. 2C). Even with a low PCR 
efficiency of 1.4, already after 14 cycles, the estimation error is below 1%. With maximum 
PCR efficiency, this number of cycles is sufficient to reduce the bias to 0.1%. 
 Comparison of the observed PCR efficiency values between different heart tissue 
samples shows that the PCR efficiency distributions overlap per amplicon and sample (Fig. 
3F). The PCR efficiencies estimated from the individual samples can, therefore, be 
considered to be independent of the tissue sample; observed PCR efficiencies seem to be 
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drawn from a random distribution around the actual PCR efficiency of the amplicon [9,24]. 
Moreover, comparison of Figs. 2C and 3F shows that the predicted bias at low cycles is small 
compared to this experimental variation.  
 Estimation of the PCR efficiency from individual sample curves requires the 
observable exponential phase to be as long as possible (see section 2.2). When the subset of 
data used for estimation of the PCR efficiency is scrutinized, the TaqMan® data show more 
variable slopes than the SYBR green data (compare Figs. 3C and 3D). This variability is 
reflected in the increased variance of the resulting PCR efficiencies (Fig. 3F). Note that 
plotting the data on a logarithmic scale is required to judge this efficiency variance from the 
individual amplification curves. Identical ‘slopes’ on a normal fluorescence axis [3] merely 
indicate that the transition into the plateau phase occurs in parallel.  
 These results show that when the PRC efficiency is derived from the slope of the 
amplification curves per sample the resulting PCR efficiency will be correct when the data 
points used are beyond cycle 15. With low PCR efficiency and high abundance samples, one 
should be aware that in early cycles, the cumulative fluorescence curve has a steeper slope 
than the non-cumulative curve, and this will lead to an overestimation of the derived PCR 
efficiency. 
 
1.6 Cq DETERMINATION   
 The second parameter that has to be derived from the qPCR data set is the 
quantification cycle (Cq) which is the fractional number of cycles needed to reach the 
quantification threshold (Nq). Cq values have been the mainstay of qPCR data analysis since 
the introduction of fluorescence monitoring of the PCR reaction [6,43]. The Cq value marks 
the position of the amplification curve on the cycle axis and is proportional to the logarithm 
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of the initial target concentration at constant amplification efficiency. Cq values are also 
referred to as Ct or Cp but this is discouraged in the MIQE guidelines [4]. 
 Recommendations for placing the quantification threshold vary in literature. Some 
authors place the threshold at the level where amplicon DNA just becomes detectable [8,35] 
or at least at the low end of the exponential phase [6,10,20]. Other papers describe the 
threshold setting as arbitrary [44,49] or recommend specific positions like the midpoint of 
the exponential phase [45]. High threshold settings have mostly been avoided because of the 
variation in plateau phase levels. However, it was also recommended to avoid the lower end, 
and even the middle, of the exponential phase, because this region is still influenced by 
baseline noise [41]. Because the threshold is used in calculation based on the exponential 
amplification of DNA, the threshold should intersect with the exponential phase of the 
amplification curve [19]. Note that the threshold level is sometimes called ‘noise band’ [6], 
‘benchmark’ [50] or ‘detection threshold’ [51] thereby adding to the confusion on the issues 
of baseline, background, threshold and variation in qPCR data analysis.  
 Alternatively, a Cq value has been derived from individual amplification curves by 
determining the fractional cycle at which a second derivative of a smoothed curve fitted to a 
subset of the observed data points reaches its maximum [38,52]. This second derivative 
maximum (SDM) marks the cycle at which exponential amplification no longer can be 
sustained and the curve begins to taper into the plateau phase [53]. This method gained 
popularity because it does not involve any decision by the user [52]. However, although the 
fluorescence level at the second derivative maximum typically will be similar for a given set 
of reaction conditions, this method is based on the assumption that information in the curve 
shape is more predictive of the target quantity than the fluorescence levels at each cycle. A 
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comparison of different Cq determination methods showed that in assays with variable 
baseline and plateau conditions the threshold method showed superior precision [53] . 
 The validity of the use of the Cq value is tightly linked to the exponential nature of the 
PCR amplification. Obviously the quantification threshold will be reached in an earlier cycle 
when the monitored fluorescence accumulates. This effect can clearly be seen when the Cq 
values that are observed with a cumulative fluorescent probe are plotted against the Cq values 
resulting from non-cumulative monitoring of the same simulated samples (Fig. 2D). At high 
Cq the negative bias in the Cq becomes constant and is then given by Eq. 4. This Cshift is 
especially large when the PCR efficiency is low. At low efficiencies it also takes a large 
number of cycles to reach this constant Cshift. This is why the standard curve-derived 
efficiency will be biased when at low PCR efficiencies such low Cq values are included (see 
section 2.3.1). 
 The relation between PCR efficiency and Cq value that is present in Fig. 2C is not 
observed in the analysis results of the quantitative PCR data (Fig. 3E). The non-cumulative 
SYBR green data, as well as the cumulative TaqMan® data show no correlation between 
PCR efficiency and Cq values. 
 Because of the cumulative nature of the fluorescence resulting from hydrolysis 
probes, the Cq values observed with these probes are lower than expected from their PCR 
kinetics. This shift is minimally 1 cycle when the PCR efficiency is 2, but lower PCR 
efficiency leads to a larger Cshift (Fig. 2D). The magnitude of this bias is similar to the error 
observed in Cq values between replicate measurements of the same sample, which is 
generally described to be low, especially when compared to operator, kit and probe 
differences [54]. Replicate measurements on the same sample show Cq differences of 0.2 
[49] or 0.4 cycles [55]. Intra-assay coefficients of variation for replicate Cq values were 
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reported in the order of 1% [20], 7 % [56] and 10% [36]. The last percentage translates into a 
standard deviation of 2 cycles. This comparison of the Cshift bias with random experimental 
error is partly flawed because random error is averaged out whereas a systematic bias does 
not, and may go unnoticed when no reference is available.  
 
1.6 CORRECTION OF CSHIFT 
 Because N and Cshift are fully dependent on the slope of the amplification curve in 
the exponential phase, a correction for this bias can be based on the constant PCR efficiency 
during this phase (Fig. 4). This PCR efficiency can be derived from a standard curve or from 
a subset of data points in the exponential phase of the amplification curves [34]. On a 
logarithmic fluorescence scale, the slope of the amplification curve is the logarithm of the 
PCR efficiency. Therefore, the known PCR efficiency can be used to calculate N and Cshift. 
The sum of the observed Cq and Cshift results in a corrected Cq value, representing the value 
that would have been found when the same fluorescent dye had behaved non-cumulatively. 
This corrected Cq value can then be used to calculate the correct N0 value. Note that in qPCR 
analysis algorithms that assume that the PCR efficiencies of all amplicons are equal, or at 
least similar enough to allow the difference to be ignored, like the comparative Cq method, 
the Cshift correction will have no effect on the result of the analysis. 
 The correction principle is illustrated in Fig. 4 and has to be applied to individual 
PCR samples. In case the PCR efficiency is derived from the individual amplification curves, 
the mean of all individual PCR efficiencies per amplicon has to be used to calculate the  
required Cshift. The latest version of the qPCR analysis program LinRegPCR 
(http://LinRegPCR.HFRC.nl) [24] implements this correction. 
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Figure 4. Correction of Cq values determined from cumulative fluorescence curves.  
The circles represent the data points originating from monitoring the PCR reaction with a 
cumulative fluorescent probe. After setting the quantification threshold Nq (horizontal solid 
line) the Cq value can be determined. Using the estimated PCR efficiency value (E), the 
vertical distance to the equivalent non-cumulative fluorescence curve (dashed curve) can be 
calculated (Eq. 3). Because the slope of both curves is equal to log(E), simple geometry 
suffices to calculate the horizontal distance (Cshift) between the curves. The observed Cq 
value of the cumulative fluorescence curve can then be corrected to the Cq value (vertical 
dotted line) that would have been observed when the fluorochrome had not accumulated. The 
figure also illustrates the setting a window-of-linearity [34] (horizontal dotted lines) which is 
used to determine the PCR efficiency of the current sample by linear regression using the 
data points in the window (black circles). Parameters: N0: 1, PCR efficiency: 1.8. Cshift is 
1.38 in this example. 
 
 
 
 
 
 175 
1.7 CALCULATE TARGET QUANTITY (N0) AND GENE EXPRESSION RATIO 
  Although papers describing qPCR results often only report Cq values it is clear that 
interpretation of these results cannot be done without knowledge of the PCR efficiency 
values [57]; Cq values should not be compared as such but converted into and reported as 
target quantities [58]. Because of the exponential nature of PCR, small differences in PCR 
efficiency between amplicons can lead to large differences in Cq value whereas similar Cq 
values for different amplicons can represent very different target quantities when the PCR 
efficiencies differ between amplicons [11,24]. As stated above, an observed Cq of 30 cycles 
can represent a 5-fold difference in target quantity when the PCR efficiency of two 
amplicons differs only as much as from 1.9 to 2. . Thus, restricting qPCR analysis to assays 
with a PCR efficiency above 1.9 will not prevent the variance introduced by ignoring the 
actual PCR efficiency. To avoid the tedious interpretation of Cq values it is recommended to 
use the estimated PCR efficiency, quantification threshold and Cq value to calculate a target 
quantity with the inverse of Eq. 1. The resulting N0 value is an estimate of the target quantity 
in arbitrary fluorescence units. 
 Target quantities were calculated for simulated data sets monitored with non-
cumulative and cumulative fluorescent chemistries (Fig. 5A). This simulation shows that the 
expected bias is dependent on the PCR efficiency because the vertical distance N of the 
parallel curves is associated with a horizontal shift, Cshift, at the level of the quantification 
threshold (Eq. 4; Fig. 4). When the Cshift is ignored in PCR data analysis, biases will arise in 
the estimated target quantities (Eq. 5, Fig. 5A) and gene expression ratios (Eq. 6, Fig. 5B). 
The magnitude of these biases depends on the PCR efficiencies of the target and the 
reference genes. This effect is direct through the use of the efficiency value in calculating N0 
with the inverse of Eq. 1 and indirectly through the contribution of the efficiency to the Cshift. 
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Fig. 5A shows that the bias in estimated N0 values approaches the value calculated with Eq. 5 
at high Cq. With low PCR efficiency, low Cq values show the largest bias. This is because in 
these circumstances, the non-cumulative and cumulative curves are not yet completely 
parallel and biased efficiency values will be estimated (Fig. 2C). Moreover, a low PCR 
efficiency results in a smaller N but larger Cshift (Fig. 2D). With high PCR efficiencies, the 
bias in N0 is constant and minimal at the maximum efficiency of 2. 
 To study the effectiveness of the Cshift correction on the observed target quantity, its 
effect was simulated and the relative error in the resulting N0 value was calculated (Fig. 6). 
This calculation shows that after the Cshift correction, for an amplicon with a PCR efficiency 
of 2, the N0 values are within 0.5% of the given value already at a Cq of 12. With lower 
efficiency values, higher Cq values are required to reach the same small error. The 
dependence of the remaining error in N0 on the Cq value results from the fact that at lower 
cycle numbers, the non-cumulative and cumulative amplification curves are not yet fully 
parallel (Fig. 2B). However, the observed remaining errors are well within the experimental 
and biological variation of quantitative PCR experiments [59,60]. 
 Even when the accumulation of fluorescence is ignored, the gene expression ratio is 
unbiased when the PCR efficiencies of the target and the reference amplicon are equal (Fig. 
5B). In that situation, the Cshifts cancel each other, resulting in unbiased gene expression 
ratios. For optimized PCR reactions, with efficiency values of 1.8 or higher, the bias in gene 
expression ratio will be limited to 12% (Fig. 5B). However, biases from 0.57 to 1.75 can be 
observed when these efficiencies range from 1.4 to 2. In this calculation of the bias in a gene 
expression ratio (Appendix C; Eq. 6), a single reference gene is used. When the geometric 
mean of the expression levels of multiple reference genes is used for normalization of the 
target quantity [61], the resulting bias depends on the efficiency values of the individual 
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reference genes. When these efficiencies are distributed around the PCR efficiency of the 
target amplicon, bias will be reduced.   
 Also the bias in the gene expression ratio can be removed by applying the described 
Cshift correction. Depending on the PCR efficiency and the Cq values, the Cshift correction 
procedure will completely remove the bias. When the PCR efficiencies of target and 
reference amplicons differ, some bias in the gene expression ratio may remain when Cq 
values are low.  
 The bias in the gene expression per sample as predicted by Eq. 6 is independent of the 
Cq values of the target and reference genes in the sample. This means that in a comparison of 
the relative difference of the gene expression ratios between different samples in an 
experiment the bias due to ignoring cumulative fluorescence cancels out; the same fold-
difference between samples would be obtained with or without Cshift correction. However, 
this result is only unbiased when the PCR efficiency values of target and reference amplicons 
were included in the calculations. Moreover, for the calculation of unbiased absolute 
differences between samples in an experiment the Cshift correction is required. 
2.7 Conclusions 
Although monitoring PCR amplification with a cumulative fluorescent reporter gives higher 
observed fluorescence data, a correct PCR efficiency can be derived from the exponential  
phase from such a cumulative curve or from a standard curve based on Cq values derived 
from these data. The downward shift in Cq values is dependent on the PCR efficiency and 
can be corrected when this efficiency is known. When the accumulation of fluorescence is 
ignored, target quantities are at least two-fold too high. However, the error in the 
target/reference ratio of starting quantities is small when the PCR efficiencies of the target 
and reference amplicons are similar. When PCR efficiencies are derived from the exponential  
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Figure 5. Results are biased when the accumulation of fluorescence is ignored.  
A. Although Eq. 5 (section 4) predicts that the bias in the estimated target quantity (N0) is 
independent of Cq, in practice N0 is negatively biased when the Cq value, and thus the subset 
of data points used to calculate the PCR efficiency, is in the early cycles. To generate this 
graph, the Cq values and PCR efficiency values shown in Fig. 2C were used to calculate the 
observed N0. The relative error in N0 was then calculated as the ratio between observed and 
given N0 value. This relative error is independent of N0. Parameters: N0: 0.000001, PCR 
Efficiency: 1.4 - 2.0. 
B. The bias in the gene expression ratio, calculated by dividing the starting amount of a 
target gene by that of a reference gene in the same sample depends on difference between the 
PCR efficiencies of the target and reference amplicon (Eq. 6). When the PCR efficiencies of 
both amplicons are equal, the gene expression ratio is unbiased. However, when the PCR 
efficiencies differ, positive and negative biases can occur. The parameters used in the 
calculation are the same as in Fig. 5A.  
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Figure 6. Cshift correction does not remove all bias in N0. 
The fact that the bias in N0 is dependent on the Cq value (see Fig. 5A) makes that the Cshift 
correction illustrated in Fig. 4 is not removing the bias in all situations. After application of 
the correction to the data of Fig. 5A a small error in the estimated N0 values remains present. 
The graph shows the remaining bias in these estimated N0 values. The Cq values that have to 
be observed to restrict this bias to at most 0.5% are plotted for a range of PCR efficiency 
values. The graph shows that, to limit the error to 0.5%. 
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phase of the amplification curves, the researcher should select a fluorophore-quencher pair 
with a high ∆Rn value to facilitate baseline estimation and thus reduce the variation in the 
estimated PCR efficiency. 
3.8 APPENDICES 
Appendix A. Derivation of N 
Appendix B. Derivation of bias in N0 when Cshift is ignored 
Appendix C. Derivation of bias in the gene expression ratio when Cshift is ignored 
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Appendix A. Derivation of Eq. 3 
N is defined as the distance between the logarithmic curves resulting from cumulative and 
non-cumulative fluorescence monitoring of PCR amplification. At high cycle numbers this 
distance approaches a limit of log(1/(1-(1/E))), because the distance at cycle number C is 
equal to the geometric series of 1/E up to C-1:  
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The latter equation requires that the PCR efficiency E>1 which is always the case in 
quantitative PCR. 
Appendix B. Derivation of the bias in N0 when Cshift is ignored (Eq. 5) 
The observed N0 value, calculated with the Cq value of a cumulative fluorescence curve will 
be biased because the observed Cq value is too low due to the Cshift (Eq. 4). The starting 
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concentrations N0 can be estimated from the quantification threshold (Nq), the PCR 
efficiency and the number of cycles (Cq) required to reach the threshold. 
When the observed N0 is give by: shiftq
CC
q E NN
 /  observed 0  
and the real N0 is give by: q
C
q ENN /  real 0   
and the bias in defined as the observed N0 divided by the real N0 then the bias is: 
         00  /real observed  bias NN  
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q //
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     shiftqq CCC EE  /  
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With Eq. 4 for Cshift this bias simplifies to 1/(1-(1/E)). 
 
Appendix C. Derivation of the bias in the gene expression ratio when Cshift is ignored 
(Eq. 6) 
The gene expression ratio is defined as the ratio of the estimated starting concentrations of a 
target and a reference gene: 
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The observed gene expression ratio, calculated with the Cq value of the cumulative 
fluorescence curves of target and reference genes will be biased because the Cq values are too 
low due to the Cshift (Eq. 3).  
When the observed gene expression ratio is: 
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and the real gene expression ratio is: 
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then the bias, defined as observed ratio divided by the real ratio is:  
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